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Primary aldosteronism (PA) accounts for 5-10% of all hypertension. One of the major causes 
of PA is sporadic formation of aldosterone-producing adenomas (APAs). These benign 
tumours develop in the cortical region of adrenal glands and autonomously secrete excessive 
amounts of aldosterone. This hormone increases sodium retention and water reabsorption 
by the kidneys, leading to high blood pressure. Landmark discoveries of somatic mutations in 
APAs led to better understanding of molecular mechanisms causing autonomous aldosterone 
secretion. The first mutations were found in KCNJ5, followed by ATP1A1, ATP2B3 and 
CACNA1D, all encoding cation-channels or transporters. Several in vitro studies showed 
disruption of cellular ion-balance leading to the phenotype of hyper-aldosterone secretion 
from APAs.  
 
Following our lab’s discovery of initial four somatic mutations by whole exome sequencing, 
over 30 single-base change mutations have been reported in the CACNA1D gene, which 
encodes the 1 subunit of an L-type Ca2+ channel (LTCC), CaV1.3. Initial and several subsequent 
mutations cause electrophysiological gain-of-function with increased activation and/or 
slowed inactivation of CaV1.3. Prior to the discovery of these mutations, L-type Ca2+ channels 
were not considered important in regulation of aldosterone production. In the first part of my 
thesis, I investigated two of the mutations and showed that the gain-of-function results in 
increased aldosterone secretion from an adrenocortical carcinoma cell line, H295R, when 
transiently transfected with the mutants. I also showed that CaV1.3 can play a role in 
physiological aldosterone secretion, finding that CYP11B2 expression is reduced by 50% in the 
adrenals of CaV1.3 knockout mice. The discovery of mutations in CACNA1D led to a  
 Award from  in which high-throughput screening of CaV1.3-
expressing cells was undertaken against  1.8M compound library. I identified the adrenal 
isoforms of the channel's alpha and beta subunits (CACNA1D and CACNB2), and helped 
development of the stable HEK293 cell line used for screening. This led to 3 tool compounds 
(A, B & C) that were selective antagonists for CaV1.3 over  in high-throughput 
electrophysiological experiments using  and  platforms. I showed 
compound B to effectively inhibit aldosterone secretion in both H295R and primary adrenal 
cells isolated from a normal adrenal. This finding is a significant step in developing compound 
B further into a CaV1.3-selective drug for treating PA patients without cardiovascular side 
effects as in the case of existing dihydropyridine class of Ca2+ channel blockers. 
 
The second part of my thesis focused on genotyping and whole exome sequencing of 59 APAs 
from 52 patients, in order to identify further genes underlying primary aldosteronism. 
Mutations in previously reported genes were identified in 34 of the APAs (57.6%). CACNA1D 
was the most commonly mutated gene (20.3%) in this cohort, but not KCNJ5 (16.9%) as 
previously reported. This variation in the frequencies observed is perhaps due to the different 
methods used for screening PA. For example, many of our patients were detected by renin 
measurement in resistant hypertension, and their APA identified by a unique PET-CT (using 
C11 metomidate), in place of adrenal vein sampling.  
 
In addition to this, novel somatic mutation was found in a gene not encoding an ion channel, 
however, this protein was previously linked to cell-cell adhesion and tumour suppression. The 
gene identified is CADM1, a cell adhesion molecule 1, and the mutation found leads to 
substitution of valine by aspartate  in the single transmembrane domain of this cell 
surface protein. The likely significance of this discovery was greatly enhanced when we 
ascertained that one of the 'private' somatic mutations found on whole exome sequencing of 
APAs in Munich was in fact a similar substitution in the adjacent amino acid of the 
membrane-spanning domain.  
 
High expression of CADM1 in zona glomerulosa (ZG) was found, the site of aldosterone 
synthesis in the adrenal cortex and in the APAs, as well as the aldosterone producing cell 
clusters (APCCs) within the ZG. In vitro experiments using H295R cells showed both mutations 
in CADM1 lead to 10-20 fold upregulation of CYP11B2 transcription, on qPCR, resulting in 2-
4-fold increase of aldosterone secretion, compared to the wild-type CADM1. Despite the 
introduction of a negative charge into the transmembrane domain, both mutants could 
translocate to the cell surface. The evidence to date, points to the loss of cell-cell adhesion in 
the presence of mutant CADM1 as the cause of uncontrolled aldosterone synthesis. Silencing 
of CADM1 in H295R cells revealed downregulation of aldosterone synthesis and secretion. 
Transcriptome analysis by RNAseq, of H295R cells expressing wild-type or mutant CADM1 or 
silenced CADM1 showed a large number of differentially expressed genes. Mutant CADM1 
upregulated genes involved in steroidogenesis and ACTH response pathways. A possible role 
of CADM1 was found to be in the regulation of inter-cell communication via gap junction 
protein, connexin-43 (Cx43). This was upregulated with higher expression on plasma 
membrane in the CADM1 silenced cells. TSG101, a protein involved in lysosomal degradation 
of Cx43 was downregulated in the absence of CADM1 and possibly the mechanism for 
increased Cx43 expression. Also, immunostaining of adrenal sections showed internalised 
para-nuclear staining localisation of Cx43 in the ZG, APAs and APCCs, regions with high 
CADM1 expression compared to membranous localisation of Cx43 in ZF.  
 
In contrast to the common and numerous mutations in CACNA1D, mutations in CADM1 are 
rare. Nonetheless, they may enhance our understanding of the functional significance of 
glomerular structure of the outer zone of adrenal cortex, where cell-cell adhesion and 
intercellular communication appear critical for the regulation of aldosterone secretion. 
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THESIS SUMMARY 
Primary aldosteronism (PA) accounts for 5-10% of all hypertension. One of the major causes 
of PA is sporadic formation of aldosterone-producing adenomas (APAs). These benign 
tumours develop in the cortical region of adrenal glands and autonomously secrete excessive 
amounts of aldosterone. This hormone increases sodium retention and water reabsorption 
by the kidneys, leading to high blood pressure. Landmark discoveries of somatic mutations in 
APAs led to better understanding of molecular mechanisms causing autonomous aldosterone 
secretion. The first mutations were found in KCNJ5, followed by ATP1A1, ATP2B3 and 
CACNA1D, all encoding cation-channels or transporters. Several in vitro studies showed 
disruption of cellular ion-balance leading to the phenotype of hyper-aldosterone secretion 
from APAs.  
 
Following our lab’s discovery of initial four somatic mutations by whole exome sequencing, 
over 30 single-base change mutations have been reported in the CACNA1D gene, which 
encodes the 1 subunit of an L-type Ca2+ channel (LTCC), CaV1.3. Initial and several subsequent 
mutations cause electrophysiological gain-of-function with increased activation and/or 
slowed inactivation of CaV1.3. Prior to the discovery of these mutations, L-type Ca2+ channels 
were not considered important in regulation of aldosterone production. In the first part of my 
thesis, I investigated two of the mutations and showed that the gain-of-function results in 
increased aldosterone secretion from an adrenocortical carcinoma cell line, H295R, when 
transiently transfected with the mutants. I also showed that CaV1.3 can play a role in 
physiological aldosterone secretion, finding that CYP11B2 expression is reduced by 50% in the 
adrenals of CaV1.3 knockout mice. The discovery of mutations in CACNA1D led to a  
 from  in which high-throughput screening of CaV1.3-
expressing cells was undertaken against  1.8M compound library. I identified the adrenal 
isoforms of the channel's alpha and beta subunits (CACNA1D and CACNB2), and helped 
development of the stable HEK293 cell line used for screening. This led to 3 tool compounds 
(A, B & C) that were selective antagonists for CaV1.3 over  in high-throughput 
electrophysiological experiments using  and platforms. I showed 
compound B to effectively inhibit aldosterone secretion in both H295R and primary adrenal 
cells isolated from a normal adrenal. This finding is a significant step in developing compound 
B further into a CaV1.3-selective drug for treating PA patients without cardiovascular side 
effects as in the case of existing dihydropyridine class of Ca2+ channel blockers. 
 
The second part of my thesis focused on genotyping and whole exome sequencing of 59 APAs 
from 52 patients, in order to identify further genes underlying primary aldosteronism. 
Mutations in previously reported genes were identified in 34 of the APAs (57.6%). CACNA1D 
was the most commonly mutated gene (20.3%) in this cohort, but not KCNJ5 (16.9%) as 
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previously reported. This variation in the frequencies observed is perhaps due to the different 
methods used for screening PA. For example, many of our patients were detected by renin 
measurement in resistant hypertension, and their APA identified by a unique PET-CT (using 
C11 metomidate), in place of adrenal vein sampling.  
 
In addition to this, novel somatic mutation was found in a gene not encoding an ion channel, 
however, this protein was previously linked to cell-cell adhesion and tumour suppression. The 
gene identified is CADM1, a cell adhesion molecule 1, and the mutation found leads to 
substitution of valine by aspartate  in the single transmembrane domain of this cell 
surface protein. The likely significance of this discovery was greatly enhanced when we 
ascertained that one of the 'private' somatic mutations found on whole exome sequencing of 
APAs in Munich was in fact a similar substitution in the adjacent amino acid  of the 
membrane-spanning domain.  
 
High expression of CADM1 in zona glomerulosa (ZG) was found, the site of aldosterone 
synthesis in the adrenal cortex and in the APAs, as well as the aldosterone producing cell 
clusters (APCCs) within the ZG. In vitro experiments using H295R cells showed both mutations 
in CADM1 lead to 10-20 fold upregulation of CYP11B2 transcription, on qPCR, resulting in 2-
4-fold increase of aldosterone secretion, compared to the wild-type CADM1. Despite the 
introduction of a negative charge into the transmembrane domain, both mutants could 
translocate to the cell surface. The evidence to date, points to the loss of cell-cell adhesion in 
the presence of mutant CADM1 as the cause of uncontrolled aldosterone synthesis. Silencing 
of CADM1 in H295R cells revealed downregulation of aldosterone synthesis and secretion. 
Transcriptome analysis by RNAseq, of H295R cells expressing wild-type or mutant CADM1 or 
silenced CADM1 showed a large number of differentially expressed genes. Mutant CADM1 
upregulated genes involved in steroidogenesis and ACTH response pathways. A possible role 
of CADM1 was found to be in the regulation of inter-cell communication via gap junction 
protein, connexin-43 (Cx43). This was upregulated with higher expression on plasma 
membrane in the CADM1 silenced cells. TSG101, a protein involved in lysosomal degradation 
of Cx43 was downregulated in the absence of CADM1 and possibly the mechanism for 
increased Cx43 expression. Also, immunostaining of adrenal sections showed internalised 
para-nuclear staining localisation of Cx43 in the ZG, APAs and APCCs, regions with high 
CADM1 expression compared to membranous localisation of Cx43 in ZF.  
 
In contrast to the common and numerous mutations in CACNA1D, mutations in CADM1 are 
rare. Nonetheless, they may enhance our understanding of the functional significance of 
glomerular structure of the outer zone of adrenal cortex, where cell-cell adhesion and 
intercellular communication appear critical for the regulation of aldosterone secretion.  
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CHAPTER 1 -  INTRODUCTION 
 
1.1 Hypertension and Primary aldosteronism 
Hypertension or high blood pressure (>140mm of Hg systolic or >= 90mm of Hg diastolic 
pressure) is a major, but treatable risk factor for cardiovascular diseases, accounting for up to 
40% of the world’s population. It is one of the major cause of premature morbidity and 
mortality in today’s world. If an obvious single cause of elevated blood pressure cannot be 
identified, it is categorised as primary or essential hypertension. 80-90% of hypertensive cases 
fall in this category. Remaining cases can be attributed to an identifiable cause and termed as 
secondary hypertension. The underlying causes for secondary hypertension can be divided 
into two categories, depending on increased cardiac output or increased systemic vascular 
resistance (Fig. 1). Increase in blood volume due to increased aldosterone, vasopressin, and 
renal disease etc. fall into this category. Increased vascular resistance is the outcome of 
conditions such as atherosclerosis, diabetes, thyroid dysfunction, stress, cerebral ischemia 
etc.  
 
Fig. 1: Categorisation of hypertension and underlying causes. 
 
Several pathophysiologies related to adrenal glands are the underlying cause of secondary 
hypertension including Cushing’s syndrome (increased cortisol), pheochromocytoma 
(increased catecholamines), and Conn’s syndrome (increased aldosterone). 
Hyperaldosteronism can also be categorised as primary or secondary hyperaldosteronism 
depending on whether aldosterone secretion is renin independent or autonomous of renin 
stimulation respectively (Fig. 2).  
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Fig. 2: Categorisation of hyperaldosteronism and their underlying causes. 
 
Conn’s syndrome, one of the major causes of primary aldosteronism (PA) is characterised by 
hypersecretion of hormone aldosterone by the adrenal glands due to an adenoma in adrenal 
cortex. It was first described in 1955 by Dr Jerome W. Conn in a patient with episodes of 
muscular weakness, intermittent tetany (muscular spasm), paraesthesia (abnormal tingling 
and pricking sensation), polyuria (excess urination), polydipsia (excess thirst), hypokalaemia 
(low plasma potassium), hypernatremia (high plasma sodium), alkalosis (alkaline serum), and 
hypertension (Conn, 1955). These symptoms were caused by renin-independent hyper 
secretion of aldosterone from the aldosterone producing adenoma (APA), after surgical 
removal of which, the condition was cured.  
 
Since then a number of similar hypertension cases have been identified, with PA accounting 
for 5-13% of all hypertensive cases (Mulatero et al., 2004). PA also accounts for 20% of 
treatment resistant hypertensive cases (Mulatero et al., 2004; Rossi et al., 2006) and is the 
most common curable form of secondary hypertension by adrenalectomy. Diagnosis of PA 
was earlier restricted to hypokalaemic patients, but was revised a decade ago to high value 
for plasma aldosterone/renin ratio (ARR) (Young, 2003). Management of PA varies depending 
on the underlying subtype of the condition, unilateral or bilateral adrenal hyperplasia, 
adenoma or adrenocortical carcinoma (Funder et al., 2008; Stowasser and Gordon, 2003).  
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1.2 Adrenal gland and steroidogenesis 
Adrenal glands are a pair of small endocrine glands present on top of the two kidneys. They 
are the site of several steroid hormones’ synthesis. Adrenals are formed of 2 distinct regions, 
outer cortex and inner medulla, covered with a capsule of connective tissue (Fig. 3). Adrenal 
cortex produces steroid hormones and medulla secretes stress hormones, adrenaline and 
noradrenaline that are catecholamine in nature. Cortex is further divided into three distinct 
zones - outermost zona glomerulosa (ZG), middle zona fasciculata (ZF) and innermost zona 
reticularis (ZR). All these cortical layers have distinct histology and secretory functions. As the 
name suggests, cells in ZG are arranged in a glomerular or “nests” like structures. ZG cells 
have high nucleus to cytoplasmic volume ratio, compared to cells in ZF region. ZF cells have 
lipid rich cytoplasm and are arranged in column like structures. ZG is the site of 
steroidogenesis of the mineralocorticoid, aldosterone. ZF cells produce the glucocorticoid 
hormone, cortisol that plays a role in increasing blood glucose level in the conditions of stress 
by gluconeogenesis. The inner most region of cortex, ZR is the site of androgens’ synthesis 
like testosterone. 
 
 
Fig. 3: Haematoxylin and eosin (H&E) staining of human adrenal gland showing its histology 
This figure shows outer capsule, three concentric layers of adrenal cortex and inner-most medulla. Haematoxylin 
and eosin (H&E) staining of a section shows different zones in adrenal structure. 
 
Aldosterone is a steroid hormone, synthesised and secreted by ZG cells of adrenal cortex. It 
is a product of long steroidogenesis process (Fig. 4) that begins with the translocation of 
cholesterol molecule from outer mitochondrial membrane to inner mitochondrial membrane, 
facilitated by steroidogenic acute regulatory protein, StAR. The last 3 reactions of this process 
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are catalysed by aldosterone synthase (CYP11B2) in mitochondria that oxidises 11-
deoxycorticosterone to aldosterone.  
 
 
 
Fig. 4: Steroidogenesis in human adrenal gland. 
ACTH stimulates the steroidogenesis in adrenal cortex (red arrow). Blue boxes represent the enzymes catalysing 
(and encoding GENES) conversions indicated by blue lines. Adrenal zone specific steps are boxed with zones, ZG, 
ZF or ZR mentioned at the bottom. ACTH: Adrenocorticotropic hormone, OMM: outer mitochondrial membrane, 
IMM: inner mitochondrial membrane, HSD: Hydroxysteroid dehydrogenase. Adapted from (Han et al., 2014; 
Stowasser and Gordon, 2016). 
 
1.3 Aldosterone 
1.3.1 Regulation of aldosterone synthesis 
A drop in blood pressure and sodium availability in the filtrate from nephrons stimulate renin 
secretion by kidneys (Fig. 5). It proteolytically cleaves N-terminal 10 amino acids of 
angiotensinogen, which is produced by liver into circulation. The cleaved product, 
angiotensinogen I is further acted upon by angiotensin-converting enzyme (ACE) to produce 
8 amino acid peptide, known as angiotensin II (AngII). AngII stimulates secretion of hormones, 
aldosterone and vasopressin from adrenal cortex and pituitary glands respectively. Both these 
hormones mediate their effects by increasing sodium retention and water reabsorption by 
kidneys. Decreased sodium excretion with increased blood volume normalises/increases 
blood pressure, activating feedback mechanism to inhibit renin production and balance the 
electrolyte levels. 
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Fig. 5: Renin-angiotensin-aldosterone system (RAAS) 
Green arrows indicate enzyme/hormone secretion, blue arrows represent enzymatic conversions, and orange 
arrows show stimulatory effects on the target organ. 
 
 
At cellular level, aldosterone secretion is primarily stimulated by increase in plasma 
concentration of three factors: angiotensin II (AngII), potassium (K+) and adrenocorticotrophic 
hormone (ACTH) (Fig. 6) (Spät and Hunyady, 2004). ACTH activates adenylyl cyclase pathway 
via its receptor, MC2R leading to rise in cAMP levels that in turn increases cholesterol 
transport to mitochondria and transcription of several steroidogenic enzymes. On the other 
hand, though via different mechanisms both AngII and elevated extracellular K+ concentration 
stimulate aldosterone synthesis by raising cytoplasmic calcium levels. AngII binds to its G-
protein coupled receptor, AT1R and activates IP3/Ca2+-calmodulin pathway. IP3 receptors on 
endoplasmic reticulum release internally stored calcium into cytoplasm. High extracellular 
[K+] depolarises membrane potential activating and opening voltage-gated calcium channels 
(T- and L-type) (Spät, 2004). Influx of calcium ions through these channels elevates [Ca2+]i and 
expression of aldosterone synthase (CYP11B2) via its main transcriptional regulator NURR1 
(NR4A2). 
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Fig. 6: Molecular pathways for aldosterone secretion in ZG cells. 
a. Basal ZG cell. b. ZG cells on stimulation with ACTH, AngII or increased plasma K+ concentration. AC: Adenylyl 
cyclase; PKA: Protein kinase A; PLC: Phospholipase C; CAMK: Calmodulin dependent protein kinase; ER: 
Endoplasmic reticulum. 
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1.3.2 Mechanism of aldosterone action 
Secreted in the blood stream, aldosterone acts on the cytosolic mineralocorticoid receptors 
(MR) in distal tubular and collecting duct cells of kidneys, leading to its translocation to 
nucleus. MR upregulates transcription of serum glucocorticoid-induced kinase 1 (SGK1), 
which increases ENaC (epithelial Na+ channels) expression on the luminal membranes of 
collecting ducts, NCC (sodium chloride channels) in distal convoluted tubules and Na+/K+ 
ATPase pumps in both. These upregulated channels function to increase sodium retention, 
potassium excretion and water reabsorption from the blood resulting in increased total blood 
volume and blood pressure. As MR is not only present in the epithelial cells of distal renal 
tubules but also in colon and sweat glands, aldosterone mediated sodium retention, 
potassium and hydrogen ion excretion occurs in these tissues as well. This action of 
aldosterone on epithelial cells to increase blood pressure is termed as its “genomic” effect 
because of MR induced target gene transcriptional upregulation. Similar genomic effects are 
seen in non-epithelial, endothelial cells, cardiomyocytes and vascular smooth muscle cells.  
Aldosterone is reported to exert its “non-genomic” effects by activation of several signalling 
pathways in tissues expressing MR or other GPCRs on cell surface rather than cytosol in 
epithelial cells. These non-genomic effects mediated by second messengers like Ca2+, cAMP, 
IP3/DAG are much quicker than the genomic effects. 
 
1.3.3 Effects of aldosterone excess 
Aldosterone excess in PA does not only exert its effect due to uncontrolled blood pressure 
but also has adverse effects by end organ damage independent of increased blood pressure 
(Fig. 7). Aldosterone causes increased mesangial cell proliferation and podocyte injury in 
kidneys by increasing oxidative stress and inflammatory pathways. These effects lead to 
chronic kidney disease augmenting hypertension even further. In cardiovascular system, 
aldosterone excess induces hypertrophy, fibrosis and inflammation which is partly dependent 
on its action of increasing blood pressure (Milliez et al., 2005; Savard et al., 2013). High salt 
intake has been shown to exaggerate these deleterious effects of aldosterone excess on 
cardiovascular system and require to be restricted to manage the symptoms while on medical 
therapy including MR antagonists, ACE inhibitors and angiotensin receptor blockers. 
Aldosterone excess has also been implicated in increasing insulin resistance leading to 
diabetes and adding to its cardio-metabolic risks (Briet and Schiffrin, 2010). This is well 
documented in several studies showing increased morbidity and mortality among PA patients 
with age and blood pressure matched essential hypertension patients. Meta-analysis of these 
studies have shown increased risk of cardiovascular events such as coronary artery disease, 
atrial fibrillation, heart failure and stroke in PA patients (Hundemer et al., 2017; Monticone 
et al., 2017). Among all current treatments available, MR antagonism has been observed to 
minimise these risk factors most effectively. 
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Fig. 7: Effects of aldosterone excess on various tissues/systems. 
Adapted from (Stowasser and Gordon, 2016). 
 
 
1.4 Identification, diagnosis and management of PA 
With increasing evidences of deleterious effects of aldosterone excess, it is more than ever 
important to diagnose for primary aldosteronism. Funder at al. have proposed clinical practice 
guidelines for patient identification, screening and confirmatory tests, subtype testing and 
management of PA (Fig. 8). Identification of potential PA patients involves symptoms like 
severe hypertension which is drug resistant, young age at presentation of hypertension or 
family history of hyperaldosteronism (Funder et al., 2016). High plasma aldosterone to renin 
ratio (ARR), meaning hyper aldosterone secretion despite suppressed renin in circulation, in 
such potential cases is the first indication of possible PA. ARR ratio ≥20 ng/dl per ng/ml per 
hour (555 pmol/l per ng/ml per hour) along with a plasma aldosterone concentration (PAC) 
of ≥15 ng/dl (416 pmol/l) is the criteria for positive screening of primary aldosteronism 
(Mattsson and Young, 2006). If required, these patients then undergo further confirmatory 
tests such as oral sodium intake, SIT, Captopril (ACE inhibitor) and FST, followed by 
lateralisation of PA. 
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Fig. 8: Schematic representation of diagnosis and treatment of primary aldosteronism. 
CT: Computed tomography, MRI: Magnetic resonance imaging, APA: aldosterone producing adenoma; BAH: 
Bilateral adrenal hyperplasia; ACE: Angiotensin converting enzyme. Summarised from (Funder et al., 2016; 
Stowasser and Gordon, 2016). 
 
1.4.1 Lateralisation of APAs 
Traditionally abdominal thin-slice CT and MRI were used to detect adenomas in adrenal for 
PA diagnosis, but are more suitable only for classical Conn’s adenomas larger than 1cm in 
diameter and cannot differentiate between an APA and non-functioning incidentalomas 
common in patients >40 years of age. Also, if adenomas are within the whole adrenal are very 
commonly missed with these detection methods. To overcome these limitations, adrenal vein 
sampling (AVS) for both adrenals is the gold standard for detecting functioning adenomas and 
lateralisation to either side (Funder et al., 2008). Aldosterone to cortisol ratio is analysed for 
both left and right adrenal veins in addition to that in peripheral blood from inferior vena cava 
(IVC). High aldosterone to cortisol ratio confirms diagnosis for PA and unilateral or bilateral 
condition. Despite its merits over CT/MRI imaging techniques, AVS also has limitations. It is 
invasive, technically challenging especially for the right side due to its small size, and 
expensive. Stress prior to procedure induces ACTH levels which can fall down at the time of 
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sampling leading to underestimated aldosterone and cortisol secretion and the ratio. Also 
presence of APA co-secreting both aldosterone and cortisol can skew the AVS results missing 
the PA diagnosis. Recently, detection of sub-centimetre APAs has become easier by PET-CT 
using C11-labelled metomidate, a potent inhibitor of both CYP11B1 and CYP11B2 (Azizan et 
al., 2013; Burton et al., 2012; Powlson et al., 2015). Lateralisation of APAs by this method was 
found to be in consistency with that from AVS. Its utility was first demonstrated by specific 
uptake of C11-metomidate in adrenals of several primates (Bergström et al., 1998). In humans, 
only cortical tumours were shown to be positive for C11-metomidate labelling as compared to 
non-cortical tumours (Bergström et al., 2000). This method is non-invasive and faster than 
AVS with only limitation that is the short half-life of only 20min of the label C11. To overcome 
this issue, some centres are testing more stable radio-labelled I123-metomidate (Hahner et al., 
2008; Kreissl et al., 2013). 
 
1.4.2 Management of PA 
Surgical removal of unilateral APAs and adjacent adrenal gland is the first choice of curing 
primary aldosteronism as it improves hypertension in almost 100% of the cases. It has been 
shown to significantly reduce proteinuria and left ventricular size, improving cardiovascular 
events (Funder et al., 2016). If the condition is diagnosed not to be unilateral (that’s BAH or 
bilateral APA) or patient is not fit or willing for adrenalectomy, it needs to be managed 
medically. First line of recommended drugs in such cases is MR antagonists - spironolactone 
or eplerenone (Funder et al., 2016) to reduce the cardiovascular morbidity because of 
aldosterone excess. Combined therapy of spironolactone with amiloride (ENaC blocker) is also 
recommended so as to minimise the dose-dependent side-effects of spironolactone such as 
gynecomastia in males, menstrual irregularity, breast inflammation, erectile dysfunction etc. 
because ultimately synthesis of aldosterone in ZG cells require opening of calcium channels 
to raise intracellular Ca2+ levels, calcium channel blockers seem like good candidates for 
managing PA, but again selective CaV1.3 blocker would be needed to prevent cardiovascular 
CaV1.2 blockage with existing dihydropyridines (DHP).  
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1.5 APAs: subtypes, somatic mutations and prevalence 
Aldosterone-producing adenoma (APAs) are benign tumours originating in adrenal cortex and 
account for more than one-third of PA cases (Young, 2007). Existence of histologically distinct 
types of APAs (ZG-like and ZF-like APAs) has been known for long time (Ganguly, 1992; Tunny 
et al., 1991) but it was not until recently that somatic mutations in specific genes (Table 1) 
were associated with the two subtypes (Azizan et al., 2012a, 2013). APAs resembling ZF of 
adrenal cortex have large, lipid-laden cells and are generally larger (>2cm) than ZG-like APAs, 
which are smaller (1cm) and comprised of compact, lipid-sparse cells. Somatic mutations in 
the gene KCNJ5 were first reported by Choi et al. (Choi et al., 2011) and have since been found 
in various cohorts around the world with varying prevalence (Table 2). The mutations lie in 
KCNJ5 or near the selectivity filter of the G-protein regulated inward rectifying K+ channel, 
Kir3.4 though which K+ ions move freely. Histologically, APAs with KCNJ5 mutations resemble 
those in the ZF-like category. On the other hand, smaller ZG-like APAs frequently possess 
somatic mutations in CACNA1D, ATP1A1 & ATP2B3. The ZG-like and ZF-like APAs not only 
differ histologically and genetically, but also in their transcriptomes (Azizan et al., 2013). 
Despite this homogenous cellular composition of most APAs, very recently steroidogenic 
enzyme expression and genetic heterogeneity within the APAs has been found and studied 
(Nakamura et al., 2015; Nanba et al., 2016). Nearly in all cohorts KCNJ5 mutant, ZF-like large 
APAs tend to be more common in females, patients presenting at younger age compared to 
ATPases and CACNA1D mutant APAs that are more frequently found in male patients (Azizan 
et al., 2013; Beuschlein et al., 2013; Boulkroun et al., 2012). 
 
A regulated aldosterone secretion from ZG cells is maintained by highly regulated Ca2+ 
concentration in the cytoplasm, mainly by Ca2+ entry via L- and T-type calcium channels on 
the cell membrane. These voltage-gated calcium channels (VGCCs) open in response to cell 
membrane depolarisation as a result of several stimuli. These include inhibition of TASK (K+ 
channels) via AngII activated AT1R receptor, resulting in elevated intracellular K+ levels and 
membrane depolarisation. Efflux of K+ via Kir3.4/GIRK4 (KCNJ5), a G-protein activated inward 
rectifier K+ channel, maintains resting membrane potential to hyperpolarised states at which 
calcium channels remain closed (Fig. 9a). Mutations in or near the selectivity filter of 
Kir3.4/GIRK4 lead to unselective Na+ influx, depolarisation and calcium channel opening (Fig. 
9b). Mutations in Na+/K+ ATPase subunit -1 (ATP1A1) cause the loss of its physiological 
function of maintaining the concentration gradient of Na+ and K+ ions and hence results in 
depolarisation (Fig. 9) (Azizan et al., 2013; Beuschlein et al., 2013). Ca2+ ATPase3 (ATP2B3) 
maintains low cytoplasmic calcium concentration by pumping Ca2+ ions out of the cell (Fig. 
9a), but mutations in this protein also lead to its loss of function and increase in intracellular 
calcium (Fig. 9b) (Beuschlein et al., 2013). Most of the studied mutations in CACNA1D result 
in gain-of-function of the pore-forming 1-subunit of L-type calcium channel CaV1.3. Mutated 
CaV1.3 channels exhibit higher calcium conductance and altered current-voltage relationship 
29 
 
 
reflected by channel opening even at hyperpolarised membrane potentials (Fig. 9b) (Azizan 
et al., 2013; Scholl et al., 2013). As a result APA cells with mutations in any of these genes 
have persistent Ca2+ entry and upregulated CYP11B2 transcription.  
 
In addition to somatic mutations in APAs, germline mutations in KCNJ5, CACNA1D and 
CACNA1H, encoding the T-type calcium channel CaV3.2, have been associated with the familial 
forms of primary aldosteronism. Several germline mutations in KCNJ5 reported in cases of 
familial hyperaldosteronism III are same as the somatic mutations in APAs, for example 
E145Q, G151R and T158A (Monticone et al., 2013, 2015; Scholl et al., 2012). Those never 
reported in APAs and only germline include G151E and Y152C. Two de novo CACNA1D 
germline mutations, G403D and I750M both in the residues reported somatically in APAs 
were found in 2 patients with hypertension from birth and are associated with the multi organ 
syndrome known as primary aldosteronism, seizures and neurologic abnormalities (PASNA) 
(Scholl et al., 2013). Five cases of early onset of hypertension were found to be heterozygous 
for gain-of-function M1549V variant in CACNA1H (Fig. 9b), which leads to hyper aldosterone 
secretion in vitro but the mutation did not segregate with the phenotype (Reimer et al., 2016; 
Scholl et al., 2015). 
 
Very recently two independent groups reported novel germline mutations in gene CLCN2, 
encoding a voltage gated chloride channel in cases of familial hyperaldosteronism type II and 
early onset of primary aldosteronism (Fernandes-Rosa et al., 2018; Scholl et al., 2018). 
Altogether, 6 variants were reported in 9 probands and those studied in vitro showed gain-
of-function phenotype in mutant ClC-2 channels with increased efflux of Cl- ions leading to 
membrane depolarisation and hyper aldosterone secretion. 
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Fig. 9: Proposed model for constitutive aldosterone secretion from APAs with somatic mutations. 
a. Physiological roles of wild-type KCNJ5, ATP1A1, ATP2B3, CACNA1D & CACNA1H channels/transporters in a 
normal ZG cell. b. Effect of somatic mutations* in APAs and germline only mutations** in CACNA1H (CaV3.2) in 
early onset primary aldosteronism is shown. Adapted from (Monticone et al., 2014).  
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Table 1: Reported somatic mutations in APAs. 
Gene Mutation Reference 
KCNJ5 
G151R (Choi et al., 2011) 
T158A (Choi et al., 2011) 
L168R (Choi et al., 2011) 
I157del (Azizan et al., 2012b) 
E145K (Azizan et al., 2013) 
W126R (Fernandes-Rosa et al., 2014) 
A139_F142dup (Hardege et al., 2015) 
E147Q (Wang et al., 2015) 
149_150insTTT (Wang et al., 2015) 
A153_F164dup (Wang et al., 2015) 
ATP1A1 
F100_L104del (Beuschlein et al., 2013) 
L104R (Beuschlein et al., 2013) 
V332G (Beuschlein et al., 2013) 
EETA963S (Azizan et al., 2013) 
G99R (Fernandes-Rosa et al., 2014) 
M102_I106del (Åkerström et al., 2015) 
F959_E961del (Åkerström et al., 2015) 
E960_L964del (Åkerström et al., 2015) 
F956_E961del (Åkerström et al., 2015) 
M102_L103del (Åkerström et al., 2015) 
L103_M104del (Åkerström et al., 2015) 
ATP2B3 
L425_V426del (Beuschlein et al., 2013) 
V426_V427del (Beuschlein et al., 2013) 
L424_V425del (Fernandes-Rosa et al., 2014) 
T423_L425del (Åkerström et al., 2015) 
L424_V426del (Åkerström et al., 2015) 
V426_V429del (Åkerström et al., 2015) 
CACNA1D 
V259D (Azizan et al., 2013) 
G403R (8A) (Azizan et al., 2013) 
I750M/I770M (Azizan et al., 2013; Scholl et al., 2013) 
F747L (Azizan et al., 2013) 
R990H (Azizan et al., 2013) 
P1336R (Azizan et al., 2013) 
M1354I (Azizan et al., 2013) 
G403R (8B) (Scholl et al., 2013) 
G403D (8B) (Scholl et al., 2013) 
L655P (Fernandes-Rosa et al., 2014) 
S652L (Fernandes-Rosa et al., 2014) 
Y741C (Fernandes-Rosa et al., 2014) 
F747V (Fernandes-Rosa et al., 2014) 
I750F (Fernandes-Rosa et al., 2014) 
V979D (Fernandes-Rosa et al., 2014) 
K981N (Fernandes-Rosa et al., 2014) 
A998I (Fernandes-Rosa et al., 2014) 
A998V (Fernandes-Rosa et al., 2014) 
V1151F (Fernandes-Rosa et al., 2014) 
I1152N (Fernandes-Rosa et al., 2014) 
V1338M (Fernandes-Rosa et al., 2014) 
V401L (Åkerström et al., 2015) 
V748I (Wang et al., 2015) 
32 
 
 
1.5.1 Prevalence of mutations in known genes 
Prevalence rates of somatic mutations in APA candidate genes have been reported in several 
studies in different cohorts (Table 2).  KCNJ5 is the first causative gene discovered in APAs 
(Choi et al., 2011), and is therefore, the most sequenced gene in all cohorts with nearly 
complete prevalence estimates, ranging from 36-80%. A study by Lenzini et al. employed 
meta-analysis of 13 such reports to find overall prevalence of KCNJ5 mutations in APAs and 
any associated clinical features that might help predicting KCNJ5 genotype for a patient pre-
operatively (Lenzini et al., 2015). They reported overall prevalence of 44% KCNJ5 mutant 
APAs, which varied significantly between Caucasian and Asian (China and Japan) cohorts with 
prevalences of 35% and 63%, respectively. This huge difference among populations was 
attributed to high dietary salt intake in Asian population compared to Caucasian diet, 
probably predisposing them to more frequent genetic alterations and somatic mutations. 
Among clinical features, no significant differences in the blood pressure and serum K+ levels 
were found in patients with KCNJ5 mutant APAs compared to non-mutants, except for 
confirming some of the previous observations that KCNJ5 mutant APAs were larger in size and 
more often found in females, younger patients, and led to higher aldosterone levels in plasma 
compared to the non-mutants (Azizan et al., 2013; Beuschlein et al., 2013; Boulkroun et al., 
2012).  
 
Prevalence data of mutations in other genes is not as much complete because they are not 
sequenced for in most studies and hence less reliable to make any conclusions. When 
sequenced, mutations in CACNA1D gene has been reported in up to 10% cases, ATP1A1 in 
5.3% and ATP2B3 in <2% cases in a combined European cohort (ENSAT, excluding UK) 
(Fernandes-Rosa et al., 2014). One possible reason for apparent low prevalence of these 
genes could be cases that go undetected on routine CT/MRI scans due to their small size.  
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Table 2: Reported prevalence of somatic mutations in different cohorts. 
Centre 
Sample 
size 
(n) 
Mutant APAs (%) 
Reference 
KCNJ5 ATP1A1 ATP2B3 CACNA1D CTNNB1 
Uppsala 22 36.0 NS NS NS NS (Choi et al., 2011) 
UK 46 43.5 NS NS NS NS (Azizan et al., 
2012b) Australia 27 37.0 NS NS NS NS 
US 47 38.0 NS NS NS NS 
(Monticone et al., 
2012) 
ENSAT 474 38.0 5.3 1.7 9.3 NS 
(Fernandes-Rosa et 
al., 2014) 
Uppsala 36 69.4 2.8 5.6 0.0 NS 
(Åkerström et al., 
2015) 
Dusseldorf 33 45.5 3.0 0.0 0.0 NS 
Halle 8 50.0 0.0 0.0 0.0 NS 
Lubeck 20 65.0 10.0 5.0 0.0 NS 
Sydney 34 41.2 5.9 0.0 8.8 NS 
Stockholm 34 55.9 11.8 5.9 5.9 NS 
        
China 114 75.4 0.0 0.0 0.9 NS (Wang et al., 2015) 
China 168 76.8 2.4 0.6 0.6 NS (Zheng et al., 2015) 
Taiwan 148 59.5 1.4 0.7 0.0 NS (Wu et al., 2015) 
Taiwan 219 52.9 1.4 0.5 0.0 3.7 (Wu et al., 2017) 
Japan 23 65.2 NS NS NS NS 
(Taguchi et al., 
2012) 
Japan 47 78.7 NS NS NS NS 
(Okamura et al., 
2017) 
        
Meta-
analysis 
1636 44.3 NA NA NA NA 
(Lenzini et al., 2015) 
Europe  35.0 NA NA NA NA 
Asia  63.0 NA NA NA NA 
ENSAT: European Network for the Study of Adrenal Tumours; NS: Not sequenced; NA: Not analysed 
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1.6 Aims of the study 
The somatic mutations in CACNA1D have been shown to cause gain-of-function phenotype in 
the electrophysiological properties of CaV1.3. It is hypothesised that expression of these 
mutant CaV1.3 channels would increase intracellular calcium and aldosterone secretion in 
vitro by human adrenocortical carcinoma cell line, H295R. Role of endogenous CaV1.3 in non-
mutated state has not been studies previously. The primary aim of this project was to 
investigate if and how it regulates physiological aldosterone secretion. Determination of 
CaV1.3 as the main source of sustained calcium entry for regulated and/or autonomous 
aldosterone secretion led our interest towards its potential as a valuable and novel 
therapeutic target for treatment of primary aldosteronism.  project with 
 aimed at screening millions of compounds that would selectively block CaV1.3 over other 
ion channels, especially  to minimise unwanted cardiovascular side-effects. This 
selective molecule would be expected to block aldosterone production in APAs. This would 
be of significant value in treating patients with resistant hypertension driven by APAs, not 
only with CACNA1D mutations, but also those without CACNA1D mutations, by blocking 
unregulated Ca2+ influx altogether despite membrane depolarisation due to other 
dysfunctional ion channels.  
 
And the secondary aim, was to genotype all APAs in the available cohort that is enriched for 
smaller ZG-like APAs and likely to have fewer ZF-like APAs with KCNJ5 mutations.This study 
included 59 APAs from 52 patients (7 patients had 2 nodules). Genotyping was done partially 
by Sanger sequencing for known genes and by next-generation sequencing of whole exomes 
in genomic DNA extracted from paired normal adrenal and APAs. As we could detect many 
small APAs by PET-CT scans using C11-metomidate which are usually missed on routine CT 
scans, we expected to find more cases of CACNA1D, ATP2B3 or ATP1A1 mutants compared 
to KCNJ5 and hence differences in the mutational prevalence of these genes as reported 
globally. We also envisaged to find some novel genes with somatic mutations which would be 
of interest, to understand the phenotype of hyper aldosterone secretion. Discovery of novel 
somatic mutation in CADM1 gene led to an investigation of its role in aldosterone producing 
adrenal cells. 
 
  
 
 
 
CHAPTER 2 
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CHAPTER 2 -  MATERIALS AND METHODS 
 
2.1 General methods 
2.1.1 Reagents and antibodies 
Table 3: List of TaqMan Probes used for expression analysis 
Gene 
Symbol 
Target Isoform Assay ID 
Pre-designed or 
Custom made 
CACNA1D CaV1.3 (Total) Hs01073321_m1 Pre-designed 
CACNA1D CaV1.3-2137 Hs01080346_m1 Pre-designed 
CACNA1D CaV1.3-2181 Hs01073303_m1 Pre-designed 
CACNA1C CaV1.2 (Total) Hs00167681_m1 Pre-designed 
CACNB2 2 (Total) Hs00167861_m1 Pre-designed 
CACNB2 2a Hs01100746_m1 Pre-designed 
CACNB2 2d AJ39RUG Custom made 
CACNB2 2e Hs01110867_m1 Pre-designed 
CACNB3 3 Hs00893804_g1 Pre-designed 
CADM1 - Hs00942509_m1 Pre-designed 
GJA1 - Hs00748445_s1 Pre-designed 
18s rRNA - 4319413E Pre-designed 
CYP11B2 mouse Mm01204955_g1 Pre-designed 
 
Human CYP11B2 probe and primers –  
Probe: [FAM]-CTGCACCACGTGCTGAAGCACT-[TAM] 
Forward primer: 5’-GCAGAGGCAGAGATGCTG-3’ 
Reverse primer: 5’-CTTGAGTTAGTGTCTCCACCAGGA-3’ 
Drugs and reagents - Angiotensin II (Sigma, A9525), Calpeptin (Sigma, C8999), PMA 
(Calbiochem, 524400), LY-411,575 (Sigma, SML0506). 
Primary antibodies used are listed in Table 4. 
Secondary antibodies used for immunocytochemistry were all purchased from Molecular 
Probes®, Life Technologies for various species (anti-mouse, anti-rabbit, anti-chicken or anti-
goat) conjugated to Alexa Fluor – 405, 488, 568, 633 & 647. 
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Table 4 : List of primary antibodies used 
Antibody against Supplier Cat # 
Stock 
concentration 
Species 
Monoclonal/
Polyclonal 
Isotype 
Conc. 
Used* 
CaV1.3 (against 
intracellular C-
terminal domain) 
[named as 
CaV1.3-CT] 
NeuroMab N38/8 0.2mg/ml Mouse Mono IgG1 1:300 
CaV1.3 (against 
intracellular loop 
in pore forming 
domain) [named 
as CaV1.3-NT] 
NeuroMab L48A/9 0.2mg/ml Mouse Mono IgG2a 1:300 
CaV1.3 (against 
intracellular C-
terminal domain) 
[named as 
CaV1.3-CTsc] 
SantaCruz sc-25687 0.2mg/ml Rabbit Poly  1:500 
CADM1 (against 
intracellular C-
terminal domain) 
Sigma S4945 1.5mg/ml Rabbit Poly  1:1000 
CADM1 (Clone 
3E1 against 
ectodomain) 
MBL Japan CM004-3 1mg/ml Chicken Mono IgY 1:2000 
Connexin-43 Sigma C6219 0.5mg/ml Rabbit Poly  1:1000 
Aquaporin2 
Novus 
Biologicals 
NB110-
74682SS 
0.16mg/ml Rabbit Poly  1:100 
FLAG M2 Sigma F1804 1mg/ml Mouse Mono IgG1 1:2000 
Myc-tag (71D10) 
Cell Signalling 
Technology 
2278 NA Rabbit Mono IgG 1:1000 
turboGFP Origene TA150041 1mg/ml Mouse Mono IgG2b 1:2000 
EGFP Abcam ab5450 0.5mg/ml Goat Poly  1:2000 
-Actin Sigma A2066 0.5mg/ml Rabbit Poly  1:5000 
GAPDH Sigma G8795 1mg/ml Mouse Mono  1:2000 
CYP11B2 
Prof Celso E. Gomez-Sanchez (Mississippi) 
(Gomez-Sanchez et al., 2014) 
Mouse Mono IgG1  
* indicated dilutions were used for both immunostaining of cultured cells and tissues and western blotting. 
 
2.1.2 Human adrenal tissue collection and processing 
Adrenal tissues from patients who underwent adrenalectomy at Addenbrooke’s hospital were 
collected via Human Tissue Bank facility. These patients were operated on following diagnosis 
of Primary Aldosteronism. All tissues were obtained with approval from the Cambridgeshire 
2 Research Ethics Committee and written informed consent from each patient prior to 
surgery. APAs and corresponding adjacent normal adrenal tissue were dissected by the 
histopathologists and depending on the availability were collected as 3 different samples for 
further processing – 1) fresh frozen in liquid N2 and stored at -80C; 2) a piece immersed in 
RNALater® solution for 24hrs at 4C to preserve total RNA and stored at -80C after removing 
the solution; and 3) in complete cell culture media for isolation of primary cells by digestion 
with collagenase. 
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2.1.3 H295R and primary cell culture 
H295R cells were routinely grown and maintained in DMEM F-12/HAM media supplemented 
with 10% fetal-calf serum, 1% ITS (insulin, transferrin & sodium selenite), 1% L-glutamine, and 
1% penicillin-streptomycin at 37C in the presence of 5% CO2.  
 
Human adrenal primary cells from normal or APA tissue were also cultured in fully 
supplemented DMEM F-12/HAM media like H295R cells. On receipt of tissue pieces post-
adrenalectomy, APAs were minced finely and adjacent normal adrenal was dissected to 
remove fat and medulla as much as possible before mincing using sterile scalpel. Minced 
tissue samples were transferred to 50ml falcon tubes and digested with 3.3mg/ml collagenase 
in complete media. Tubes were incubated in 37C water-bath for up to 2hr while shaking to 
disperse cells by digestion of connective tissue. Falcon tubes were vortexed vigorously and 
centrifuged at 800rpm for 3min. Pelleted cells were resuspended in fresh complete media 
and transferred to cell culture flasks. Primary cells take about a week to recover and attach 
to the surface. Cell were trypsinised and plated for any experiments that could be done at the 
time or frozen in liquid nitrogen for future use.  
 
2.1.4 Genomic DNA extraction 
Genomic DNA (gDNA) from normal adrenal and APA samples was extracted using QIAamp 
DNA Mini kit (51304, Qiagen) according to manufacturer’s instructions. Up to 25mg tissue 
was used per sample and DNA was eluted in 200l nuclease-free water. All DNA samples were 
quantified with Nanodrop ND-1000 spectrophotometer (ThermoScientific). 
 
2.1.5 Sanger sequencing 
Targeted gDNA regions were amplified using specific primers and up to 100ng total DNA in a 
25l reaction according to the instructions for GoTaq® G2 Flexi DNA Polymerase (M7805, 
Promega). PCRs were performed using a touchdown PCR program with decreasing annealing 
temperature from 68C to 60C over 16 cycles (TD_68_60). Amplified PCR products were 
analysed on agarose gel and treated with a mixture of exonuclease and shrimp alkaline 
phosphatase enzymes (Exo-SAP) to remove excess primers and nucleotides for 1hr at 37C 
before setting up sequencing reaction. 5l cleaned PCR product with either forward or 
reverse primer was amplified using BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied 
Biosystems) in a 10l reaction. Sequencing reaction products were cleaned using magnetic 
beads and analysed on 3730 DNA Analyser (Applied Biosystems). In case of plasmid DNA 
sequencing, initial PCR and Exo-SAP steps were not required. 50-100ng of purified plasmid 
was directly subjected to sequencing reaction with appropriate primer and run on the 
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analyser. Sequencing results were analysed using DNA variant analysis tool Mutation Surveyor 
(SoftGenetics). 
 
2.1.6 RNA extraction from human tissues 
Tissue samples preserved in RNALater® solution (AmbionTM, Life Technologies) and stored in 
-80C were used for RNA extraction. Total RNA was extracted from about 50-100 mg normal 
adrenal tissue and APAs, using PureLink® RNA Mini Kit with Trizol® (AmbionTM, Life 
Technologies) according to manufacturer’s protocol. Tissues were dissected and 
homogenised in at least 9 times the volume of Trizol® in TissueLyser LT (Qiagen) at 4C. Prior 
to elution, RNA on column was treated with DNase (Qiagen) to digest the genomic DNA 
contamination. Final RNA was eluted in 50μl nuclease-free water and quantified with 
Nanodrop. 
 
2.1.7 RNA extraction from cultured cells 
Total RNA was extracted from freshly cultured cells using PureLink® RNA Mini Kit (AmbionTM, 
Life Technologies) according to manufacturer’s protocol. Cells were lysed in the lysis buffer 
containing -mercaptoethanol from the kit. Prior to elution, RNA on column was treated with 
DNase (Qiagen) to digest the genomic DNA contamination. Depending on the starting cell 
number, final RNA was eluted in 30-50μl nuclease-free water and quantified with Nanodrop. 
 
2.1.8 cDNA synthesis 
Single stranded complementary DNA (cDNA) was synthesised from total RNA extracted using 
AMV reverse transcriptase from Reverse Transcription System (A3500, Promega). Up to 1μg 
(or 8.9μl) RNA was reverse transcribed in a total 20μl reaction. In case of tissue samples, equal 
amount of RNA was used for every paired normal and APA samples. For cell culture 
experiments, equal RNA was used for all samples in an experiment in order to achieve 
comparative Ct values for house-keeping gene, 18s in qPCRs. Mix of 8.9μl RNA with 0.5μg of 
Oligo(dT)15 and Random primers each in total volume of 10.9μl was incubated at 70C for 
10min and cooled to 4C. Once cool following reagents were added to make final reaction of 
20μl. 
MgCl2, 25mM      4.0μl 
Reverse Transcription 10X Buffer   2.0μl 
dNTP Mixture, 10mM     2.0μl 
Recombinant RNasin®Ribonuclease Inhibitor  0.5μl 
AMV Reverse Transcriptase (25u/l)   0.6μl (15u/g RNA) 
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This reaction was incubated in thermal cycler at 22C for 15 min, 42C for 1 h, and 95C for 5 
min. cDNA was diluted with nuclease-free water 5 times to final volume of 100μl prior to qPCR 
reaction setup. 
 
2.1.9 Real Time – quantitative PCR and data analysis 
Gene (mRNA) expression in cDNA was quantified using pre-designed or custom made TaqMan 
probes (Applied Biosystems) for targets listed in respective chapters. Duplicate qPCR 
reactions were set up for each sample with every target probe. 15l reaction comprised of 
7.5l Fast Advanced TaqMan® Gene Expression Master Mix, 2X (Applied Biosystems), 0.75l 
TaqMan probes, 20X (Applied Biosystems), 2-5l diluted cDNA and 1.75-4.75l nuclease-free 
water. qPCR plates were run on ABI 7900 Real-time PCR system. 
 
Threshold cycle number (Cт value) was automatically calculated by the software in the 
exponential phase of amplification. Duplicates were averaged and ΔCт was calculated by 
subtracting house-keeping gene, 18s Cт from target gene Cт for normalisation. 2-ΔCтx107 
values were used to express relative gene expression for paired normal and APA samples and 
2-ΔΔCт method was used for analysis of gene expression in cell culture experiments. 
 
2.1.10 Immunohistochemistry 
Formalin-fixed paraformaldehyde embedded (FFPE) tissue sections of human normal adrenal 
and/or APA for immuno-staining were prepared at Human Tissue Bank at Addenbrooke’s 
hospital. FFPE sections were deparaffinised before antigen retrieval was performed. This was 
achieved by two sequential 10min incubations of slides in Histo-Clear II solution followed by 
two washes in 100% methanol for 5min each. Slides were further washed in 90% and 70% 
methanol for 5min each. Slides were rinsed once in Milli-Q water and boiled in R-Universal 
antigen retrieval buffer (Aptum Biologics) placed in pressure steamer, 2100-Retriever (Aptum 
Biologics) for 30min followed by cooling for 2hrs before proceeding with staining procedure 
by either method.  
 
2.1.10.1 DAB method 
After antigen retrieval, sections were stained by colorimetric method using EnVision®+Dual 
Link System-HRP (DAB+) kit (K4065, Dako) according to manufacturer’s instructions. This kit 
contains horseradish peroxidase (HRP) labelled polymer conjugated to anti-mouse and anti-
rabbit secondary antibodies, making it suitable for staining with any mouse or rabbit origin 
primary antibodies. Briefly, endogenous peroxidase activity was blocked by incubation with 
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the Dual Endogenous Enzyme Block solution for 10mins, followed by a 5min wash in PBS. 
Sections were incubated with appropriately diluted primary antibodies in the Antibody 
Diluent (S0809, Dako) for 30min in a humid chamber at room temperature. Negative control 
slides were incubated with the diluent only. All slides were washed with PBS for 5min and 
incubated with HRP-labelled Polymer for 30min and washed again with PBS for 5 min. 
Substrate-Chromogen solution containing DAB+ chromogen was used to develop brown 
coloured precipitate for up to 10min under observation. No colour development was 
observed in the negative control slides. Chromogen solution was washed off promptly from 
all slides using deionised water and Haematoxylin counterstaining for nuclei was performed 
by incubating in Mayer’s Haematoxylin solution (MHS1, Sigma) for 5min. Slides were dipped 
8 times in destain solution containing 50% methanol and 1% HCl followed by dipping in tap 
water for development of blue nuclei stain. Slides were dehydrated in gradient methanol 
solutions in the reverse order as deparaffinisation and hydration. Slides were finally mounted 
using Histomount (National Diagnostics) and curated for 24hrs in a fume extractor hood. 
Slides were scanned at 40x magnification using Aperio scanner at the Tissue Bank and 
analysed using Aperio ImageScope (Leica Biosystems). 
 
2.1.10.2 Immunofluorescent staining  
If needed, sections were incubated with 2ug/ml wheat germ agglutinin (WGA)-Alexa 
Fluor®633 (W21404, ThermoFisher) for 5min at room temperature and washed twice in PBS. 
Sections were permeabilised using 0.05% Triton X-100 in PBS (PBST) for 5min at room 
temperature and washed with PBS. Non-specific binding was blocked by incubating sections 
in 2% BSA-PBS for 2hrs at room temperature in a humid container. Sections were washed 
once with PBS and incubated with appropriately diluted primary antibodies in 1% BSA-PBS 
overnight at 4C in humid container. Slides were washed with PBST for 5min while agitation 
and incubated with 1:500 diluted different Alexa Fluor®-conjugated secondary antibodies 
(ThermoFisher) in 1% BSA-PBS for 2hrs at room temperature. Slides were again washed in 
PBST for 5mins and mounted with ProLong Diamond mounting media with DAPI (P36966, 
ThermoFisher). After at least 24hrs of curating slides at 4C, slides were scanned for 
immunofluorescence using Axioscan Z1 Slidescanner (Zeiss) and analysed using software Zen 
Blue Edition (Zeiss). 
 
2.1.11 Plasmids used and their propagation 
Various vector plasmids used in this study are listed in Table 5. 
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Table 5: List of plasmids and vectors used. 
Plasmid Source Use 
Antibiotic 
resistance  
E. Coli strain 
used 
pCR-
Blunt® 
TOPO 
Zero Blunt® PCR 
Cloning Kit 
(ThermoFisher) 
Initial TOPO cloning of CaV1.3 fragments 
which were later assembled into pcDNA3.1 
vector. 
Kanamycin NEB Stable 
pcDNA3.1 
Prof Sadaf 
Farooqi’s Lab (IMS) 
Cloning of N-terminally Flag-tagged full-
length CaV1.3 cDNA for overexpression in 
H295R cells. 
Ampicillin NEB Stable 
pIRES2-
AcGFP1 
Prof Sadaf 
Farooqi’s Lab (IMS) 
Cloning of C-terminally Myc-tagged 2d and 
2e cDNA for overexpression in tsA-201 
cells. There is AcGFP cDNA expression 
under IRES sequence. 
Kanamycin NEB Stable 
pENTR™/D
-TOPO 
pENTR™/D-TOPO® 
Cloning Kit 
(ThermoFisher) 
Entry vector for initial cloning of CADM1 
cDNA with a C-terminal Myc-tag for 
gateway cloning into lentiviral pLOC 
plasmid. 
Kanamycin 
OneShot 
Top10 
pLOC 
Prof Celso Gomez-
Sanchez (University 
of Mississippi) 
2nd generation lentivirus expression vector 
for CADM1 containing tGFP under IRES 
sequence as marker of 
transfection/transduction. 
Ampicillin NEB Stable 
pLVTH 
Didier Trono 
(Addgene# 12262) 
2nd generation lentivector for expression 
of shRNA under H1 promoter and GFP as 
marker. 
Ampicillin NEB Stable 
psPAX2 
Didier Trono 
(Addgene# 12260) 
2nd generation lentiviral packaging 
plasmid. 
Ampicillin 
Received as 
bacterial 
stab. 
pMD2.G 
Didier Trono 
(Addgene# 12259) 
VSV-G envelope expressing plasmid for 
producing lentivirus. 
Ampicillin 
Received as 
bacterial 
stab. 
 
 
2.1.12 Lentivirus production and titration 
HEK293T cells were cultured in complete media (high glucose DMEM supplemented with 10% 
FBS, antibiotics and L-glutamine) in a 75cm2 flasks up to the confluency of 60-70%. At the time 
of transfection culture media was gently replaced with 8ml of fresh DMEM F-12/HAM media 
supplemented with 10% FBS, but no antibiotics (media appropriate for the target H295R or 
primary adrenal cells). Cells were co-transfected with 2g of psPAX2 (packaging plasmid), 1g 
of pMD2.G (VSV-G envelope expressing plasmid) and 4g of pLOC (over-expression of cDNA) 
or pLVTH (shRNA) constructs using 21l of 1mg/ml PEI transfection reagent 
(Polyethylenimine-Max, 24765, Polysciences). The mix of plasmid DNAs and PEI were diluted 
into 800l of serum-free DMEM media and incubated at room temperature for 15min before 
adding to the cells dropwise. As both pLOC and pLVTH plasmids contained GFP coding 
sequence as markers of transfection efficiency, GFP fluorescence was observable at 24hrs. 
48hrs from transfection, lentivirus containing culture media was collected from the flask and 
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stored in fridge. Fresh 8ml antibiotic-free DMEM F-12/HAM was gently added to the cells for 
another 24hr incubation to enhance lentivirus production. At 72hrs, media from the flask and 
media collected at 48hrs were pooled for lentivirus concentration procedure. 
 
About 16ml of lentivirus containing media was centrifuged at 2,000rpm for 5min at 4C and 
supernatant was filtered through 0.45M PVDF filters using a 20ml syringe. Cleared 
supernatant was concentrated about 70-fold to 230l lentivirus stock by centrifugation in 
Amicon-15 30k filters (Millipore) at 4,000xg for 30min at 4C. Concentrated lentivirus was 
stored at -80C as 20-30l aliquots. 
 
Prepared lentivirus was titrated using flow cytometry to estimate the concentration of 
transducing units in the stock by calculating percentage of GFP positive cells using method 
described by Kutner and colleagues as a guideline (Kutner et al., 2009). H295R cells were 
plated at a density of 8x104cells/well in 24-well plates. 24hrs later, total number of cells in a 
well were counted by trypsinising 3-4 wells. This number is the number of cells at the time of 
transduction. Media in rest of the wells was replaced with 250l of complete media 
containing 8g/ml Polybrene (Hexadimethrine bromide, 107689, Sigma). 15, 10, 5, 2 or 1l 
each of lentivirus to be titrated was added to a well. Some wells were kept un-transduced as 
controls. Transduced cells were incubated at 37C for 20hrs and lentivirus containing media 
was replaced with fresh complete media. Cells were incubated for another 2 days, by when 
transduced cells expressed GFP and fluorescence was observed. All transduced and un-
transduced control cells were trypsinised and resuspended in 150l PBS. This cell 
resuspension was subjected to flow cytometry on BD FACSCanto II (BD Biosciences) to collect 
data for every condition and percentage of GFP+ cells was analysed using Flowing software 
(Perttu Terho, Turku Centre for Biotechnology, Finland). Finally, lentivirus titre was expressed 
as transducing units (TU)/ml using formula TU/ml=(FxNx1000)/V, where F is the percentage 
of GFP+ cells, N is the number of cells at the time of transduction and V is the volume (l) of 
lentivirus added to each well for transduction. 
 
2.1.13 Lentivirus transduction 
H295R or primary adrenal cells were plated in 48 or 96-well plates at a density of 
5x104cells/well in 250l or 2x104cells/well in 100l complete media respectively. 24hrs later, 
lentiviral particles were added at multiplicity of infection (MOI) of 2-5 in the presence of 
8g/ml Polybrene in complete media. Culture media containing lentivirus was replaced with 
fresh complete media after 20hrs incubation. Depending on the experiment, transduced cells 
were either starved overnight at 72hrs with nil media for drug stimulations or harvested for 
RNA or protein at the time point of 96hrs. 
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2.1.14 Immunocytochemistry and confocal imaging 
H295R cells were grown on coverslips and transfected/transduced with appropriate 
constructs. When required, plasma membrane marker WGA-Alexa Fluor® 633 was used at 
2ug/ml in complete media for 10 mins at 37C and rinsed with PBS twice. Cells were fixed 
with 4% paraformaldehyde (PFA) or chilled methanol for 10mins at room temperature and 
washed with PBS thrice. Cells were permeabilised using 0.1% Triton X-100 in PBS (PBST) for 
5min at room temperature and washed twice with PBS. Cells were blocked with 3% BSA-PBST 
for 1hr at room temperature and washed once with PBS. Cells were incubated with 
appropriately diluted primary antibodies in 3% BSA-PBST for overnight at 4C. Cells were 
washed thrice with PBS and incubated with appropriate secondary antibody diluted in 3%BSA-
PBST for 1hr at room temperature. Cells were washed thrice with PBS and coverslips were 
mounted in Vectashield with DAPI (Vector Laboratories) on slides. After at least 24hrs of 
curating slides at 4C, confocal imaging was performed on 510 Meta (Ziess) or SP8 (Leica) 
confocal microscopes. 
 
2.1.15 Drug treatments on H295R and primary cells 
Drug treatments on H295R and primary adrenal cells were always performed after an 
overnight starvation step in the serum-free media. Starved cells were incubated with 
appropriately diluted drugs and corresponding vehicle controls for 24hr, unless indicated 
otherwise. In the experiments of drug treatments on H295R cells transduced with lentivirus, 
starvation was performed at 72hrs from transduction followed by addition of drugs for 24hrs. 
Except for angiotensin II, all drugs used were dissolved in DMSO of which the final 
concentration in cell culture media was kept to 0.1% or less, if possible. Angiotensin II stock 
at 1mM was prepared in sterile water and further dilutions were made in PBS. 
 
2.1.16 Aldosterone assay 
Conditioned media from cultured cells was collected into fresh plates and centrifuged to 
remove any dead cells. 10l of cleared media sample was assayed for aldosterone 
concentration using HTRF based Aldo assay kit (Cisbio Bioassays) according to manufacturer’s 
instructions. When required, cell lysis buffer was added to original cell culture plate for total 
protein estimation by BCA assay for normalisation of aldosterone concentrations and 
represented as pM/ug. Within an experiment, aldosterone assays data is represented as 
aldosterone levels relative to control condition. 
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2.1.17 Protein assay and Western blotting 
H295R or HEK293 cells in plates were rinsed with PBS and lysed in minimum volume of the 
chilled cell lysis buffer required. Lysis buffer used contained freshly added protease inhibitor 
cocktail solution. Cells were incubated in lysis buffer on ice briefly to ensure complete lysis 
and lysates were transferred to 1.5ml microfuge tubes. Lysates were cleared of any cell debris 
by centrifugation at 13,000xg for 20min at 4C. Cleared supernatant was transferred to fresh 
tubes and total protein concentration was estimated. 
 
In case of adrenal tissues (normal adrenal and APAs), samples were minced in lysis buffer as 
much as possible and transferred to 2ml microfuge tubes. Tissue samples were homogenised 
by brief shaking periods in the TissueLyser LT (Qiagen) using 5mm Stainless Steel Beads 
(Qiagen) at 4C. Homogenised lysate was transferred to fresh 1.5ml tubes and centrifuged at 
13,000xg for 20min at 4C. Supernatant was transferred to fresh tubes and total protein 
concentration was estimated. 
 
Total protein concentration was estimated by using Pierce™ BCA Protein Assay Kit (23227, 
ThermoFisher) according to manufacturer’s instructions. The assay is a colorimetric assay 
using detection of cuprous ions (Cu1+) by bicinchoninic acid (BCA). Briefly, most cell lysates 
were diluted 10-15 times in lysis buffer for the protein assay. Protein standards were prepared 
by 1:2 serial dilutions of 2mg/ml BSA stock solution. 10l protein standards or diluted samples 
were added to flat bottom 96-well plate. Reagent A was diluted in Reagent B at a 
concentration of 1:50 and mixed well. 80l of this protein assay reagent was added to each 
well of standards or samples. Plates were sealed and incubated at 37C for 20min for purple 
colour development. The assay plate was analysed in the plate reader for absorbance at 
562nm wavelength. Sample protein concentration was calculated by interpolated values from 
the linear standard curve obtained.  
 
Depending on the protein of interest, SDS-PAGE and western blotting protocols were 
optimised and varied to obtain best possible results. These variable protocols are explained 
in relevant sections. 
 
2.1.18 Statistics analysis 
Analysis was performed using GraphPad Prism 7 software. All data are presented as the mean 
 standard error or mean (s.e.m.). Differences among the groups were analysed using a one- 
or two-way ANOVA, followed by the Dunnett’s test to determine whether the groups were 
different from a control group, or the Sidak’s test to compare multiple pairs in groups. 
 
 
 
CHAPTER 3 
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CHAPTER 3 -  ROLE OF L-TYPE CALCIUM CHANNEL, 
CaV1.3 IN ALDOSTERONE SECRETION 
 
3.1 Abstract 
Prior to the discovery of CACNA1D mutations, L-type Ca2+ channels were not considered 
important in regulation of aldosterone production. Since our lab's discovery of four somatic 
mutations in CACNA1D, over 30 single-base change mutations have been reported in this 
gene, which encodes the 1 subunit of an L-type Ca2+ channel (LTCC), CaV1.3. All mutations 
found initially, and several subsequent mutations cause gain-of-function in the 
electrophysiological properties with increased activation and/or slowed inactivation of 
CaV1.3. I investigated if the mutations in CaV1.3 influence aldosterone production, and 
whether the role of the CaV1.3 is confined to states of aldosterone excess, or crucial in 
physiological aldosterone regulation too. 
 
Firstly, the most predominant transcripts for CaV1.3 and the auxiliary -subunit in the human 
adrenals, APAs and the adrenocortical carcinoma cell line, H295R was determined. This was 
necessary to study the functional consequences of CaV1.3 mutants in the presence of 
appropriate -subunit. CaV1.3 transcript that is 2137 amino acids long and contains exon 8A 
makes most of the channel expressed. 2d splice variant of 2 subunit encoded by CACNB2 
was found to be the most predominant isoform expressed in normal adrenals and APAs. 
Compared to the adjacent normal adrenal glands of the same patients, CaV1.3-2137aa and 2 
expression was upregulated only in the ZG-like APAs, and not in ZF-like APAs. 2e was 
upregulated in the ZG-like APAs. Due to differences in their N-termini sequences 2d and 2e 
exert distinct modulatory effects on 1 channel kinetics. No significant differences were found 
in 2 subunit mediated voltage dependence of activation of WT or mutant V259D CaV1.3, but 
only inactivation properties were influenced by the type of 2 variant co-expressed. 2e, the 
membrane-associated subunit, abolished the fast inactivation of only V259D CaV1.3, 
compared to that seen in the presence of non-membrane associated 2d subunit. Two of the 
CaV1.3 mutations studied led to increased aldosterone secretion in H295R cells.  
 
Secondly, the role of endogenous, non-mutant CaV1.3 in aldosterone secretion was 
investigated. Nuclear localisation of intracellular c-terminal of CaV1.3 in H295R brought our 
attention to its potential role as transcription factor.  Its susceptibility to calpain-mediated 
cleavage was confirmed by increased levels of full-length CaV1.3 protein detected in H295R 
cells treated with calpeptin, a calpain inhibitor. Calpeptin treatment also inhibited 
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aldosterone secretion. Consistent with these observations was the nuclear localisation of 
overexpressed C-terminal chain of CaV1.3 resulting in increased aldosterone secretion. 
Though target genes for CaV1.3’s C-terminal as transcription factor were not investigated, its 
significant role in aldosterone secretion was ascertained by 50% reduction in CYP11B2 
expression in the adrenals of CaV1.3-/- mice compared to wild-type animals. 
 
Lastly, with the  project, scientists at  conducted a high-throughput 
screening of CaV1.3-expressing cells against their 1.8 million compound library. The lower 
resting membrane potential of -80mV to -60mV in aldosterone producing adenoma cells 
(especially with CACNA1D mutation) that is more negative than other tissues was exploited 
in the compound screen. This screen led to 3 tool compounds (A, B & C) that were selective 
antagonists for CaV1.3 over  in high-throughput electrophysiological experiments. Of 
these 3 compounds, I found compound B the most effective in inhibiting aldosterone 
secretion in both H295R and primary cells isolated from normal adrenals. This finding is a 
significant step in developing compound B further into a CaV1.3-selective drug for treating PA 
patients without cardiovascular side effects as in the case of existing dihydropyridine class of 
Ca2+ channel blockers. 
 
In this study, we have not only shown CaV1.3 is crucial for physiological aldosterone secretion, 
but also discovered a novel mechanism that it might fulfil this significant role by acting as a 
transcription factor in addition to calcium entry point. Discovery of compound B, a potential 
selective antagonist for CaV1.3 proves promising as a translational application of CACNA1D 
mutations in primary aldosteronism and possibly other CaV1.3 channelopathies like 
Parkinson’s disease and autism.  
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3.2 Introduction 
3.2.1 L-type calcium channels 
As the name suggests, voltage-gated calcium channels (VGCCs) are ion channels through 
which Ca2+ ions enter the cells from external medium. These channels open in response to 
depolarisation of the membrane potential and are present in all excitable cells, like neurons 
and endocrine cells. For the CaV1 (L-type) and CaV2 (P/Q-, N- & R-types) families, the 
functional calcium channel is a heteromeric protein structure formed by a principal pore-
forming 1 subunit with auxiliary  (1-4) and 2 (2-1 - 2-4) subunits. These auxiliary 
subunits regulate channel trafficking to the cell membrane and modulate its 
electrophysiological properties. CaV3 (T-type) channels are believed not to require these 
auxiliary subunits.  Depending on the presence of one of the many 1 subunit types present, 
the voltage-dependence (high or low voltage activation) and kinetics of the channel are 
determined. All channels exhibit distinct properties and are differentially expressed in various 
cell/tissue types, from neurons to skeletal and cardiac muscles to endocrine glands. 
 
CaV1.3 is the 1 subunit that forms an L-type calcium channel, where L stands for long-lasting 
inward calcium currents through these channels. Like every 1 subunit, CaV1.3 also has a 4 
homologous repeat structure (I-IV), with each repeat consisting of 6 transmembrane -
helices. The fourth transmembrane helix (S4), containing positively charged amino acids, of 
each repeat along with S1-S3 act as the voltage sensor domain of the channel, whereas S5 & 
S6 together with their linker loop, line the pore of the channel. 
 
 subunits, encoded by CACNB1-CACNB4, are cytoplasmic proteins containing a Src homology 
3 (SH3) and an inactive guanylate kinase (GK)-like domain (McGee et al., 2004). They interact 
with the 1 subunit at the intracellular loop between repeats I and II. This interaction is 
required not only for increased channel trafficking to the plasma membrane, but also for 
channel activation and inactivation (Findeisen and Minor, 2009; Yamaguchi et al., 2000). 
 
2 subunits, encoded by genes CACNA2D1-CACNA2D4, interact with the 1 subunit at its 
extracellular domains. Post-translation, 2 subunits are cleaved into 2 and  subunits in a 
proteolytic reaction. The 2 subunit localises extracellularly but remains bound by a 
disulphide bond to the  subunit that is itself anchored to the plasma membrane either by a 
short transmembrane domain or glycosyl-phosphatidylinositol (GPI)-anchor. Expression of 
2 has an additive effect on the enhanced membrane expression and channel conductance 
of 1 subunit in the presence of  subunits (Yamaguchi et al., 2000). 
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3.2.2 Regulation of CaV1.3 channel kinetics 
Alternative splicing of any expressed gene is a well-recognised phenomenon that adds to 
molecular diversity of structural and functional proteins. Of all CaV1 channels, alternative 
splicing of rat CaV1.3 at its C-terminal is best described. Depending on the length and specific 
domains present in the C-terminal splice variant, it can be categorised as a “long” or “short” 
isoform (Xu and Lipscombe, 2001). In addition to pre-IQ and IQ domains, the “long” isoforms 
also contain proximal C-terminal regulatory domain (PCRD) and distal C-terminal regulatory 
domain (DCRD) domains forming C-terminal modulatory domain (CTM), that is lacking in 
“short” isoforms (Singh et al., 2008). Calcium-free calmodulin (apoCaM) binds to the IQ 
domain that is followed by calcium binding to apoCaM/IQ complex when intracellular or local 
intracellular Ca2+ concentration increases, initiating a negative feedback mechanism 
described as calcium-dependent inactivation (CDI) of the channel. Inactivation of channels is 
of critical importance in protection of cells from Ca2+ overload in conditions of long 
depolarisation. The DCRD competes with CaM for binding to the IQ domain resulting in weak 
CDI in the transcripts containing the full length CTM domain. 
 
Compared to CaV1.2, CaV1.3 is 20-fold less sensitive to nimodipine, a dihydropyridine (DHP) 
and activates at 25mV more hyperpolarised potentials (Xu and Lipscombe, 2001). These 
differences are further exaggerated due to alternative splicing in the C-terminal domain of 
CaV1.3 that not only regulates its CDI, but also extends to DHP sensitivity (Huang et al., 2013) 
and voltage-dependent activation characteristics (Singh et al., 2008) of various transcripts. 
DHP sensitivity was reported to be inversely related to CaM/IQ binding mediated CDI. Long 
variants with weak CDI (e.g. CaV1.342) are more prone to DHP blockade compared to short 
variants with strong CDI (e.g. CaV1.342a) (Huang et al., 2013). CaV1.342a, with truncated C-
terminal domains activates much faster at more negative voltages compared to CaV1.342 
(Singh et al., 2008). This is more likely due to the absence in short transcripts of the inhibitory 
effect that CTM has on coupling of voltage-sensor S4 movement with the S5-S6 lined pore 
opening (Lieb et al., 2014). 
 
Another form of regulation of CDI of CaV1.3 was reported by Huang et al. in rodent brain and 
isolated primary neurons. This unique mechanism, RNA editing is the post-transcriptional 
modification of adenosine-to-inosine (A to I) in mRNA sequence which translates into 
alternative amino acids. This phenomenon is reported in many proteins and recently in CaV1.3 
too. It occurs in the IQ domain of CaV1.3 producing proteins with modified amino acid 
sequences like MQDY, IQDC or MQDC as opposed to unedited IQDY. CaV1.3 channels with 
edited IQ domain sequences were shown to exhibit weakened CDI by reducing the CaM 
affinity for PCRD in the C-terminus (Huang et al., 2012). 
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In addition to calcium-dependent inactivation calcium channels exhibit voltage-dependent 
inactivation (VDI) which is triggered by the same membrane depolarisation that initially 
activates and opens the channel. As the name suggests VDI reduces the open probability of 
calcium channels during long or subsequent membrane depolarisations. Similar to CDI, one 
of the major regulators of VDI is the associated  subunit (Cens et al., 1999). All  subunits, 
except for membrane bound 2a, have been demonstrated to promote VDI of the channels 
(Buraei and Yang, 2010). 
 
3.2.3 Expression and pathophysiology of CaV1.3 
Along with CaV1.2, CaV1.3 is expressed in many excitable cells in brain and heart. Platzer et al. 
generated CaV1.3 null mice by inserting neomycin resistance gene within the exon 2 in the 
reverse strand by homologous recombination. This led to introduction of multiple stop 
codons in all 3 frames and hence translation into a truncated peptide.  
 
These CaV1.3 knockout mice showed abnormal cochlear morphology due to degeneration of 
outer hair cells of ears. Complete loss of Ca2+ currents in inner hair cells led to complete 
hearing loss in the absence of CaV1.3 (Platzer et al., 2000). It is also expressed in the heart, 
particularly in the pacemaker cells of sinoatrial node (SAN) and atrioventricular node (AVN) 
where it plays a significant role in the pace-making activity as revealed by reduced heart rate 
and cardiac arrhythmia in CaV1.3 null mice (Mangoni et al., 2003).  These phenotypes are 
replicated in humans suffering from SAN dysfunction and deafness (SANDD) syndrome due to 
a loss of function mutation, G403dup in CACNA1D (Baig et al., 2011).  
 
In addition to the somatic mutations in 5 APAs, Scholl et al. reported 2 cases of de novo 
germline mutations, G403D and I770M in CACNA1D. These patients were diagnosed with 
neurological disorders and hypertension from birth, with elevated aldosterone levels despite 
suppressed plasma renin activity (PRA) (Scholl et al., 2013). This multi organ syndrome has 
been termed as primary aldosteronism, seizures and neurologic abnormalities (PASNA). Three 
de novo mutations in CACNA1D - G407R, A749G and V401L were reported in the patients 
suffering from autism spectrum disorder and epilepsy (Pinggera et al., 2015, 2017). Similar to 
the most somatic mutation in APAs, all these de novo germline mutations result in gain of 
function of CaV1.3 with a shift in voltage dependence of activation and inactivation to more 
negative voltages and reduced channel inactivation.  
 
Increased mitochondrial oxidative stress due to CaV1.3-mediated increased Ca2+ currents in 
the dopaminergic neurons has been implicated in cell death associated with Parkinson’s 
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disease. Surmeier et al. presented some evidence of preventing cell death in the substantia 
nigra neurons (SNc) by using low doses of dihydropyridines to inhibit CaV1.3 as a potential 
therapeutic target for treatment of Parkinson’s disease (Surmeier et al., 2011).  
 
CaV1.3 probably plays a role in the regulation of aldosterone secretion but its endocrine 
function is studied in more detail in pancreas and adrenal medulla. It plays a critical role in 
the proliferation of pancreatic  cells (Namkung et al., 2001), but there are no evidences of 
impaired insulin secretion or difference in the plasma glucose levels of the knockout mice, 
which could be due to compensatory increased expression of CaV1.2 (Platzer et al., 2000). 
CaV1.3’s pace-making role was also evident in the normal firing of action potentials in mouse 
chromaffin cells (MCCs), which was reduced in the MCCs from CaV1.3 knockout mice 
(Marcantoni et al., 2010). This pace-making activity of chromaffin cells is essential for normal 
secretion of catecholamines from adrenal medulla.  
 
3.2.4 Role as transcription factor 
It has been reported that the C-terminal of CaV1.2 is cleaved to generate calcium channel 
associated transcription factor (CCAT) which translocates to nucleus regulating expression of 
itself and various other proteins in neurons and cardiomyocytes (Gomez-Ospina et al., 2006, 
2013; Schroder et al., 2009). A similar phenomenon is recently reported for CaV1.3 acting as 
transcriptional regulator in atrial myocytes, where its cleaved C-terminal translocates to 
nucleus in a directly regulated manner by levels of intracellular Ca2+. CaV1.3 c-terminal 
upregulates the expression of MLC2, myosin light chain 2 (Lu et al., 2015), which plays an 
important role in the regulation of myosin ATPase activity and is required for the surface 
expression of Ca2+ activated K+ channels (SK2) in myocytes. Cleaved c-terminal is believed to 
be exported out of nucleus when intracellular calcium increases, possibly to inhibit the 
channel activity and also to alter gene transcription. The proteolytic cleavage of CaV1.1 in 
skeletal muscles and CaV1.2 in hippocampal neurons is mediated by proteases of calpain 
family (Hell et al., 1996) at an alanine residue downstream of PCRD (Hulme et al., 2005). 
Calpain2, CAPN2 is the most predominantly expressed of all calpains in the adrenal cortex 
(Shaikh et al., 2015; Zhou et al., 2015). It is important to note that despite high conservation 
of putative cleavage site sequence among CaV1.1, CaV1.2 and CaV1.3, there was no evidence 
of proteolytic cleavage of CaV1.3 in mice brain homogenates (Scharinger et al., 2015). The 
cleavage of c-terminal domain modulates the channel activity by removal of DCRD which 
normally competes with calmodulin for binding to PCRD. Properties of the residual CaV1.3 
channel activity were not studied (Lu et al., 2015), but cleaved CaV1.2 is reported to carry 
more current due to lack of auto-inhibitory c-terminal domain (Hulme et al., 2006). 
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3.2.5 Calcium channels in adrenals 
Microarray analysis for calcium channels’ subunits expression in human adrenals revealed 
1D (CaV1.3), 2-1 and 2 to be the most predominant of all types (Table 6) (Shaikh et al., 
2015; Zhou et al., 2015). Until recently, the low voltage activated T-type calcium channel 
CaV3.2 was thought to be the primary mode of Ca2+ entry into the ZG cells, activating 
downstream pathways for aldosterone synthesis and secretion (Cohen et al., 1988; Payet et 
al., 1994). But discovery of gain-of-function somatic mutations in the gene CACNA1D provided 
evidence for critical role of the L-type calcium channel, CaV1.3 in this system (Azizan et al., 
2013; Scholl et al., 2013). More recently, a germline gain-of-function mutation M1549V in 
CACNA1H, the gene encoding CaV3.2 was discovered in 5 patients with the onset of 
hypertension with PA by the age of 10 years (Scholl et al., 2015). The mutated channel 
exhibited slower activation and inactivation resulting in increased calcium entry.  
 
Table 6: Microarray expression data for Ca2+ channel subunits in ZG and ZF of adrenal cortex. 
Subunit Type Gene ID log2 expression 
CaV1.3) CACNA1D 6.36 
 CACNA2D1 6.15 
 CACNB2 5.90 
CaV3.2) CACNA1H 3.83 
 CACNG8 3.58 
CaV3.3) CACNA1I 3.15 
 CACNB3 3.12 
 CACNB1 2.99 
 CACNB4 2.84 
 CACNA2D4 2.74 
 CACNG7 2.73 
 CACNG4 2.72 
 CACNG1 2.64 
 CACNG6 2.63 
CaV2.2) CACNA1B 2.53 
CaV1.4) CACNA1F 2.52 
CaV2.3) CACNA1E 2.52 
CaV1.2) CACNA1C 2.51 
CaV3.1) CACNA1G 2.47 
CaV2.1) CACNA1A 2.46 
 CACNA2D2 2.44 
 CACNA2D3 2.44 
CaV1.1) CACNA1S 2.44 
 CACNG5 2.34 
 CACNG2 2.25 
 CACNG3 2.18 
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For a number of years ZG cells were believed to be electrically unexcitable (Quinn et al., 1987), 
but Hu et al. provided evidence for their electrical activity in intact glomeruli structures. They 
argued that Ca2+ release from intracellular stores is insufficient for sustained aldosterone 
secretion from ZG cells and continuous Ca2+ entry from extracellular media is essential (Hu et 
al., 2012). This would normally be not possible in isolated ZG cells that are too hyperpolarised 
(at -80mV, very close to K+ equilibrium) in resting conditions to favour opening of any calcium 
channels (Quinn et al., 1987; Spät, 2004). They demonstrated ZG cells within the intact 
glomeruli structures in mouse adrenal slices were electrically excitable and had intrinsic 
oscillations of membrane potential facilitating periodic calcium entry. These oscillations in the 
membrane potential are sensitive to Ni2+ but not nifedipine, indicating a more important role 
of CaV3.2 over CaV1.3 in the pacemaker activity in mouse ZG cells (Barrett et al., 2016; Hu et 
al., 2012).  
 
3.2.6 CaV1.3 antagonists 
Various classes of calcium channel blockers (CCBs) used are dihydropyridines (nifedipine, 
isradipine, nimodipine, amlodipine, etc.), phenylalkylamines (e.g. verapamil) and 
benzothiazepines (e.g. diltiazem), which bind reversibly to different subunits of calcium 
channels inhibiting calcium entry. DHPs are the major class of these drugs that bind close to 
the pore-forming domains of the 1 subunit of L-type calcium channels, inducing inactivated 
state of the channel. DHPs are not selective and inhibit all CaV1.1– CaV1.4 with variable 
affinities. In general among all LTCCs, CaV1.2 is the most sensitive to DHPs, making them first 
choice of treatment for hypertension by targeting CaV1.2 in cardiovascular tissues. Verapamil 
and diltiazem also inhibit calcium channels by blocking the calcium entry pore.  
 
In patients with resistant hypertension (PA) aldosterone receptor antagonist, spironolactone, 
is the only drug used at the moment but has its limitations due to its affinity for androgen and 
progesterone receptors. The dose and efficacy of spironolactone is limited in male patients 
because of its side-effects causing gynaecomastia and sexual dysfunction. It also causes 
menstrual irregularities in female patients. Eplerenone, also an MR antagonist is more 
selective with fewer sex-related side effects can also be used, but is more expensive in many 
countries. 
 
3.2.6.1 Compound 8 
The lower sensitivity of CaV1.3 for DHPs makes them less favourable for CaV1.3 specific 
blockade as required in conditions such as Parkinson’s disease or primary aldosteronism. 
Higher doses of DHPs required for blocking CaV1.3 would potentially lead to deleterious 
cardiovascular side effects because of unwanted CaV1.2 blockade. In an attempt to find a 
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selective CaV1.3 antagonist, Kang et al. used a small molecular screen and discovered a 
pyrimidinetrione (PYT), 1-(3-chlorophenethyl)-3-cyclopentylpyrimidine-2,4,6-(1H,3H,5H)-
trione, named as compound 8 to be 600-fold selective antagonist for CaV1.3 over CaV1.2 in a 
fluorescent imaging plate reader (FLIPR) assay on HEK293 cells stably expressing these 
calcium channels (Kang et al., 2012). But soon contradictory reports emerged suggesting 
compound 8 belongs to a new class of LTCCs agonist rather than antagonist as it increased 
overall Ca2+ currents by slowing activation, inactivation and tail currents of CaV1.3 (Ortner et 
al., 2014). Another group then provided evidence for selectivity of compound 8 being highly 
dependent on the type of  subunit present in the system (Huang et al., 2014). They found 
compound 8 inhibited CaV1.3 only modestly and only in the presence of non-membrane 
associated  subunits (1, 3 or 4) but not the palmitoylated 2a. Also currents though CaV1.2 
were inhibited to greater extent in the presence of 2a than those through CaV1.3 (Huang et 
al., 2014). Our group studied the effect of compound 8 on aldosterone secretion from H295R 
and primary adrenal cells (Xie et al., 2016). We found that at 1M concentration, compound 
8 stimulated aldosterone secretion in H295R cells which express both CaV1.3 & CaV1.2, but 
not in primary cells mainly expressing CaV1.3. At higher concentrations of 10 and 100M 
aldosterone was inhibited in both cell types, similar to a commonly used dihydropyridine, 
nifedipine. 
 
3.2.7 CaV2 subunit 
CaV2 subunit is encoded by the CACNB2 gene that was first cloned along with CACNA1D 
(CaV1.3) in 1992 using a human hippocampal cDNA library (Williams et al., 1992). In following 
years five alternatively spliced variants 2a-2e were cloned and studied for their influence 
on functional properties of the 1 subunit of L-type calcium channels (Allen and Mikala, 1998; 
Yamaguchi et al., 2000).  These five transcripts vary in sequence at their N-terminal due to 
alternative splicing of the first and/or second exons (Fig. 10) (Takahashi et al., 2003). 2 
transcripts are expressed in all excitable tissues, like brain and heart, and are developmentally 
regulated (Table 7). 
 
Heterologous expression of recombinant 2 splice variants in HEK293 cells demonstrated their 
differential sub-cellular localisation to be the key factor influencing their modulatory roles on 
L-type calcium channel kinetics. 2a and 2e localise to plasma membrane constitutively even 
in the absence of 1 subunit, whereas 2b, 2c and 2d remain in the cytoplasm (Takahashi et 
al., 2003). This preferential localisation of 2a and 2e subunits slows the voltage-dependent 
inactivation of LTCCs as compared to when expressed with any of 2b-2d. The 2a variant 
remains plasma membrane bound due to palmitoylation of two cysteine residues present in 
its N-terminal (Chien et al., 1996). On the other hand, 2e is recruited to plasma membrane 
by electrostatic forces between two amino acid residues (positively charged lysine and 
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hydrophobic tryptophan) in its N-terminal and anionic phospholipids of the membrane (Kim 
et al., 2015; Miranda-Laferte et al., 2014). Neither of these two characteristic features for 
plasma membrane localisation are present in the N-termini of 2b-2d. 
 
 
Fig. 10: Alternative splicing of 2 subunit transcripts. 
Green arrows show translational initiation sites for each transcript and membrane associated 2a & 2e are 
shown in red. Adapted from (Takahashi et al., 2003) 
 
Table 7: Tissue distribution of 2 subunit transcripts 
(Buraei and Yang, 2010) 
2 Tissue distribution 
β2 
Expressed in brain (hippocampus–becoming the most abundant isoform there, 
cerebellum, pontine nucleus, susbtantia nigra, central grey, habenula, pineal gland, 
thalamic nuclei, cerebrum), heart, lung, nerve endings at the NMJ, T cells, and 
osteoblasts, but not in kidney, liver, pancreas, or spleen. Brain expression is constant 
during development. 
β2a 
Expressed in brain, heart, and aorta; its heart and brain levels seem lower than other β 
subunits and isoforms. 
β2b Expressed in brain, heart, and aorta. It is the most abundant β in human heart. 
β2c 
Expressed in brain and heart, where it is the second most abundant β. Its expression 
declines in adults. 
β2d,e Expressed in heart. β2e expression is robust only in young animals. 
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3.2.8 Aims and Hypotheses 
The somatic mutations in CACNA1D have been shown to cause gain-of-function phenotype in 
the electrophysiological properties of CaV1.3 (Azizan et al., 2013; Scholl et al., 2013). It is 
hypothesised that expression of these mutant CaV1.3 channels would increase intracellular 
calcium and aldosterone secretion in vitro by human adrenocortical carcinoma cell line, 
H295R.  
 
Role of endogenous CaV1.3 in non-mutated state requires detailed investigation to establish 
if and how it regulates physiological aldosterone secretion. 
 
Determination of CaV1.3 as the main source of sustained calcium entry for regulated and/or 
autonomous aldosterone secretion led our interest towards its potential as a valuable and 
novel therapeutic target for treatment of primary aldosteronism.  
 aimed at screening millions of compounds that would selectively block CaV1.3 over 
other ion channels, especially  to minimise unwanted cardiovascular side-effects. This 
selective molecule should be able to block aldosterone production in APAs. It would be of 
significant value in treating patients with resistant hypertension driven by APAs, not only with 
CACNA1D mutations, but also those without CACNA1D mutations, by blocking unregulated 
Ca2+ influx altogether despite membrane depolarisation due to other dysfunctional ion 
channels.   
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3.3 Materials and methods 
3.3.1 Molecular cloning and site directed mutagenesis 
3.3.1.1 CaV1.3 in pcDNA3.1 
Total cDNA from H295R cells was used to amplify coding sequence for any one of the 3 long 
transcripts of CaV1.3 in 3 fragments with overlapping sequences using specific primers listed 
in Table 8. All fragments were amplified using Q5 DNA polymerase 2X master mix and cloned 
into pCR-Blunt® TOPO vector of Zero Blunt® PCR Cloning Kit (Invitrogen). Several clones were 
screened for each fragment and sequence verified.  
 
Table 8: Primers used for CaV1.3 cDNA amplification 
Amplicon Primer Name Sequence 
Amplicon 
size (bp) 
Amp-1 
CaV1.3-Start-F ATGATGATGATGATGATGATGAAAA 
2227 
CaV1.3-R5 GAATATAGTTACCACAAATGAAG 
Amp-2 
CaV1.3R5-F CTTCATTTGTGGTAACTATATTC 
2242 
CaV1.3-F11-R CTTTGCCTCAGGGTCATATTCTG 
Amp-3 
CaV1.3-F11 CAGAATATGACCCTGAGGCAAAG 
1991 
CaV1.3-Stop-R CTACAAGGTGGTGATGCATATCA 
 
 
Coding sequence for FLAG-tag was added in the forward primer for first fragment that will 
produce N-terminally FLAG-tagged protein. TOPO construct with CaV1.3-Amp1 was used as 
template to produce FLAG-tagged fragment that was later used in Gibson assembly reaction. 
 
KpnI-FLAG-BamHI-CaV1.3-F 
GTTGGTACCGCCACCATGGATTACAAGGATGACGACGATA
AGGGATCCATGATGATGATGATGATGATGAAAA 
 
FLAG-CaV1.3-Amp1 PCR product and TOPO constructs with CaV1.3-Amp2 & CaV1.3-Amp3 
were used as templates to amplify overlapping fragments compatible with the Gibson 
assembly kit (NEB) using primers shown in Table 9. The assembly reaction was set up using 
0.25pmoles each of 3 purified PCR products and pcDNA3.1 vector (digested with KpnI and 
XhoI). Total 1pmole DNA fragments were mixed with 2X Gibson Assembly mix and incubated 
at 50C for 1hr followed by transformation into Stable Competent E. coli (NEB) according to 
manufacturer’s instructions. Clones were screened and sequence verified to a final construct 
of FLAG-CaV1.3 in pcDNA3.1. The insert cDNA of CaV1.3 corresponded to 2137 amino acid long 
transcript (NM_001128839). 
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Table 9: Primers used for CaV1.3 Gibson Assembly 
Amplicon Primer Name Sequence 
Amplicon 
size (bp) 
GAmp-1 
KpnI-FLAG-
CaV1.3-GA1_F 
TTTAAACTTAAGCTTGGTACCGCCACCATGGATTACAAG 
2274 
CaV1.3-GA1_R ACAAATGAAGAGGATGATGAAGTAGATGC 
GAmp-2 
CaV1.3-GA2_F TCATCATCCTCTTCATTTGTGGTAACTATATTCTAC 
2239 
CaV1.3-GA2_R TCATATTCTGACCATATTCTTTTGAATTCATCTAAATG 
GAmp-3 
CaV1.3-GA3_F AGAATATGGTCAGAATATGACCCTGAGG 
2026 
CaV1.3-XhoI-
GA3_R 
TTTAAACGGGCCCTCTAGACTCGAGCTACAAGGTGGTGATGCATATC 
 
3.3.1.2 CaV1.3 mutagenesis 
FLAG-CaV1.3 construct was used for generating 7 mutants using Q5 site-directed mutagenesis 
kit (NEB). Mutagenesis primers were designed using NEBaseChanger online tool (NEB) (Table 
10). Linear mutant PCR product was generated by Q5 DNA polymerase master mix, 2X (NEB) 
and treated with KLD enzyme mix for 5min at room temperature followed by transformation 
into Stable Competent E. coli (NEB) according to manufacturer’s instructions. 
 
Positive clones were selected on Ampicillin LB-Agar plates and verified by sequencing. 
 
3.3.1.3 2 constructs in pIRES2-AcGFP1 
Myc-FLAG-tagged 2c construct (pCMV6-Entry vector, NM_201571) was purchased from 
Origene Technologies, which served as the template for 2d (NM_201596) and 2e 
(NM_201570) constructs by mutagenesis using following primers (Table 11). 
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Table 10: List of CaV1.3 mutagenesis primers 
Mutagenesis Primer 
Sequence 
(lower case = mutant nucleotide) 
CaV1.3_V259D_F AGTTTACAAGaTGTCCTGAACTCC 
CaV1.3_V259D_R GGGCACTCCTGACACTAG 
CaV1.3_G403R_F TCTTGTACTTcGTGTATTGAGCG 
CaV1.3_G403R_R TTTAGTACGAAAAATGACCC 
CaV1.3_F747L_F TGAATGTCTTgTTGGCCATCG 
CaV1.3_F747L_R GTAGAATATAGTTACCACAAATG 
CaV1.3_I750M_F TCTTGGCCATgGCTGTAGACA 
CaV1.3_I750M_R AGACATTCAGTAGAATATAGTTACC 
CaV1.3_R990H_F AGGGTCCTGCaTCCCCTCAGG 
CaV1.3_R990H_R TAAGACCCTCAGAATCTTCACAACG 
CaV1.3_P1336R_F CAGGCGCTCCgGTATGTGGCC 
CaV1.3_P1336R_R AAAGGACTTAATAAAAGTCCACAGCAATG 
CaV1.3_M1354I_F TCATTGGCATaCAGATGTTTGG 
CaV1.3_M1354I_R CCGCATAGATGAAGAACAG 
 
 
Table 11: List of 2 mutagenesis primers 
Primer Sequence (Uppercase = target-specific primer) 
2d insert1 F 
cccacagcggcggcggcggtggcgcaggagTCATATGGAAAAGGAGCCAG
AAGGAAAAACAGATTTAAAGG 
2d insert1 R aggcgacttggacatgtccctttggaccatGGCGATCGCGGCGGCAGA 
2d insert2 F 
cccgcgggggcgctcggagccgccgcacagTCATATGGAAAAGGAGCCAG
AAGGAAAAACAGATTTAAAGGATCTG 
2d insert2 R agccacgttctctagcagttccatctggatCTCCTGCGCCACCGCCGC 
2e insert F 
caagggaggaaggctgaagaattctgatatctgtGGTTCGGCAGACTCCTAC
ACTAGC 
2e insert R gctcttttcagaagcctgatccaggtggccttcatGGCGATCGCGGCGGCAGA 
 
As before, Q5 site-directed mutagenesis kit and Stable Competent E. coli (NEB) were used 
according to manufacturer’s instructions. Once clones were verified by sequencing for 
presence of 2d or 2e complete ORF, they were sub-cloned, by Gibson assembly method, 
into pIRES2-AcGFP1 plasmid between EcoRI and BamHI restriction sites with a C-terminal 
Myc-tag. 
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3.3.1.4 CaV1.3 C-terminal cloning in pLOC 
To study the role of C-terminal of CaV1.3 in aldosterone secretion, this fragment was cloned 
in pLOC vector in 3 steps. Firstly, the pore-forming region of CaV1.3 was deleted from the full-
length CaV1.3 construct in pcDNA3.1 (described in 3.3.1.1) using NEB site directed 
mutagenesis kit. Resulting construct contained 682 amino acids corresponding to the 
intracellular c-terminal peptide sequence of CaV1.3 2137 amino acid long transcript 
(NM_001128839) with a FLAG tag on N-terminal, which was amplified for directional TOPO 
cloning in pENTR vector. At this stage, a Myc-tag sequence was added in the 3’ primer to 
generate “FLAG-CaV1.3 CT-Myc” construct in the Gateway cloning entry vector. All primers 
used in this cloning are listed in Table 12. Lastly, the recombination reaction was performed 
to transfer the ORF sequence from pENTR construct to pLOC vector using LR Clonase II enzyme 
mix (11791020, Invitrogen) according to manufacturer’s instructions. Recombined plasmids 
reaction was transformed into Stable competent cells (NEB) and selected on LB agar plates 
containing ampicillin. Positive clones were miniprep’d and sequence verified. Clones with 
correct sequences were maxiprep’d and used for preparing lentivirus by transfection of 
HEK293T cells. 
Table 12: CaV1.3 C-terminal cloning primers 
Primer name Primer Sequence 
CaV1.3-delPore-F ACCCGGGACTGGTCTATTTT 
CaV.3-delPore-R CATGGTGGCGGTACCAAG 
TOPO-FLAG-F CACCATGGATTACAAGGATG 
CaV1.3-CT-Myc-R 
GAATTCCTACAGATCTTCTTCGCTAATCAGTTTCTGTTCCAAGGTGGT
GATGCATATCATTTC 
 
The original pLOC plasmid which contains ccdB gene between attR cloning sites, was not 
recommended for transfection of mammalian cells. Therefore in addition to the CaV1.3CT 
construct in pLOC, a control vector was prepared by cloning puromycin resistance gene into 
pENTR and recombining with original pLOC. The PuroR-pLOC construct was used as the 
transfection control empty vector (EV) in this study. 
 
3.3.1.5 CaV1.3 shRNA in pLVTH 
shRNA sequences for scrambled (non-targeting control) or specific to CaV1.3 [shRNA1: 
CCGAATAGCTCCAAGCAAA and shRNA2: GGAAGACCCAGAGATACA, as used by (Samak et al., 
2011)] (Fig. 11) were inserted in the pLVTH vector using Q5 site-directed mutagenesis kit 
(NEB). Mutagenesis primers were designed using NEBaseChanger online tool (NEB) to insert 
shRNA, consisting of sense, loop and antisense sequences into the vector (Table 13). 
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a. 
 
b. 
 
Fig. 11: Sequences for scrambled (a) and CaV1.3 (b) shRNAs in pLVTH 
 
Table 13: CaV1.3 shRNA cloning primers 
Primer Name Primer sequence 
scrambled-F tccaacgaggttattacgtaaggtattTTTTTGGAAAAGCTTATCGATAC 
scrambled-R tccaacgaggttattacgtaaggtatccGGGGATCTGTGGTCTCAT 
shCaV1.3-1-F atccgtttgcttggagctattcggTTTTTGGAAAAGCTTATCGATACC 
shCaV1.3-1-R atcaatttgcttggagctattcggGGGGATCTGTGGTCTCATAC 
shCaV1.3-2-F atccgtgtatctctgggtcttccTTTTTGGAAAAGCTTATCGATACC 
shCaV1.3-2-R atcaatgtatctctgggtcttccGGGGATCTGTGGTCTCATAC 
 
Mutagenesis KLD reaction was used to transform NEB Stable E.coli and selected on LB agar 
plates containing ampicillin. Positive clones were miniprep’d and sequence verified. Clones 
with correct sequences were maxiprep’d and used for preparing lentivirus by transfection of 
HEK293T cells. 
 
3.3.2 Electrophysiology 
3.3.2.1 tsA-201 cell culture and transfection by Fugene 
tsA-201 cells were routinely grown and maintained in DMEM media (Gibco), supplemented 
with 10% fetal-calf serum, 1% L-glutamine and 1% penicillin-streptomycin at 37C in the 
presence of 5% CO2. 
tsA-201 cells were plated in 3.5cm cell culture dishes at about 50% confluency. 3-4hrs later 
cells were transfected with plasmid constructs for calcium channel subunits, 1::2-1:YFP 
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in the ratio of 3:2:2:0.4 g respectively using Fugene (Promega) according to manufacturer’s 
instructions and incubated at 37C in the presence of 5% CO2. 
 
3.3.2.2 Whole-cell patch-clamp electrophysiology 
48hrs post transfection, tsA-201 cells were replated in new 3.5cm cell culture dishes in 2ml 
complete medium. Generally transfected cells were lifted using cell dissociation medium 
(Gibco) and depending on the confluency 1/8th to 1/12th of cells were plated in new dishes 
and incubated at 37C in the presence of 5% CO2 for at least 2hrs. Cells were rinsed with whole 
cell patch clamping external solution containing 10mM CaCl2 or BaCl2 as indicated. CsCl buffer 
was used as the internal solution to fill 2-4M borosilicate glass electrodes. Cells positive for 
YFP fluorescence were patched for whole cell patch clamp recordings at room temperature 
and 70% compensated for series resistance and capacitance before any recordings were 
taken.  
 
Cells were held at a holding potential of −80mV before a step protocol of 50ms to different 
voltages was applied to determine the current-voltage (I-V) relationship. Currents were leak 
subtracted using a P/8 protocol. I-V curves were fitted to the equation 
I=Gmax(V−Vrev)/(1+exp−(V−V50)/k), where Vrev is the reversal potential, V the test potential, I 
the peak current, Gmax the maximum conductance, V50 the half-maximal activation voltage 
and k the activation slope factor. The voltage dependence of the Ca2+ or Ba2+ conductance 
was fitted according to a Boltzman distribution G=Gmax/(1+exp−(V−V50)/k) using GraphPad 
Prism 6 (GraphPad Prism software). 
 
The inactivation time course was measured during 1s depolarizations from −80mV to 
indicated voltages (-20 to 30mV) and r300 was calculated as the fraction of current remaining 
at 300ms from the start of the depolarisation step. 
 
The steady state inactivation was measured by applying pre-sweep conditioning voltages for 
5s and a subsequent 50ms test pulse to Vmax (30 s recovery between protocols). Inactivation 
was calculated as the ratio between the current amplitudes of the test pulses versus current 
amplitude at Vmax (I/IVmax). Steady-state inactivation parameters were obtained by fitting the 
data to a modified Boltzmann equation G=(1−Gmax)/(1+exp(V−V50)/k)+Gmax. 
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3.3.3 Transfection of H295R cells by electroporation 
Up to 5x106 cells were aliquoted and resuspended in 100l Mirus Ingenio electroporation 
solution (Mirus) per transfection and mixed with 3g of each plasmid DNA. Cells were 
electroporated in 0.2cm cuvettes in Amaxa Nucleofactor system (Lonza) using program T-20 
and diluted in serum-containing antibiotic-free media to plate 1.5x105 cells in 200l 
media/well of a 96-well plate. 
 
3.3.4 Western blotting 
According to the experiment and availability of total protein estimated by protein assay, 10-
40g cell lysate protein was diluted with the 4X NuPAGE™ LDS Sample Buffer (NP0007, 
ThermoFisher) and 10X NuPAGE® Sample Reducing Agent (NP0009, ThermoFisher). Samples 
were incubated at 37C for 5 min before running on NuPAGE™ 3-8% Tris-Acetate Protein Gels 
(ThermoFisher) in NuPAGE™ MOPS SDS Running Buffer (NP0001, ThermoFisher) at 150V for 
1hr at room temperature. 500l NuPAGE™ Antioxidant (NP0005, ThermoFisher) was diluted 
in 200ml running buffer in the upper chamber of running tank to prevent the re-oxidation of 
proteins. 
 
For western blotting, gels were removed from gel-casting plates and nitrocellulose membrane 
with no auto-fluorescence were equilibrated in the transfer buffer prepared from 20X 
NuPAGE Transfer Buffer (NP0006, ThermoFisher), 10% methanol, 0.05% SDS and 0.1% 
NuPAGE™ Antioxidant for 10min and 5min before setting up the transfer stacks. Protein 
transfer was set up at 10-15V for overnight in the cold room.  
 
Nitrocellulose membranes with transferred proteins were blocked in 5% fat-free milk-TBS 
solution for 1hr at room temperature and incubated with primary antibodies diluted in 5% 
milk-TBST (with 0.1% Triton X-100) overnight at 4C. Two primary antibodies from different 
species (mouse, rabbit or chicken) were used at the same time at this step as species-specific 
secondary antibodies conjugated with either IRDye 680RD or IRDye 800CW fluorophores 
were used for detection by Odyssey scanner, Li-Cor. Membranes incubated with primary 
antibodies were washed in TBST 3 times for 5min each at room temperature and incubated 
with secondary antibodies diluted in 5% milk-TBST for 1hr. Membranes were washed again in 
TBST for 30min and rinsed in deionised water before scanning for protein detection using 
700nm and 800nm channels in the Odyssey scanner. Resulting images were analysed with 
ImageStudio Lite software (Li-Cor). 
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3.3.5 RNA extraction from mice adrenals 
Both, left and right adrenals from wild-type and CaV1.3 knockout mice were embedded in OCT 
solution by Dr. Petronel Tuluc, University of Innsbruck. They were received frozen for RNA 
extractions using miRNeasy Micro Kit (Qiagen, 217084) according to manufacturer’s 
instructions. Briefly, adrenals in OCT were defrosted on ice and OCT was removed. Both 
adrenals for each sample were minced finely using scalpels and lysed in 700l QIAzol lysis 
reagent. Lysates were vortexed vigorously and incubated at room temperature for 5-10min 
to ensure complete lysis. Lysates were transferred to QIAshredder columns and centrifuged 
at 13,000rpm for 2min for complete homogenisation. Cleared lysate was transferred to fresh 
1.5ml microfuge tubes and 140l chloroform was added. Samples were shaken vigorously for 
15sec and incubated at room temperature for 2min. Samples were centrifuged at 12,000xg 
for 15min at 4C. Upper aqueous phase containing RNA was transferred to new 1.5ml 
microfuge tubes and 1.5 volume of absolute ethanol was added. Samples were mixed 
thoroughly and proceeded with column purification using RNeasy MinElute spin columns in 
the kit. On-column DNase treatment was done and finally RNA was eluted in 15l water. 
Eluted RNA was quantified by Nanodrop and cDNA for RT-PCR and qPCRs was prepared as 
described earlier (Section 2.1.8).  
 
3.3.6 High-throughput compound screening at  
This work was done by scientists at  as part of . For this, 
preliminary experiments were performed in the lab to identify adrenal relevant CaV1.3 and -
subunit transcripts (Result sections 3.4.1 & 3.4.2). These experiments identified CaV1.3 
transcript that is 2137 amino acids in length to be the most predominantly expressed in the 
normal adrenals and APAs. The FLAG-tagged CaV1.3 construct in pcDNA3.1 vector prepared, 
as described earlier (Section 3.3.1.1) was transferred to  team.  
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In conclusion, team identified three true  selective molecules over . 
The relative profile of these compounds are distinct enough that they can serve as useful tool 
compounds. The exact mechanism of action of these compounds could not be determined 
from these experiments and so further investigation would be required. I received these 
compounds from to test their effects on aldosterone secretion from H295R and primary 
adrenal cells. 
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3.4 Results 
3.4.1 Isoform and expression analysis of CaV1.3 in normal adrenal cortex & 
APAs 
Real-time qPCR revealed significant differences in the expression levels of two LTCCs, CaV1.3 
and CaV1.2. In all tissue types tested expression levels for CaV1.3 were 10-30 fold higher than 
CaV1.2 (Fig. 17a). CaV1.3 was highly upregulated in ZG-like APAs as compared to normal tissue 
adjacent to such APAs from same patients. Similar upregulation was not seen in ZF-like APAs 
compared to their paired normal adrenal tissue and was specific to ZG-like APAs. CaV1.3 
transcripts were also analysed and 2137aa long transcript formed the most of this 
upregulation of CaV1.3 in ZG-like APAs (Fig. 17b). 
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Fig. 17: Endogenous calcium subunit expression in normal adrenal and APAs. 
a. Comparison of CaV1.3 and CaV1.2 expression in ZG- or ZF-like APAs and their adjacent normal adrenals. b. 
Expression data for CaV1.3 “long” transcripts, 2181 amino acid or 2137 amino acid in length. c. Comparison of 2 
and 3 subunit expression. d. Expression data for 2 transcripts 2a, 2d, 2e. Legend, ZG-N: normal adrenal next 
to ZG-like APA; ZG-T: ZG-like APA; ZF-N: normal adrenal next to ZF-like APA; ZF-T: ZF-like APA. ZG-T and normal, 
n=11 and ZF-T and paired normal, n=3. (Two-way ANOVA, *P≤0.05, **P≤0.01, ***P≤0.001 compared to adjacent 
normal tissue). Error bars represent s.e.m. Relative expression is calculated as 2-CTx107, where 2-CT = CTTarget gene-
CT18s. 

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3.4.2 Isoform and expression analysis of subunit in normal adrenal cortex & 
APAs 
Similar analysis for  subunit expression revealed 2 as the most predominant type in adrenal, 
consistent with our microarray data (Fig. 17c). 2 was also upregulated only in ZG-like APAs 
compared to paired normal tissue and not in ZF-like APAs. Among tested 2 transcripts 
variants, 2d was found to be the most predominant isoform followed by 2e (Fig. 17d). 2a 
expression was negligible in all samples. 
 
3.4.3 Mutant CaV1.3 upregulates aldosterone secretion 
H295R cells transfected with wild-type CaV1.3 showed marginally higher aldosterone 
secretion compared to untransfected or cells transfected with empty vector in presence of 3 
and 2-1 constructs (Fig. 18). Cells expressing CaV1.3 mutants G403R or I750M, both of which 
lie in the channel activation gate towards the cytoplasmic end of S6 in pore-forming domain, 
secreted higher aldosterone to varying levels compared to WT. Reasonable stimulation of 
aldosterone secretion with angiotensin II was also observed in all groups. 
U T V e c to r W T G 4 0 3 R I7 5 0 M
0
1 0
2 0
3 0
4 0
A
ld
o
s
t
e
r
o
n
e
 (
p
M
/

g
)
U n tre a te d
1 0 n M  A n g II
#
@
@
@
 
Fig. 18: AngII stimulation of aldosterone secretion from transfected H295R cells.  
H295R cells were transfected by electroporation with pcDNA3.1 (Vector), FLAG-CaV1.3 wild-type (WT) or 
mutants G403R or I750M along with 3 and 2-1 constructs. UT: un-transfected. All cells were treated with 
10nM angiotensin II (AngII, black bars) or vehicle only (PBS, grey bars) for 24 hrs before harvesting cells for 
aldosterone assay (pM) and total protein estimation (ug) (n=3 in quadruplicate). (One-way ANOVA, # P<0.001, 
@ P<0.0001, compared to WT). Error bars represent s.e.m.  
  
As previously seen in electrophysiological studies, mutant CaV1.3 proteins have higher 
probability of channel activation at less depolarised membrane potentials and slowed 
inactivation, it was investigated whether these changes were solely the cause of increased 
aldosterone secretion or if there is any increase in membrane localisation of mutant proteins 
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compared to the wild-type. For this H295R cells were co-transfected with 3, 2-1 subunits 
and the GFP-tagged WT or mutant CaV1.3. No differences in the sub-cellular localisation of 
GFP-tagged CaV1.3 wild-type or mutants, V259D, G403R, I750M or P1336R were observed. All 
groups showed cells with GFP-fluorescence in both cytoplasm and cell membrane (Fig. 19). 
 
 
Fig. 19: Subcellular localisation of transfected CaV1.3 WT or mutants (GFP-tagged) in H295R cells. 
H295R cells were transfected using Lipofectamine with a. GFP-CaV1.3 wild-type (WT) or mutants b. V259D, c. 
G403R, d. I750M and e. P1336R along with 3 and 2-1 constructs. Cell membranes were stained with WGA-
633 (red) and nuclei with DAPI (blue). Membrane and nuclei staining not shown for the mutants (b-e). 
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3.4.4 Whole-cell patch-clamp electrophysiology 
3.4.4.1 Current activation for CaV1.3 WT and mutants in presence of 3 subunit 
The I-V relationship was studied by whole-cell patch-clamping technique on tsA-201 cells 
transfected with FLAG-tagged CaV1.3 wild-type or mutants along with 3 and 2-1. Calcium 
currents were recorded using 10mM Ca2+ bath solution and by applying 10mV step 
depolarisations for 50ms each (Fig. 20i). Of the seven mutants tested, four mutants V259D, 
G403R, F747L and I750M showed I-V curves shifted towards more negative voltages (Fig. 20b-
e & Fig. 21a). Compared to WT, mutants R990H, P1336R and M1354I showed no differences 
in the channel activation properties (Fig. 20f-h & Fig. 21a). The G/Gmax as a measure of channel 
conductance was also calculated, which showed a similar left-ward shift for the same four 
mutants and no differences for other three (Fig. 21b). These data are represented as V50, the 
voltage for half maximal conductance for each group, and summarised in Fig. 21c. A significant 
decrease of 10-20mV was found in V50 for mutants V259D, G403R, F747L and I750M CaV1.3 
channel in the presence of the 3 subunit. 
 
Fig. 20: Exemplary IV-traces for all CaV1.3 WT and mutants expressed with 3 and 2-1 subunits.  
a. WT, b. V259D, c. G403R, d. F747L, e. I750M, f. R990H, g. P1336R and h. M1354I. IV protocol for 10mV step 
depolarisation from -90mV holding potential for 50 ms is represented in i. 
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Fig. 21: Current-voltage (IV) relationship (ICa) of CaV1.3 WT or mutants in presence of 3. 
a. Currents were recorded from 10mM Ca2+ in bath solution and I/Imax is displayed as voltage dependence of 
channel activation. b. G/Gmax is calculated as voltage dependence of channel conductance. c. Voltage for half 
maximal conductance (V50) is tabulated for each group. Number of cells (n) for each group is given in parenthesis 
in the figure legends. Error bars represent s.e.m. *P≤0.05, ***P≤0.001, ****P≤0.0001 compared to WT. 
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3.4.4.2 Effect of different  subunits on CaV1.3 WT activation 
The tsA-201 cells were transfected with FLAG-CaV1.3 WT, 2-1 and 3, 2d or 2e constructs 
and their I-V relationships were determined, as before in the presence of 10mM Ca2+. CaV1.3 
showed very similar activation and channel conductance profile in the presence of 3 or 2d 
(Fig. 22 & Fig. 23), whereas these properties are significantly depolarised by 10mV when 2e 
is present. 
 
Fig. 22: Exemplary IV-traces for CaV1.3 WT expressed with 3, 2d or 2e and 2-1 subunits.  
a. 3, b. 2d and c. 2e. IV protocol for 10mV step depolarisation from -90mV holding potential for 50 ms is 
represented in d. 
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Fig. 23: Current-voltage (IV) relationship (ICa) of CaV1.3 WT in presence of 2d, 2e or 3.  
a. Currents were recorded from 10mM Ca2+ in bath solution and I/Imax is displayed as voltage dependence of 
channel activation. b. G/Gmax is calculated as voltage dependence of channel conductance. Voltage for half 
maximal conductance (V50) is tabulated for each group. Number of cells (n) for each group are represented in 
parenthesis in figure legends. Error bars represent s.e.m. **P≤0.01 compared to 3 and 2d. 
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3.4.4.3 2 subunit dependent inactivation 
10mM Ba2+ was used as the charge carrier in these experiments to minimise the calcium-
dependent inactivation of CaV1.3. The tsA-201 cells expressing CaV1.3 WT or mutant V259D 
with 2d or 2e were subjected to I-V, steady-state inactivation and time-course inactivation 
protocols. Independent of 2 subunit splice variant, mutant V259D showed a hyperpolarising 
shift of about 12-15 mV compared to WT (Fig. 24 & Fig. 27a), similar to that seen in the 
experiment in which 3 subunits were used (Fig. 21a). A modest effect on voltage dependent 
channel activation was induced by 2e only on WT CaV1.3, compared to 2d, whereas V259D 
activation was not affected (Fig. 27b). As expected, membrane -associated 2e shifted steady-
state inactivation curves to more positive voltages for both WT and V259D, compared to the 
non-membrane-associated 2d subunit (Fig. 25 & Fig. 27c). Interestingly, as represented by 
r300 fast, inactivation of the WT channel during long depolarisations of 5 s was negligible in 
the presence of either 2 subunit (Fig. 26a-b & Fig. 27d). On the other hand, the V259D 
channel showed significant inactivation at all tested voltages only in the presence of 2d. 2e 
subunit prevented any significant reduction in channel currents from V259D (Fig. 26c-d & Fig. 
27d). 
 
 
Fig. 24: Exemplary IV-traces for CaV1.3 WT or V259D expressed with 2d or 2e and 2-1 subunits.  
a. WT+2d, b. WT+2e, c. V259D+2d and d. V259D+2e. IV protocol for 10mV step depolarisation from -90mV 
holding potential for 50 ms is represented in e. 
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Fig. 25: Exemplary steady-state inactivation traces for CaV1.3 WT or V259D expressed with 2d or 
2e and 2-1 subunits. 
a. WT+2d, b. WT+2e, c. V259D+2d and d. V259D+2e. After pre-conditioning at voltages of -70mV to 70mV, 
steady-state inactivation protocol involving depolarisation to Vmax from -100mV holding potential for 50 ms is 
represented in e. 
 
 
Fig. 26: Exemplary 1 sec inactivation traces for CaV1.3 WT or V259D expressed with 2d or 2e and 
2-1 subunits. 
a. WT+2d, b. WT+2e, c. V259D+2d and d. V259D+2e. Protocol for 1 second long inactivation to 10mV step 
depolarisation -80mV holding potential is represented in e. 
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Fig. 27: Activation and inactivation of CaV1.3 WT or mutant, V259D in the presence of 2d or 2e. 
a. Currents were recorded from 10mM Ba2+ in bath solution (IBa) and I/Imax is displayed as voltage dependence 
of channel activation. b. G/Gmax represents channel conductance. c. I/IVmax is represented for steady state 
inactivation protocol. d. Fast channel inactivation is represented as r300, the fraction of current remaining 300ms 
into the depolarisation step to indicated voltages. Number of cells (n) for each group are represented in 
parenthesis in figure legends. Error bars represent s.e.m. *P≤0.05 for WT+2d vs WT+2e in c. and *P≤0.05, 
**P≤0.01 compared to V259D+2e in d. 
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3.4.5 Localisation of endogenous CaV1.3 in H295R cells 
Untransfected H295R cells were stained with different CaV1.3 antibodies against its pore-
forming domain or intracellular C-terminal chain. As expected, staining with antibody towards 
the pore-forming domain (NeuroMab Clone L48A/9), called here as N-terminal (NT) antibody 
shows membranous localisation for CaV1.3 (Fig. 28a). Surprisingly, the two independent 
antibodies against the intracellular c-terminal (CT) chain of CaV1.3 (NeuroMab Clone N38/8 
and SantaCruz sc-25687) mainly showed diffused cytoplasmic and nuclear localisation (Fig. 28 
b & c). No clear membranous staining with either CT antibodies was a matter of concern 
suggesting doubts over specificity of these antibodies. 
 
a. 
 
b. 
 
c. 
 
Fig. 28: Immunostaining of endogenous CaV1.3 in H295R cells.  
Localisation of endogenous CaV1.3 in H295R cells by immunostaining with a. NeuroMab N-terminal (green); b. 
NeuroMab C-terminal (green) and c. SantaCruz C-terminal (red) antibodies. Plasma membranes were stained 
using wheat germ agglutinin (WGA, red in a. and b.) and nuclei were stained with DAPI (blue). 
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3.4.6 Cleaved C-terminus of CaV1.3 translocates to nucleus and upregulates 
aldosterone secretion 
Intracellular C-terminal of CaV1.3 cloned in pLOC vector (tagged with FLAG and Myc 
sequences, Fig. 29a) was overexpressed in H295R cells via lentiviral transduction to study its 
subcellular localisation and effect on aldosterone secretion. Western blot of lysates of H295R 
cells expressing CaV1.3-CT using anti-Myc antibody showed the presence of 2 bands 
corresponding to the expected sizes of transduced C-terminal and cleaved peptide (Fig. 29b). 
The smaller fragment lacks the FLAG-tag sequence confirming c-terminal undergoing 
cleavage. Immunofluorescence with FLAG antibody showed prominent nuclear localisation of 
the transduced CaV1.3-CT, but unfortunately, this peptide in nucleus was not positive for myc-
tag (Fig. 30). Interestingly expression of CaV1.3-CT upregulated aldosterone secretion from 
H295R cells compared to the control cells by 1.5 folds (Fig. 31). 
 
Fig. 29: Western blot for overexpressed CaV1.3-CT in HEK293 cells. 
a. Schematic representation of cloned C-terminal sequence of CaV1.3 with putative calpain cleavage site 
indicated with a red arrow. b. Western blot for whole cell lysate of HEK293 cells untransfected (UT) or 
transfected with CaV1.3-CT (CavCT) or empty vector (EV) using PEI transfection reagent (n=3). Anti-Myc and anti-
FLAG antibodies show expression of CavCT. Anti-tGFP and anti-Actin were used as loading controls. 
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Fig. 30: Immunostaining of CaV1.3-CT overexpressed in H295R cells. 
H295R cells were transduced with the lentivirus for FLAG-CaV1.3-CT-Myc and immuno-stained with anti-FLAG 
(blue) and anti-Myc (red) antibodies. MitoTracker (yellow) shows mitochondrial staining for all cells in the view 
and tGFP (green) from pLOC plasmid shows nuclei of transduced cells. 
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Fig. 31: Aldosterone secretion from H295R cells overexpressing C-terminal of CaV1.3 
H295R cells were either untransduced (UT) or transduced with lentivirus for empty vector (EV) or C-terminal of 
CaV1.3 (CavCT). Aldosterone secretion was measured over 48hrs from transduction (n=3 in triplicate). (One-way 
ANOVA, *P=0.0243 compared to EV). Error bars represent s.e.m. 
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3.4.7 CaV1.3 is a substrate for calpain proteases 
Unexpected localisation of C-terminal of CaV1.3 in the nuclei of H295R cells led to the 
hypothesis that similar to CaV1.2, intracellular domain of CaV1.3 also undergoes calpain 
mediated cleavage and released c-terminal chain translocates to nucleus. To test this 
hypothesis, first the effect of calpain inhibition on aldosterone secretion was studied. H295R 
cells were treated with 0-50M range of calpeptin and basal or AngII stimulated aldosterone 
secretion was measured. Calpain inhibition did not influence aldosterone secretion under 
basal conditions (black bars in Fig. 32), but significantly reduced the AngII stimulated 
aldosterone at concentrations of 5M or higher (red bars in Fig. 32). 
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Fig. 32: Aldosterone secretion from H295R cells treated with calpeptin 
H295R cells were treated with increasing dose of calpain inhibitor, calpeptin in presence or absence of 10nM 
angiotensin II and aldosterone secretion was measured (n=3 in triplicate). (Two-way ANOVA, ***P=0.0003 and 
****P<0.0001). Error bars represent s.e.m. 
 
 
Despite the uncertainty of the antibody specificity (due to the detection of multiple bands), 
western blot using CaV1.3 C-terminal antibody (NeuroMab, N38/8) for the lysates of calpeptin 
treated H295R cells showed some increase in the levels of full-length CaV1.3 (>250kD), 
suggesting reduction of the calpain mediated cleavage of C-terminal peptide (Fig. 33). In 
addition to the effect of calpeptin on CaV1.3 protein, down-regulation of CaV1.3 
transcriptional expression was also observed at the concentrations that significantly reduced 
aldosterone secretion (Fig. 34a & b). Expression of CYP11B2 was observed to be unchanged 
with calpeptin treatment except for a complete knockdown at 100M concentration which 
could be a result of non-specific effect at high dose of calpeptin (Fig. 34c). 
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Fig. 33: Western blot for CaV1.3 in H295R cells treated with calpeptin. 
Whole cell lysate of H295R cells treated with the dose range of calpeptin in the presence of AngII was western 
blotted with anti-CaV1.3 C-terminal antibody (NeuroMab, N38/8). Black arrow indicates the band for full-length 
CaV1.3 (n=2). 
 
0 1 5 2 0 5 0 1 0 0
0
5 0
1 0 0
1 5 0
C a lp e p tin  ( M )
A
ld
o
s
te
ro
n
e
(%
 o
f 
u
n
tr
e
a
te
d
)
* * *
* * *
* * * *
0 2 0 5 0 1 0 0
0 .0
0 .5
1 .0
1 .5
C a lp e p tin  ( M )
C
a
V
1
.3
 m
R
N
A
(f
o
ld
 c
h
a
n
g
e
)
* *
* * * *
0 2 0 5 0 1 0 0
0 .0
0 .5
1 .0
1 .5
C a lp e p tin  ( M )
C
Y
P
1
1
B
2
 m
R
N
A
(f
o
ld
 c
h
a
n
g
e
)
* *
a .
b . c .
 
Fig. 34: Aldosterone secretion and CaV1.3 expression in H295R cells treated with calpeptin. 
H295R cells were treated with 0-100M calpeptin in the presence of 10nM angiotensin II. a. Aldosterone 
secretion was measured (One-way ANOVA, 20M vs 0 ***P=0.0004, 50M vs 0 ***P=0.0001, 100M vs 0 
****P<0.0001). b. qPCR analysis for CaV1.3 expression in response to calpeptin at concentrations that 
significantly decreased aldosterone (n=3 in quadruplicate). (One-way ANOVA, **P=0.0046, ****P<0.0001). c. 
qPCR analysis for CYP11B2 expression (One-way ANOVA, **P=0.0069). Error bars represent s.e.m. 
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3.4.8 Silencing of CaV1.3 in H295R cells 
To further establish the role of endogenous CaV1.3 in aldosterone secretion, shRNA mediated 
knockdown in H295R cells was performed. However, the silencing of CaV1.3 was not very 
efficient as there was no significant reduction in CaV1.3 mRNA levels in the shRNA transduced 
cells compared to the control cells (Fig. 35a), and hence no effect on aldosterone secretion 
was observed (Fig. 35b). 
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Fig. 35: shRNA mediated CaV1.3 knockdown in H295R cells and aldosterone secretion. 
H295R cells were transduced with lentivirus for scrambled/non-targeting (NT) or two CaV1.3 specific shRNA 
sequences (sh1 & sh2). a. Efficiency of knockdown was measured by qPCR for CaV1.3. b. aldosterone secretion 
from all conditions was measured. No significant changes were observed in CaV1.3 levels or aldosterone 
secretion in either shRNA treated cells compared to untransduced (UT) or NT cells (n=3 in triplicate). Error bars 
represent s.e.m. 
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3.4.9 CaV1.3 knockout mice show down-regulated CYP11B2 expression 
Though silencing of CaV1.3 was unsuccessful in H295R cells, its significant role in aldosterone 
secretion in vivo was found. Adrenals of CaV1.3 knockout mice generated and studied by 
Platzer et al. were received from the collaborators (Platzer et al., 2000) and RNA was 
extracted. RT-PCR for CaV1.3 expression in cDNA of WT and knockout mice confirmed the 
complete absence of transcripts that would produce CaV1.3 proteins (Fig. 36). qPCRs showed 
CYP11B2 expression was downregulated by approximately 50% in the CaV1.3 null mice 
compared to age-matched WT animals (all 8-weeks old), irrespective of the gender (Males: 
1.00 ± 0.06 vs 0.56 ± 0.07, n=5; Females: 1.00 ± 0.15 vs 0.46 ± 0.11, n=4; All: 1.00 ± 0.07 vs 
0.51 ± 0.06, n=9) (Fig. 37). 
 
Fig. 36: RT-PCR for CaV1.3 expression in adrenal cDNA of WT and knockout mice. 
RT-PCR for analysing expression of CaV1.3 in the WT and KO mice whole adrenal cDNA samples. Indicated arrows 
at 368bp and approximately 1kb correspond to expected amplicon sizes from WT and transgenic (KO) samples, 
respectively. 
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Fig. 37: Expression of CYP11B2 in adrenals of WT and CaV1.3 knockout mice. 
Expression of CYP11B2 in the whole adrenals of age-matched WT or CaV1.3 knockout (KO) mice. a. CYP11B2 
mRNA fold change in WT and KO mice adrenals from males (n=5, 2-tailed T-Test **P=0.0014) and females (n=4, 
2-tailed T-Test *P=0.0235). b. Combined data for both males and females (n=9, 2-tailed T-Test ****P<0.0001). 
Error bars represent s.e.m.  
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3.4.10 Effect of CaV1.3 selective inhibition by compounds A, B & C on 
aldosterone secretion 
The tool compounds A, B and C, that were found to be selective inhibitors for CaV1.3 (WT or 
mutant P1336R) over CaV1.2 were tested for their efficacy for inhibition of aldosterone 
secretion from H295R cells and primary cells isolated from human adrenals. 
 
In H295R cells, compound A showed no inhibition of aldosterone secretion even at the highest 
concentration tested. There was no concern for solubility of compound A up to 100M final 
concentration in the cell culture media. But compounds B & C showed cloudiness at final 
concentrations of 100M and 50M as indicated by black arrowheads in Fig. 38a. Compound 
C showed a mixed effect on aldosterone secretion, that’s inhibition by ~50% at 1M, but no 
effect at 10M. Higher concentrations were not completely soluble and are probably too high 
to conclude any specific effect on aldosterone secretion. Only compound B showed a typical 
dose dependent inhibition on aldosterone secretion from H295R cells. its effect was observed 
starting at 1M, leading up to 85% reduction in aldosterone at 50M. IC50 for compound B 
was calculated to be 6.6  1.4M (Fig. 38b). 
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Fig. 38: Dose response curve for compounds A-C on aldosterone secretion in H295R cells. 
a. Inhibition of aldosterone secretion from H295R cells treated with a dose range of 0.01-100M concentration 
of compounds A, B and C for 24hrs. Aldosterone values were normalised as percent of aldosterone secreted by 
cells treated with DMSO only. Black arrow heads indicate incomplete solubility of compounds at the particular 
concentration. b. Dose curve for compound B only (n=3 in quadruplicate). Error bars represent s.e.m. 
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Primary adrenal cells from 2 patients were tested for compound A, B & C inhibitory effects on 
aldosterone secretion. Only 3 concentrations of 1, 10 & 50M for all 3 compounds were 
tested. Results were variable for two patients’ cells, with overall no significant activity of 
compound A as seen in case of H295R cells (Fig. 39 a & b). Compound B showed significant 
reduction on aldosterone in cells from patient-2 at 10 and 50M, but its significant effect on 
cells from patient-1 was observed only at 1M. Again no significant effect of compound C was 
seen in cells from patient-1, but a dose-dependent inhibition of aldosterone was observed in 
cells from patient-2. 
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Fig. 39: Effects of compounds A-C on aldosterone secretion from primary adrenal cells. 
Aldosterone secretion from primary cell of normal adrenals of 2 patients (a. and b.) on treatment with 1, 10 and 
50M concentrations of compounds A, B and C in quadruplicates (Two-way ANOVA, *P<0.05, #P<0.001, 
@P<0.0001). Black arrow heads indicate incomplete solubility of compounds at the particular concentration. 
Error bars represent s.e.m. 
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3.5 Discussion 
The members of L-type calcium channel family (CaV1.1-CaV1.4) are expressed in neurons, 
endocrine glands, retina and skeletal and cardiac muscles. Until the discovery of somatic 
mutations in CACNA1D/CaV1.3 in APAs (Azizan et al., 2013; Scholl et al., 2013), CaV3.2 (a T-
type calcium channel) was believed to be the main source of Ca2+ entry in the adrenal 
endocrine cells because resting zona glomerulosa cells are too hyperpolarised for activation 
of high voltage LTCCs. Microarray studies from our lab showed CaV1.3 to be the most 
predominant 1-subunit forming calcium channels (Shaikh et al., 2015; Zhou et al., 2015) in 
adrenal cortex and APAs. qPCRs for CaV1.3 and CaV1.2 confirmed the microarray findings, with 
10-20 fold higher CaV1.3 than CaV1.2 in normal adrenal tissues (Fig. 17a). It was found that in 
ZG-like APAs, CaV1.3 expression levels are highly upregulated as compared to their paired 
adjacent normal tissue or ZF-like APAs. Further analysis of CaV1.3 transcripts expression 
showed only one of the three ‘long’ isoforms to be most expressed and upregulated in ZG-
like APAs (Fig. 17b). This isoform, 2137 amino acid in length lacks several alternatively spliced 
exons compared to the longest transcript (2181 amino acids) but contains exon 8A (8B in 
2181aa transcript) in which one of the common somatic mutation G403R is reported. 
 
Expression levels of 2 and 3 subunits were analysed and again microarray findings were 
confirmed establishing 2 as the main  subunit in adrenal tissues, which is nearly 5-fold 
upregulated only in ZG-like APAs compared to paired normal adrenals (Fig. 17c). It was 
hypothesised that constitutive aldosterone secretion from APAs could also be driven by 
upregulation of 2 subunits that lead to slow inactivation of CaV1.3. 2 transcript expression 
analysis for membrane bound 2a and 2e and cytoplasmic 2d variants revealed data 
opposite to expected. None of the samples had detectable levels of 2a transcript without 
any significant differences in 2d and 2e levels in the normal adrenals. Strikingly, the most 
predominant transcript in ZG-like APAs was 2d rather than the other membrane associated 
2e subunit (Fig. 17d). These results could be explained by some kind of negative feedback 
mechanism favouring alternative splicing for 2d expression over 2e. These findings further 
support existence of very different transcriptome and underlying molecular mechanisms for 
aldosterone secretion in two histologically distinct ZG-like and ZF-like APAs. 
 
This isoform analysis was crucial for the FastTrack Discovery project so the compound 
screening is performed using adrenal relevant transcripts of both CaV1.3 and  subunit, which 
could be different from those expressed in heart and blood vessels. This was to minimise the 
off-target effects of the potential compounds. 
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Functional studies to assess the effect of CaV1.3 mutations on aldosterone secretion from 
H295R cells have demonstrated their gain-of-function phenotype in electrophysiological 
properties (Azizan et al., 2013; Pinggera et al., 2014) translates downstream into higher 
aldosterone production from cells expressing mutant CaV1.3 compared to the WT (Xie et al., 
2016) (Fig. 18). There are some technical issues with experiments where H295R cells had to 
be transfected by electroporation. I observed electroporated cells to be less healthy than the 
non-electroporated (un-transfected) cells and appeared to have clumped together due to loss 
of membrane integrity. They also appeared to be “leaky” releasing any intracellularly stored 
aldosterone as cells transfected just with the empty vector released more aldosterone as 
compared to the non-electroporated cells. Alternative method of milder transfection using 
Lipofectamine transfection reagent was also not ideal for achieving high transfection 
efficiency in case of CaV1.3 plasmids that require co-transfection of another 2 constructs for 
2-1 and  subunits.  
 
Application of step depolarisation protocols in whole cell patch clamping experiments on 
transfected tsA-201 cells showed current activation at more negative voltages for the mutants 
V259D (in the cytoplasmic S4-S5 linker coupling the voltage-sensing domain to the pore), 
G403R, F747L and I750M (in the channel activation gate) in the presence of 3 subunit (Fig. 
21). The other three mutants R990H (in the voltage sensor), P1336R (also in the cytoplasmic 
S4-S5 linker coupling the voltage-sensing domain to the pore) and M1354I (on the 
extracellular end of S5 voltage-sensing domain) did not show any significant differences in 
voltage dependence of channel activation compared to WT CaV1.3. Despite the different  
subunit used here (3 vs 1b), these findings are consistent with the previously reported 
functional studies for V259D, I750M and P1336R mutants (Azizan et al., 2013).  
 
Subsequent to establishing the main  subunits expressed in the adrenals, whole cell patch 
clamping experiments were performed on tsA cells expressing CaV1.3 WT or V259D in the 
presence of 2d or 2e subunits. There were no differences found in calcium currents through 
WT channels in the presence of 3 or 2d, but 2e led to rightward shift in the voltage-
dependence of current activation, such that voltage for half maximal conductance (Vmax) was 
10mV more depolarised potentials (13.49  0.73 vs 1.32  0.41 mV), suggesting slower 
channel activation in the presence of 2e subunit (Fig. 23). In the presence of Ba2+ as the 
charge carrier, type of 2 subunit present did not influence current activation for either WT 
or V259D CaV1.3 channels (Fig. 27a & b).  
 
As expected, membrane bound 2e subunit led to significantly slower inactivation of CaV1.3-
WT as calculated by V50 of inactivation compared to 2d (-7.32  1.60 vs -15.42  2.59 mV) 
(Fig. 27c). The mutation V259D that shifts the voltage-dependent activation and steady-state 
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inactivation of CaV1.3 by 15mV to more negative voltages was not influenced by the type of 
2 subunit present. Fast channel inactivation kinetics as calculated by r300 values (the fraction 
of current remaining at 300ms from the start of the depolarisation step) of V259D, on the 
other hand, was influenced by the type of 2 subunit expressed. As evident from the r300 
values, the V259D channel expressed with 2d exhibited currents inactivated by almost 50% 
at all voltages tested (Fig. 27d). Unexpectedly, WT channel showed almost no fast inactivation 
in the presence of either 2 subunit. These results suggest that the voltage dependence of 
channel activation is mainly determined by the CaV1.3 subunit, i.e. WT or mutant but  
subunit variants predominantly influence steady state inactivation and time constants of fast 
inactivation, due to their differential membrane association properties. Whole cell patch 
clamp experiments on tsA-201 cells provide critical evidences for modulation of channel 
properties under various conditions, but in the context of aldosterone synthesis, this 
knowledge is of limited significance unless primary cells from normal adrenal and APAs 
harbouring CACNA1D somatic mutations are studied. 
 
Nuclear localisation of endogenous CaV1.3 in H295R cells as seen by staining with antibodies 
specific to cleavable c-terminal chain (Fig. 28), but not with antibody towards pore-forming 
domain suggests CaV1.3 to play a role as transcription factor in adrenals cells similar to that 
reported in mouse atrial cells (Lu et al., 2015). Here I showed that transfected c-terminal 
peptide translocates to nucleus of H295R cells (Fig. 30) and possibly also undergoes a 
protease-mediated cleavage at a site that’s putatively sensitive to calpain proteases (Fig. 29). 
Overexpression of CaV1.3 C-terminal upregulated aldosterone secretion in H295R cells (Fig. 
31). A slight puzzling observation was nuclear staining only with FLAG antibody and not with 
Myc antibody. There is a possibility that Myc antibody could not penetrate into the nucleus, 
but it needs further investigation. In order to find direct evidence of CaV1.3, like CaV1.1 and 
CaV1.2 in skeletal muscles, cardiomyocytes and neurons being a substrate for calpain or 
similar proteases (Gomez-Ospina et al., 2006, 2013; Hulme et al., 2005; Schroder et al., 2009), 
H295R cells were treated with a cell-permeable calpain inhibitor, calpeptin. Western blot 
using anti-CaV1.3 antibody towards the intracellular C-terminal showed increased levels of 
full-length CaV1.3 in the calpeptin treated cells compared to those in untreated cells (Fig. 33), 
suggesting calpain inhibition prevented proteolytic cleavage of CaV1.3 C-terminal. 
Interestingly, aldosterone secretion is significantly reduced in the calpeptin treated cells, 
where downregulation of CaV1.3 transcription was also observed (Fig. 34). These observations 
indicate the phenomenon of self-regulatory expression by c-terminal peptide as reported for 
CaV1.2. It is interesting to note that the nuclear translocation of c-terminal chain is negatively 
regulated by intracellular calcium concentration (Lu et al., 2015). 
 
These experiments have provided essential insights into the role of cleaved c-terminal of 
CaV1.3 that is overexpressed CaV1.3-CT upregulates aldosterone secretion up and reduced 
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CaV1.3-CT levels by inhibiting calpains downregulates aldosterone secretion. Despite these 
findings it was necessary to investigate whether CaV1.3 is a vital source of calcium entry for 
normal endocrine function of ZG or if it is only the gain-of-function in mutated APAs that 
makes CaV1.3 a target for pathological studies. To answer this question, effects of CaV1.3 
knockdown by shRNA transfection in H295R cells was studied. Unfortunately only negligible 
knockdown of CaV1.3 transcription was achieved in this in vitro system (Fig. 35). For this study, 
only adrenal tissue was available but not the CaV1.3 knockout mice blood samples to measure 
plasma aldosterone levels. Quantitative PCRs showed approximately 50% downregulated 
expression of aldosterone synthase, CYP11B2 in the CaV1.3 null mice compared to the age 
matched wild-type animals of both genders (Fig. 37). This data suggests that CaV1.3 does play 
a crucial role in the regulation of aldosterone secretion under normal physiological conditions 
of  non-mutated states in the normal zona glomerulosa. 
 
Pharmacological studies with the new tool compounds identified in the high-throughput 
screening at  also supported importance of CaV1.3 function in aldosterone secretion. Of 
the three CaV1.3 selective (over  compounds tested, compound B showed the most 
promising aldosterone inhibition in H295R cells (Fig. 38). Aldosterone suppression was also 
observed in the primary adrenal cells treated with compound B, but no definite conclusions 
could be drawn on the basis of only 2 sets of primary cells tested (Fig. 39). More experiments 
with other patients’ cells are required in future studies. With recent reports of CACNA1D 
being the most commonly mutated gene in the APCCs, it is possible that either the 2 samples 
tested here or the one’s that will be used in future, contain such somatically mutated APCCs. 
Knowledge of these genetic determinants would be crucial for any further development of 
target compounds for primary aldosteronism therapeutics. 
  
 
 
 
CHAPTER 4 
 
92 
 
 
CHAPTER 4 -  GENOTYPING AND WHOLE EXOME 
SEQUENCING OF APAs TO FIND NEW SOMATIC 
MUTATIONS 
 
4.1 Abstract 
With great technological advancements in the development of next-generation sequencing 
and data analysis of paired pathological and normal tissue samples discovery of somatic 
mutations in APAs was made possible. Since the first such report in 2011 of somatic mutations 
in the gene KCNJ5, functional mutations in several other genes encoding ion channels or 
transporters have been discovered. Mutations in these genes, CACNA1D, ATP1A1 and ATP2B3 
and also KCNJ5 have been implicated in membrane depolarisation in APA cells resulting in 
raised intracellular calcium levels and hence, autonomous aldosterone production. Another 
gene that is common to many cancers but rarely found in APAs is CTNNB1. APAs are visualised 
in potential PA patients or as incidentalomas by CT or MRI scan. These methods are efficient 
in detecting mainly large ZF-like APAs that exist outside the adrenal body. In contrast, PET-CT 
using C11-metomidate was used in our hospital not only for lateralisation (overcoming 
technical difficulty associated with AVS), but also for detecting small (<1cm) ZG-like APAs 
within the adrenal mass.  
 
We had a number of APAs that had not been sequenced for these known genes, so samples 
were genotyped and prepared for whole exome sequencing, in order to find some novel 
genes especially in the sub-cm adenomas. Of 59 APAs (from 52 patients) with unknown 
genotypes, we found mutations in 34 APAs (58% APAs or 65% patients) in the previously 
reported genes either by genotyping or WES. We found CACNA1D to be the most commonly 
mutated gene in our cohort accounting for 20.5% APAs (n=12 APAs, 23% patients). As 
expected, prevalence of KCNJ5 mutated APAs in this study was only 17% APAs (n=10 APAs, 
19% patients), which was much lower than 40% as reported in previous studies. ATP1A1 and 
ATP2B3 were mutated in 5 APAs each (8.5% APAs or 10% patients) and CTNNB1 mutations 
were found in 2 APAs. We did not find any cases with a second hit in other nodule among 7 
patients with 2 APAs. This difference in the prevalence of different genes probably arises from 
different approach to screening for PA in Addenbrooke’s Hospital. Many of our patients were 
detected by renin measurement in resistant hypertension, and their APAs identified by the 
unique C11-metomidate PET-CT, instead of adrenal vein sampling. 
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Apart from different prevalence of mutations in the known genes, we found a novel somatic 
mutation in a gene not encoding an ion channel/transporter, but in the gene CADM1 encoding 
cell adhesion molecule that is previously linked to cell-cell adhesion and tumour suppression. 
The mutation we found is a single nucleotide variant leading to substitution of  
 ( ) in the single transmembrane domain of this cell surface protein. The likely 
significance of this discovery was greatly enhanced when we ascertained that one of the 
'private' somatic mutations found on whole exome sequencing of APAs in Munich was a 
similar substitution in the adjacent amino acid ( ) of the membrane-spanning domain 
of CADM1. 
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4.2 Introduction 
4.2.1 Aim and Hypotheses 
We aimed to genotype all APAs in our cohort that is enriched for smaller ZG-like APAs and 
likely to have fewer ZF-like APAs with KCNJ5 mutations. There were 59 APAs from 52 patients 
(7 patients had 2 nodules) analysed in the study. This was done partially by Sanger sequencing 
for known genes and by next-generation sequencing of whole exomes in genomic DNA 
extracted from paired normal adrenal and APAs. As we could detect many small APAs by PET-
CT scans using C11-metomidate which are usually missed on routine CT scans, we expected to 
find more cases of CACNA1D, ATP2B3 or ATP1A1 mutants compared to KCNJ5 and hence 
differences in the mutational prevalence of these genes as reported globally. We also hoped 
to find some novel genes with somatic mutations which would be of interest in understanding 
the phenotype of hyper aldosterone secretion. 
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4.3 Materials and methods  
4.3.1 Sample gDNA preparation and selection 
All available APAs that had not been previously genotyped or whole exome sequenced in the 
lab were tested for known or novel somatic mutations in different batches by genotyping for 
hotspots, or whole exome sequencing at Barts Genome Centre and Genome Institute of 
Singapore. Genomic DNA for paired adjacent normal adrenal and APA(s) was extracted mainly 
from freshly frozen tissue samples using QIAamp DNA Mini Kit as described earlier. If such 
sample was not available, tissue sample preserved in RNALater was used preferably (using 
the same kit) over and lastly from FFPE sections dissolved in xylene using QIAamp DNA FFPE 
Tissue Kit (Qiagen, 56404). DNA concentration and quality for all samples was initially 
estimated by Nanodrop. There was good quality gDNA samples available from 59 APAs 
(labelled as T for tumour/APA) and 52 normal adrenals (labelled as N for normal) from 52 
patients who had adrenalectomy at Addenbrooke’s Hospital. 
 
4.3.2 Samples/patients in the study 
Table 17: List of samples 
Sample 
Source of gDNA for 
Normal / Tumour 
APA size 
(mm) 
Gender 
Age at 
surgery (y) 
14T F/F  Female  
30T F/F  Male 55 
43T FFPE/F    
96T NA 28 or 5 Male 47 
121T FFPE/FFPE 18 Male 45 
136T F/F 12 Male 59 
139T NA 8 Male 58 
141T F/F 7 Male 53 
148T F/F 11 Male 54 
156T F/F 33 Male 66 
171T F/F 17 Female 34 
176T R/R 15 Male 64 
180T F/F 16 Female 41 
181T F/R 7 Male 44 
182T F/F 10 Male 41 
183T F/F 16 Male 56 
184T F/R 6 Male 47 
185T F/F 15 Female 42 
186T1 F/F 10 
Male 42 
186T2 F/F 10 
187T F/F 10 Male 33 
190T F/F 20 Female 47 
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191T F/F 8 Female 39 
192T F/F 
Too 
small 
Male 63 
194T F/R 15 Male 55 
195T F/F 9.8 Female 36 
196T F/F 12 Male 63 
198T F/F 8 Female 41 
200T F/F 15 Male 59 
202T F/R 10 Male 53 
204T F/F 12 Female 28 
206T F/F 22 
Female 40 
206Tsmall F/F  
207T FFPE/F 24 Female 58 
208T1 F/F 28 
Female 44 
208T2 F/F  
210T F/F  Male 49 
214T F/F 7 Male 49 
216T1 F/F 13 
Male 42 
216T2 F/F  
218T F/F 14 Female 56 
219T F/F 19.2 Female 49 
221T1 F/F 12.3 
Male 63 
221T2 F/F  
223T R/R 14 Male 65 
226T F/F  Male 66 
227T F/F  Male 59 
228T F/F  Male 50 
233T F/F  Male 47 
235T F/F  Male 34 
238T R/R  Female 35 
239T1 R/R  
Male  
239T2 R/R  
240T F/F  Male 57 
244T F/F  Female 55 
247T F/F  Male 61 
250T F/F  Male 69 
252TL F/F  
Male 52 
252TM F/F  
F: Freshly Frozen, R: RNALater; FFPE: Formalin-fixed paraffin-embedded; NA: Info not available 
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4.3.3 Targeted hotspot sequencing - primers and PCR conditions 
Genotyping for known mutations in the genes ATP1A1, ATP2B3, CACNA1D, CTNNB1 and 
KCNJ5 was performed by Sanger sequencing (Section 2.1.5) using primers aligning to gDNA 
sequence of frequently mutated/hotspot regions (Table 18). All primer pairs used were 
designed to amplify 200-600bp target sequences. PCRs were performed as described 
previously using GoTaq polymerase and TD_68_60 PCR program. Mutations were detected 
using Mutation Surveyor (SoftGenetics, USA). 
 
Table 18: List of primers for genotyping of hotspot regions. 
Target 
gene 
Sequencing 
region 
Primer name Primer sequence 
ATP1A1 
Exon 4 
ATP1A1_L104R_F TCCACTGCTTCTCAGGGATT 
ATP1A1_L104R_R GAACTCACATTATCGTTTTGAGGTT 
Exon 21 
ATP1A1_960-964del_F CTCCAAGTTTTCAAGTACAGCTAA 
ATP1A1_960-964del_R GGGGAAAAGCCACACATACT 
ATP2B3 Exon 8 
ATP2B3_T423fs_F GTCTGCCATCACCGTCATC 
ATP2B3_T423fs_R CCCCAGTTTCCGAGTCTGTA 
CACNA1D 
Exon 6 
CACNA1D_V259_F GCTTTGAAATACCTCTTTGAATTTT 
CACNA1D_V259_R ATTTTGTTTTAGATTTTCCCCAAAC 
Exon 8A 
CACNA1D_G403_F TCCTCTTATTAACCCACTCCTATG 
CACNA1D_G403_R AATGTCTGGCAACCCCTCTT 
Exon 8B 
CACNA1D_Ex8B_F GGAGCACTAACCTTCAGCAAA 
CACNA1D_Ex8B_R CATGCAGAGAAGCTGTCAGG 
Exon 15 
CACNA1D_I650_F CGGCAACCAGTCACATCC 
CACNA1D_I650_R GGGAAATTGTCAAAGGTGCT 
Exon 17 
CACNA1D_F747_F AACACTTGGGACGGTCACTT 
CACNA1D_F747_R CAAACACGTCAGGGGAAAAT 
Exon 24 
CACNA1D_R990_F TGTGCAGGGATACTAAAGTGAAGA 
CACNA1D_R990_R CTCAGCTCTGCCCAGAAGA 
Exon 28 
CACNA1D_F1147_F TGGTTTTTCTCTCTCTAGGTTGC 
CACNA1D_F1147_R TCCTGACCAAGGGACAGAAG 
Exon 34 
CACNA1D_P1336_F CGTGGAATAGAAAGGAAGCA 
CACNA1D_P1336_R AGAGGCATTTGGCTGAAAAA 
CTNNB1 Exon 2 
CTNNB1_Ex2_F CATCACTGAGCTAACCCTGGC 
CTNNB1_Ex2_R CTCGAGTCATTGCATACTGTCC 
KCNJ5 Exon 1 
KCNJ5_G151R_L168R_F GCTTCATTTGGTGGCTCATT 
KCNJ5_G151R_L168R_R GAGATGACTGCGTTGTTGGA 
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4.3.4 WES sample preparation and QC 
About 1g of gDNA in 20-50l volume was sent to the laboratories performing whole exome 
sequencing. The samples were checked for DNA integrity and more accurate quantification 
by using PicoGreen DNA binding reagent (QuBit Nucleotide Quantification) before preparing 
libraries according to the kits used. 
 
4.3.5 WES methodology 
Following is the brief explanation of the whole exome sequencing methodology performed at 
Genome Centre, Barts and Genome Institute of Singapore. Extracted gDNA was run on a gel 
to ensure good integrity. Concentration and purity of DNA was verified and 1ug was 
fragmented by sonication, optimized to give a distribution of 200-500 base pairs. Libraries 
were prepared using Kapa DNA HTP Library Preparation Kit (KAPA Biosystems) or Nextera 
Rapid Capture Exome Kit (Illumina). Hybridization of the adapter ligated DNA was performed 
at 47C, for 64 to 72hr, to a biotin-labelled probe included in the Nimblegen SeqCap EZ Human 
Exome Kit (Roche). Libraries were sequenced using the Illumina Hiseq 2500 sequencing 
system and paired-end 101bp reads were generated for analysis.  
 
4.3.6 Somatic mutation detection-Mutect2 pipeline 
Following bioinformatics analysis for detection of somatic mutations in the tumour samples 
was performed by Dr Claudia Cabrera at Centre for Translational Bioinformatics, William 
Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen 
Mary University of London and Ms Kuan Jyn Ling in Dr Roger Foo’s team at Genome Institute 
of Singapore, National University of Singapore. Somatic mutations were detected by following 
the recommended “Best Practices” algorithm for a specialised tool, Mutect2 (Fig. 40) available 
as part of Genome Analysis Tool Kit (GATK, Broad Institute, Massachusetts). Briefly, the 
exome sequences were aligned to the NCBI/build37.2 human reference genome using the 
Burrows-Wheeler Aligner (BWA-MEM, bwa-0.7.12). Picard Tools software (picard-tools-
1.119) was used to sort alignments for each paired-exome sequence and merge bam files, 
followed by marking of PCR duplicates. Quality score recalibration was performed with GATK 
(GenomeAnalysisTK-3.6) using dbSNP, Mills, and 1000 genomes as reference resources. 
IndelRealigner and base quality score recalibration was also done to minimize base 
mismatches near indels. The final variants output were called using HaplotypeCaller for 
germline variants and MuTect2 for somatic variants. In Mutect2, normal and tumour DNA 
cross contamination estimates were calculated for each normal-tumour pair using GATK. PON 
(panel of normal) files were created for every normal sample which were then used to create 
a single PON file using CombineVariants tool in GATK. Mutect2 was then run for making single 
nucleotide variants (SNVs) and insertion-deletion variant calls (Indels) in each tumour sample 
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by running data against created PON file, COSMIC database and dbSNP. Variants were filtered 
on basis of quality scores, and that scored less than 0.01 in population databases including 
1000G and ExAC were retained. Finally, all calls were annotated using an online annotator 
named Oncotator [http://portals.broadinstitute.org/oncotator/]. Variants were further 
selected for only those leading to non-synonymous, splicing and frameshift changes. Variants 
were also annotated by algorithms to predict pathogenicity by SIFT. 
 
 
Fig. 40: Best Practices for Somatic SNVs and Indels calling in whole genome or exome sequencing 
data by Mutect2, GATK.  
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4.4 Results 
4.4.1 Sample workflow and mutation detection 
Of the 59 gDNA samples from APAs, some were genotyped for all hotspots in the known 
genes. Among 37 samples that were whole exome sequenced, some were partially genotyped 
by Sanger sequencing, mainly for mutations in KCNJ5 (Table 19). Somatic mutations in the 5 
candidate genes were found in 27 APAs by WES. Paired analysis by Mutect2 (GATK) for normal 
and APA gDNA sequencing data helped detection of a novel mutation in a gene CADM1 in 
sample 184T. Of 22 samples that were not whole exome sequenced, genotyping for hotspots 
in the known genes and CADM1 was done and mutations in 7 samples were detected, though 
none were in CADM1.  
  
Table 19: Sample workflow and mutations found. 
Sample 
All 
hotspots 
sequenced 
WES 
WES Batch OR 
Reason for no 
WES 
Mutant 
Gene 
Mutation 
Mutation 
detection 
method 
KCNJ5 
genotype 
141T No Yes 1-Barts ATP2B3 del425-426 WES NS 
184T No Yes 1-Barts CADM1 V380D WES NS 
187T No Yes 1-Barts ATP1A1 L104R WES WT 
192T No Yes 1-Barts ATP2B3 del425-426 WES NS 
195T No Yes 1-Barts CACNA1D I650N WES NS 
198T No Yes 1-Barts KCNJ5 L168R WES Mutant 
202T No Yes 1-Barts CACNA1D F1147L WES WT 
214T No Yes 1-Barts CACNA1D F747L WES NS 
14T No Yes 2-Singapore CTNNB1 T41A WES WT 
30T No Yes 2-Singapore    WT 
136T No Yes 2-Singapore    WT 
148T No Yes 2-Singapore ATP2B3 del425-426 WES NS 
156T No Yes 2-Singapore ATP2B3 del425-426 WES NS 
176T No Yes 2-Singapore ATP1A1 L104R WES WT 
181T No Yes 2-Singapore CACNA1D G403R-8A WES NS 
182T No Yes 2-Singapore ATP1A1 L104R WES WT 
183T No Yes 2-Singapore    WT 
185T No Yes 2-Singapore KCNJ5 G151R WES Mutant 
194T No Yes 2-Singapore CACNA1D V1338M WES NS 
196T No Yes 2-Singapore CACNA1D R990G WES NS 
200T No Yes 2-Singapore ATP1A1 EETA963S WES NS 
204T No Yes 2-Singapore KCNJ5 L168R WES Mutant 
218T No Yes 2-Singapore    WT 
219T No Yes 2-Singapore KCNJ5 L168R WES Mutant 
221T1 No Yes 2-Singapore KCNJ5 L168R WES Mutant 
223T No Yes 2-Singapore CACNA1D I750M WES WT 
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227T No Yes 3-Barts    WT 
228T No Yes 3-Barts ATP1A1 L104R WES WT 
233T No Yes 3-Barts CACNA1D P1336R WES WT 
235T No Yes 3-Barts    WT 
238T No Yes 3-Barts CTNNB1 S45P WES WT 
239T1 No Yes 3-Barts CACNA1D G403R-8B WES WT 
240T No Yes 3-Barts CACNA1D F747L WES WT 
247T No Yes 3-Barts    WT 
250T No Yes 3-Barts    WT 
252TL No Yes 3-Barts CACNA1D V1338M WES WT 
252TM No Yes 3-Barts    WT 
139T Yes No Known mutation CACNA1D G403R-8B Genotyping WT 
171T Yes No Known mutation KCNJ5 G151R Genotyping Mutant 
190T Yes No Known mutation KCNJ5 G151R Genotyping Mutant 
191T Yes No Known mutation KCNJ5 L168R Genotyping Mutant 
207T Yes No Known mutation KCNJ5 L168R Genotyping Mutant 
226T Yes No Known mutation ATP2B3 del425-426 Genotyping WT 
244T Yes No Known mutation KCNJ5 L168R Genotyping Mutant 
43T Yes No     WT 
96T Yes No     WT 
121T Yes No     WT 
180T Yes No     WT 
186T1 Yes No     WT 
186T2 Yes No     WT 
206T1 Yes No     WT 
206T2 Yes No     WT 
208T1 Yes No     WT 
208T2 Yes No     WT 
210T Yes No     WT 
216T1 Yes No     WT 
216T2 Yes No     WT 
221T2 Yes No     WT 
239T2 Yes No     WT 
WES:  Whole exome sequencing; WT: Wild-type; NS: Not sequenced. 
 
 
4.4.2 New cases with mutations in known genes 
On compiling all genotyping and whole exome sequencing results, number of mutant APAs 
for the known genes were calculated (Table 20). Mutations in these genes were found in 57% 
of APAs (=34/59), with the most number of CACNA1D mutants (20%). Surprisingly, mutations 
in KCNJ5 were found only in 17% APAs.  
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Table 20: Mutant samples per gene 
Mutant 
gene 
Mutant APAs: 
n 
Males:  
n (%) 
Females: 
n (%) 
% of APAs 
(n=59) 
% of patients 
(n=52) 
KCNJ5 10 1 (10) 9 (90) 16.9 19.2 
ATP1A1 5 5 (100) 0 8.5 9.6 
ATP2B3 5 5 (100) 0 8.5 9.6 
CTNNB1 2 0 2 (100) 3.4 3.8 
CACNA1D 12 11 (92) 1 (8) 20.3 23.1 
Total 
Mutants 
34  
(+1 - CADM1) 
22 (65) 
 
 
12 (35) 
 
 
 
57.6 
 
 
 
65.4 
 
 
 
 
4.4.3 Novel somatic mutations - CADM1 
As mentioned in Section 4.4.1, a novel mutation in the gene CADM1 was found in one of the 
APAs without any variants in the known genes previously described in aldosterone producing 
adenomas. The mutation in tumour sample of patient 184 was confirmed to be somatic as no 
traces of the variant allele were seen in adjacent normal tissue gDNA sequences (Fig. 41). The 
mutation “c. 1139 T>A, p. V380D” lies in the exon 11 of CADM1, a gene encoding cell adhesion 
molecule 1 (Fig. 43 & Fig. 44 in next chapter). To identify more cases harbouring identical or 
nearby variants in CADM1, 22 APAs that were not whole exome sequenced and had no 
mutation in known genes, were genotyped for exon 11 of CADM1.  
 
 
Fig. 41: Chromatograms for CADM1 sequencing for normal adrenal and APA gDNA samples of 
patient 184 showing single nucleotide variant, c. 1139 T>A, p. V380D. 
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Though no other cases could be identified in our study cohort, collaborators at the University 
of Munich, Germany found only one case amongst the 70 samples used for exome sequencing 
for somatic mutations in CADM1.  These 70 samples mainly harboured uncommon/unique 
mutations and were referred to as cases having ‘private’ mutations. This sample also 
harboured a single nucleotide variant “c. 1136 G>A, p. G379D”, substituting amino acid 
adjacent to the one in Cambridge patient (Fig. 42). The Munich patient presented at 44 years 
with hypokalaemic primary aldosteronism and was lateralised by adrenal vein sampling. 
Adrenalectomy revealed the presence of 1.5cm adenoma. Case report of patient 184 is 
discussed in detail in section 5.2.7 of next chapter. 
 
 
Fig. 42: Chromatograms for CADM1 sequencing for normal adrenal and APA gDNA samples of 
Munich patient showing single nucleotide variant, c. 1136 G>A, p. G379D. 
 
Both somatic mutations lead to substitution of uncharged amino acids, glycine (G) and valine 
(V) to negatively charged aspartate (D) residue in the single membrane spanning domain of 
the adhesion molecule CADM1. With only 2 cases of CADM1 mutations in total 129 APAs (59 
in Cambridge and 70 in Germany) it is clearly very rare but the close proximity of both 
substitutions made a strong case to pursue further investigation into the effects of CADM1 
mutations on its physiological function in normal adrenal and aldosterone secretion, which 
has not been studied previously. 
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4.5 Discussion 
In this study we have genotyped or whole exome sequenced 59 APAs from our cohort. 
Genotyping involved targeted Sanger sequencing for hotspots in the known 5 candidate genes 
– KCNJ5, CACNA1D, ATP1A1, ATP2B3 and CTNNB1. 37 APAs were subjected to whole exome 
sequencing and somatic mutations in known genes were found in 27 APAs. Mutations in 7 
APAs were found by complete genotyping of 22 APAs that could not be whole exome 
sequenced. We found a high mutation rate of 57% among 59 APAs, or of over 65% among 52 
patients. This mutation rate is comparable to that reported in large studies on Caucasian 
populations (Åkerström et al., 2015; Fernandes-Rosa et al., 2014). But interesting point to 
note here is the composition of genetic spectrum within similar overall mutation rates. We 
report much lower prevalence for KCNJ5 mutant APAs, that is only 17% compared to nearly 
40% in most cohorts (Table 20 vs Table 2). We found CACNA1D to be the most common of all 
candidate genes with mutations in over 20% APAs compared to the highest proportion of only 
10% reported in ENSAT cohort (Fernandes-Rosa et al., 2014). This high prevalence of 
CACNA1D mutations is supported by the report of it being the most commonly mutated in 
APCCs, possibly the precursors of CACNA1D mutant APAs (unpublished data). 
 
Interestingly, susceptibility to the mutations in different genes is much more exaggerated by 
gender in our study. We found only 1 (10%) male patient among 10 KCNJ5 mutants and 1 (8%) 
female amongst the 12 CACNA1D mutants (Table 20). Additionally, 5 mutants identified for 
each of the ATP1A1 and ATP2B3 genes were all males and 2 CTNNB1 gene mutants were 
females. Interestingly, the patient with the 6mm APA harbouring novel CADM1 mutation was 
also a male. The reason for this huge gender bias is still unknown and would require further 
investigation. 
 
We propose the differences in the prevalences of mutant genes in our study are due to 
different clinical practice in Addenbrooke’s Hospital where PET-CT using C11-metomidate has 
been preferred over AVS for detection of small APAs. Our findings greatly support the 
superiority of C11-metomidate PET-CT over AVS and other imaging methods so as to not miss 
cases that could potentially be cured by unilateral adrenalectomy. Rather short half-life of C11 
is an issue in wide application of this method and development of alternative radio-labels for 
metomidate without losing the specificity and resolution should be pursued as a matter of 
urgency.  
 
The detection of novel somatic mutation, V380D in CADM1 made whole exome sequencing 
in this study even more worthwhile (Fig. 41). Apart from CTNNB1, which is commonly mutated 
in many cancers, still rarely in APAs, this is the first case of a non-ion channel or transporter 
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gene, but a cell-cell adhesion protein to be mutated in APAs. Our interest in pursuing 
functional studies on CADM1 was enhanced by identification of another case of CADM1 
mutation by Munich’s team of investigators. This second mutation substituted the adjacent 
residue (G379D) to the one that was identified by us (Fig. 42), which suggests that the two 
mutations lie within the single transmembrane domain of this cell surface adhesion molecule. 
In this report, the functional data on both these mutations is provided in the following 
chapter. 
 
  
 
 
 
CHAPTER 5 
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CHAPTER 5 -  NOVEL MUTATIONS IN CELL ADHESION 
MOLECULE, CADM1 FOCUS ATTENTION ON THE 
SIGNIFICANCE OF CELL-CELL COMMUNICATION IN 
ALDOSTERONE SECRETION 
 
5.1 Abstract 
On whole exome sequencing of eight APAs up to 1cm in diameter, we found seven APAs with 
mutations in genes previously described in primary aldosteronism. Paired analysis of 
sequencing data for genomic DNA from adjacent normal adrenal and APA, using Mutect2 led 
us to discover a novel somatic mutation in the gene CADM1 in the eighth sample. This somatic 
mutation in CADM1 is the first instance of APA associated mutation in a gene not encoding 
an ion channel or ion transporter. CADM1 is a protein previously linked to cell-cell adhesion 
and tumour suppression, containing three extracellular immunoglobulin-like domains, a 
transmembrane helix and short cytoplasmic chain. Its expression is either downregulated or 
absent in many cancers, hence known as a tumour suppressor gene. The mutation in the APA 
was a single nucleotide polymorphism leading to substitution of uncharged valine residue 
lying in the transmembrane domain of CADM1 with the negatively charged aspartate, V380D. 
Likelihood of this somatic mutation in CADM1 to be causative was supported by the detection 
of another such case in a different cohort of PA patients in Munich. This case was again a 
singleton among 70 paired normal and APA samples that were whole exome sequenced by 
our collaborators. Similar to the mutation in our patient, the second case was also the 
aspartate substitution of the adjacent residue within the transmembrane domain, G379D of 
CADM1.  
 
CADM1 was found to be highly expressed in the physiological aldosterone producing zona 
glomerulosa (ZG), pathological aldosterone producing cell clusters (APCCs) and APAs. 
Overexpression of either mutant CADM1 in H295R cells led to 10-20 fold upregulation of 
CYP11B2 expression, and 2-4-fold increase in aldosterone secretion, compared to the wild-
type CADM1. CADM1 is a substrate for proteases and undergoes enzymatic processing at its 
ectodomains followed by generation of intracellular c-terminal domain (ICD) in a regulatory 
pathway. The increase in aldosterone was not mediated by differences in levels or 
composition of ICD fragments generated by mutant CADM1 compared to WT, as -secretase 
inhibition could not reverse the hyper aldosterone secretion. Presence of negatively charged 
amino acid within the transmembrane domain did not affect the cell surface localisation of 
either mutants, but we found some evidences of loss of cell-cell adhesion in H295R cells 
expressing mutant CADM1. This loss of inter-cellular adhesion in mutant cells could be the 
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cause of uncontrolled aldosterone synthesis. shRNA mediated silencing of CADM1 in H295R 
cells downregulated aldosterone synthesis and secretion.  
Transcriptome analysis, by RNAseq, of H295R cells expressing wild-type or mutant CADM1 or 
silenced CADM1 showed a large number of differentially expressed genes. Interestingly, most 
of the top genes upregulated in CADM1 silenced cells were also upregulated in mutant 
CADM1 expressing H295R cells. This suggests a loss-of-function phenotype for mutant 
proteins, except for CYP11B2 expression that goes in opposite directions. Some of the 
upregulated genes included ACTH receptor and several steroidogenic enzymes. An inverse 
relation in the absolute amounts and membrane localisation of CADM1 and Cx43 in adrenal 
sections and CADM1 silenced/overexpressing H295R cells was observed. This suggests 
CADM1 plays a role in regulating gap junctional intercellular communication (GJIC). Increased 
Cx43 expression could be mediated by downregulated TSG101 expression, a protein involved 
in lysosomal degradation of Cx43.  
 
It is proposed that under normal physiological conditions CADM1 acts as a crucial checkpoint 
in maintaining aldosterone synthesis, which is lost in silenced cells, downregulating 
aldosterone synthesis. In contrast, overexpressed mutants in the presence of endogenous 
wild-type CADM1 would interfere with trans-homophilic interactions of WT molecules and 
might also make trans-heterophilic interactions with WT CADM1 molecules in adjacent cells. 
This heterophilic interaction could act as a pseudo checkpoint for many signalling pathways 
including aldosterone synthesis. This hypothesis is supported by attenuated aldosterone 
signal from mutant expressing H295R cells in the presence of higher dose of WT CADM1.  
 
This study has helped us to focus our attention on the previously unexplored mechanism of 
intercellular adhesion and communication in ZG that is essential for glomerular pace-making 
required for regulated aldosterone secretion. 
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5.2 Introduction 
5.2.1 CADM1 gene discovery and structure  
CADM1, encodes a cell adhesion molecule 1 protein highly expressed in epithelial cells and 
maps to chromosome 11. Since its discovery it has been given several names like IGSF4 
(immunoglobulin superfamily 4), TSLC-1 (tumour suppressor in lung cancer-1), SynCAM1 
(synaptic cell adhesion molecule-1), NECL2 (nectin-like molecule 2), and SgIGSF 
(spermatogenic immunoglobulin superfamily) reflecting its structure, varied expression and 
functions via its interaction with a wide range of proteins both inter- and intra-cellularly 
(Section 5.2.3). 
 
Even though the tumourigenicity of non-small cell lung cancer (NSCLC) cell line A549 cells was 
suppressed by micro-cell mediated chromosome transfer of chromosomes 3 and 11 in early 
1990’s (Satoh et al., 1993), it was not until later in the decade and early millennium when two 
teams independently discovered the presence of a single gene in the 100kb LOH region in 
chromosome 11q23 containing most of tumour suppressing activity (Murakami et al., 1998) 
and named it IGSF4 (Gomyo et al., 1999) or TSLC1 (Kuramochi et al., 2001). LOH of TSLC1 has 
was implicated as the cause of hepatocellular carcinoma and pancreatic cancers (Kuramochi 
et al., 2001). 
 
The gene spans the sizes of 328 kilo bases on locus 11q23.3 and contains 12 exons (Biederer, 
2006). Alternative splicing of CADM1 mRNA occurs only between exon 7 and exon 11 which 
translate into proteins differing in extracellular sequence just upstream of the single 
transmembrane domain encoded within exon 11 (Fig. 43). Ectodomains of SP1, SP2 and SP6 
are constitutively shed because of the presence of exon 9; SP3 lacking exons 8-10 is non-
cleavable, and ectodomain of SP4 lacking exons 9-10 is shed only in response to stimuli as 
discussed later. SP4 is the most ubiquitously and dominantly expressed of all CADM1 
isoforms. It is involved in the homophilic cellular adhesion, which is dysregulated by 
expression of SP1 (Moiseeva et al., 2012). An isoform, named SP5 retains the intronic 
sequence between exon 7 and 8. Product of this transcript that lacks the transmembrane 
domain, is secreted from the cells and has an antagonistic effect on membranous CADM1 
mediated intercellular adhesion (Biederer, 2006; Koma et al., 2004). 
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Fig. 43: Alternative splicing and transcripts of human CADM1 
Six reported transcripts of human CADM1 are represented with their exonic structures. SP1-SP4 and SP6 are 
expressed on cell surface as indicated by the presence of exon 11 coding for transmembrane domain (yellow 
bar). Secreted isoform, SP5 is shown to have retained intronic sequence between exon 7 and exon 8. Green 
arrow indicates the common translational start site for all transcripts and red crosses indicate stop sites. Length 
of translated proteins in number of amino acids is indicated. 
 
5.2.2 CADM1 protein structure and processing 
CADM1 protein belongs to the immunoglobulin (Ig) like superfamily of proteins, containing 
N-terminal signal peptide, 3 extracellular Ig-like domains, a transmembrane helix followed by 
short cytoplasmic tail (Fig. 44). The cytoplasmic terminal is further characterised to contain 
protein 4.1-binding and PDZ type II domain binding motifs (Kuramochi et al., 2001). CADM1 
Ig-like domains contain 5 sites for N-glycosylation and a juxta-membrane threonine (T) rich 
domain is O-glycosylated (Biederer, 2006; Biederer et al., 2002; Fogel et al., 2010). N-
glycosylation of CADM1 is developmentally regulated (Kuramochi et al., 2001; Wakayama et 
al., 2003) and O-glycosylation is dependent on the presence of exon 8 in the expressed 
transcripts. CADM1 plays a vital role in cell-cell adhesion by trans-homophilic (with itself) or 
trans-heterophilic interaction with proteins of the same family in the adjacent cells. This inter-
cell interaction is mediated by the 3 Ig-like domains of the two molecules, which is promoted 
by presence of N-glycans (Fogel et al., 2010). 4.1-BM and PDZ-BM are crucial for localisation 
of CADM1 to the lateral membranes of epithelial cells, possibly via interaction with MAGuKs, 
membrane-associated guanylate kinases (Masuda et al., 2005). 
 
The extracellular domain of CADM1 undergoes proteolytic cleavage by a disintegrin and 
metalloprotease 10 (ADAM10) releasing the ectodomain in the extracellular space (Nagara et 
al., 2012) and  C-terminal fragment (-CTF) in the membrane. -CTF undergoes further 
intramembranous -secretase mediated cleavage releasing intracellular domain (ICD) into the 
cytoplasm. Both -CTF, by internalisation and cytoplasmic ICD translocate to mitochondria, 
depolarising outer membrane and activating cell apoptosis. This process of CADM1 
ectodomain shedding ultimately leads to loss of cell-cell adhesion and apoptosis, a process 
which is increased in many pathological conditions (discussed in Section 5.2.4.4). 
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Fig. 44: Schematic representation of CADM1 structure. 
Structural features of CADM1 protein are represented. Sites of proteolytic cleavage by ADAM10 and -secretase 
are shown releasing different fragments of the protein. Image adapted from (Murakami, 2005; Nagara et al., 
2012) 
 
5.2.3 Physiological function in various tissues 
As discussed in the previous section, CADM1 was discovered and named independently by 
various research groups as a molecule performing varied roles in several mouse and human 
tissues. All interaction partners of CADM1, for its role of inter-cellular adhesion belong to its 
own family of nectin and nectin-like (Necl) proteins. Intra-cellularly it functions in signalling 
pathways by interacting with members of protein-4.1 family or those containing PDZ domain. 
Some of these are discussed briefly in this section- 
 
5.2.3.1 Synapses 
CADM1, named SynCAM by Biederer and colleagues, was reported as the homophilic cell 
adhesion molecule in rat brains. SynCAM was found to interact with and translocating PDZ-
domain containing proteins CASK (calcium/calmodulin-dependent serine protein kinase) and 
syntenin to the synaptic plasma membranes in a Ca2+ independent manner (Biederer et al., 
2002). 
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5.2.3.2 Spermatogenesis 
SgIGSF/CADM1 is expressed in the mouse spermatogenic cells and essential for their adhesion 
to sertoli cells during the process of spermatogenesis (Wakayama et al., 2001, 2003). CADM1 
null mice fail to produce mature sperms leading to male infertility (Fujita et al., 2006; van der 
Weyden et al., 2006; Yamada et al., 2006). This is due to abrogated trans-heterophilic 
adhesion of CADM1 with PVR (poliovirus receptor) molecules expressed on the surface of 
sertoli cells in adult mouse testis (Wakayama et al., 2007). 
 
5.2.3.3 Endocrine role in pancreas 
Expression of CADM1 has been reported in all of human islet cells, but restricted to only 
glucagon secreting alpha cells of mouse pancreas, where it promotes islet cell attachment 
and communication to the nerve cells (Koma et al., 2008). Though CADM1 expression is 
correlated with the hormonal functionality of islet cell tumours, it has an inhibitory effect on 
glucagon secretion in normal physiological conditions. This was demonstrated by 
hypersecretion of glucagon in both in vivo and in vitro models of CADM1 
knockout/knockdown. Absence of CADM1 causes impaired translocation of a gap junction 
protein, connexin-36 to the plasma membrane resulting in loss of gap junctional intercellular 
communication (GJIC) (Ito et al., 2012). 
 
5.2.3.4 Regulation of actin cytoskeleton 
CADM1 plays a role in regulation of actin cytoskeleton in various systems. It interacts with 
actin filaments via direct interaction of its 4.1-BD with DAL1, also a tumour suppressor protein 
in lung cancer (Yageta et al., 2002). Integrity of this complex is essential for cell motility 
regulation and loss of any one component of the complex can lead to metastasis of lung 
cancer. 
 
5.2.3.5 Mast cell survival 
Various isoforms of CADM1 are differentially involved in the homophilic adhesion of mast 
cells to structural cells like fibroblasts, smooth muscle cells and nerves in the human lung 
(Furuno et al., 2005; Ito et al., 2003a; Moiseeva et al., 2013). SP4 isoform over-expression is 
essential for the survival and expansion of mast cells, which is favourable for the progression 
of pulmonary conditions such as asthma and allergy (Moiseeva et al., 2012).  
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5.2.3.6 Epidermis and wound repair 
CADM1/Necl-2 is also expressed in the hair follicles and keratinocytes in the epidermis of both 
human and mice. It was shown to play an important role in the skin wound repair which was 
significantly delayed in the knockout mice (Giangreco et al., 2009).  
 
5.2.3.7 Tumour suppression by different mechanisms 
There have been a few different mechanisms reported for CADM1’s tumour suppression 
activity. In epithelial cell cancers, also known as squamous cell carcinoma (SqCC) of lungs, 
head & neck, oesophagus & cervix, a phenomenon known as immune surveillance mediated 
by CADM1 has been studied in detail. Two research groups independently reported 
interaction of CADM1 with CRTAM (class I-restricted T-cell-associated molecule) which is 
expressed only on the surface of activated CD8+ T cells and natural killer (NK) cells (Boles et 
al., 2005; Galibert et al., 2005). It was observed the interaction between CADM1 on dendritic 
cells and CRTAM on immune cells results in the cytotoxicity of NK cells and interferon  (IFN-
) secretion from CD8+ T cells. Confirming these finding in vivo, CADM1 expression was 
essential for NK cells to completely reject A549 tumours induced in nude mice by lymphocyte 
and tumour cytotoxicity (Boles et al., 2005). In addition to NK cell mediated cytotoxicity for 
tumour growth and proliferation, there are some evidences supporting CADM1 mediates 
suppression of metastasis by sensitisation of tumour cells to the CD8+ T cells (Faraji et al., 
2012).  
 
There are also evidences from in vitro studies in MDCK cells that CADM1 prolongs Rac-GTP 
activity and lowers Rho-GTP activity resulting in suppressed epithelial-mesenchymal 
transition (EMT), an important phenomenon for metastasis of tumour cells (Masuda et al., 
2005).  
 
Integrin-64 dimers together with HER2/ERBB3 drive SqCC proliferation and metastases by 
inducing intracellular JAK/STAT signalling pathway. Vallath et al. dissected the roles of CADM1 
extracellular and intracellular domains in the tumour suppression activity and found 
interaction of its ectodomain with HER2/ERBB3 and integrin-64 complex to be crucial for 
this role. By analysing downstream signalling pathways, they showed CADM1 expression 
reduces cancer cell survival by attenuating phosphorylation and activity of STAT3 and hence 
its cell proliferation and migration (Kawano et al., 2009; Mizutani et al., 2011; Vallath et al., 
2016). 
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5.2.4 Pathological roles of CADM1 
5.2.4.1 Role in oncogenesis by loss of expression 
As discussed earlier, CADM1/TSLC1 gene was discovered as the tumour suppressor gene due 
to its loss of heterozygosity in many lung, pancreatic and liver cancers or cancer-driven cell 
lines (Kuramochi et al., 2001) but somatic mutations did not explain the loss of CADM1 
expression in majority of cases (discussed in Section 5.2.4.3). Kuramochi and colleagues 
investigated and using bisulphite sequencing discovered the presence of 6 CpG sites in 
CADM1 gene which could be putatively methylated. These sites localised in the 93bp region 
of CADM1 transcription promotor sequence. They reported a strong inverse correlation 
between methylation of CpG sites and CADM1 expression in normal lungs, epithelial cancers 
and non-cancerous/cancerous cell lines. These findings suggested CADM1 promotor 
methylation is the mechanism for gene inactivation and hence, loss of its tumour suppressive 
properties. Gradually promoter methylation status was reported to be the second hit in 
addition to LOH in many other epithelial cell cancers, as summarised in Table 21. 
 
Table 21: Summary of CADM1 promoter methylation in cancers 
Tumours 
Percentage of 
tumours with CADM1 
promotor methylation 
Reference 
NSCLC 44 % (Kuramochi et al., 2001) 
Hepatocellular cancer 29 % (Kuramochi et al., 2001) 
Pancreatic cancer 27 % (Kuramochi et al., 2001) 
Prostate cancer 32 % (Fukuhara et al., 2002) 
Oesophageal cancer 50 % (Ito et al., 2003b) 
Nasopharyngeal cancer 34 % (Lung et al., 2004) 
Cervical cancer 58 % (Li et al., 2005) 
Breast cancer 33 % (Allinen et al., 2002) 
Adapted from (Murakami, 2005) 
 
5.2.4.2 Role in oncogenesis by over-expression 
Despite CADM1’s significant role in tumour suppression of epithelial cell cancers, its 
overexpression has also been implicated in oncogenesis of leukaemia. It was proposed on 
observing ectopic expression of CADM1 in primary human adult T-cell leukaemia/lymphoma 
(ATLL) cells. Sasaki et al. demonstrated that CADM1, which is not expressed in normal or 
activated T-cells, was over-expressed in ATLL cells and HTLV-1 infected T-cell lines. This 
augmented their adhesion to the vascular endothelial cells promoting infiltration of ATL cells 
into other organs (Murakami, 2005; Sasaki et al., 2005). Another group later showed CADM1 
interacts with Tiam1 (T-lymphoma invasion and metastasis 1), a Rac-specific guanine 
nucleotide exchange factor via its PDZ domain (Masuda et al., 2010) which plays a role in 
regulation of actin cytoskeleton. This interaction induces formation of lamellipodia in ATLL 
cells facilitating infiltration of leukaemic cells (Nakahata and Morishita, 2012). 
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Atopic dermatitis (AD) is an inflammatory skin disorder characterised by eczematous skin 
lesions due to increased adhesion of mast cells to sensory nerve fibres in the skin. Hagiyama 
et al. reported it is because of over 3-fold CADM1 expression in the AD-like skin lesions from 
hapten-induced AD mouse model compared to normal skin (Hagiyama et al., 2013). They 
confirmed these finding in vitro by overexpressing CADM1 in mouse origin mast-cell line, IC2 
leading to their enhanced adhesion to dorsal root ganglion neurites in co-cultures to model 
the neuro-immune interactions. 
 
5.2.4.3 Mutations in CADM1 
Discovery of CADM1 as TSLC1 included reporting of 3 somatic mutations one each in NSCLC, 
hepatocellular carcinoma (HCC) and pancreatic cancer (PaC) in a cohort of 130 tumour 
samples (Kuramochi et al., 2001). The mutations in CADM1 were (1) deletion of 2bp at codon 
423-424 leading to loss of stop codon and substitution of 19 amino acids with 52 amino acids 
in NSCLC, (2) K208X in HCC and (3) M388T in PaC. No functional studies to investigate the 
effects of mutations were reported. These 3 samples not only harboured the somatic 
mutations, but also the LOH of the wild-type TSLC1 as the second hit for complete loss of 
TSLC1 expression in tumour samples.  
 
In a cohort of 195 patients with autism spectrum disorder (ASD), Zhiling et al. identified two 
patients with heterozygous missense mutations in CADM1 (Zhiling et al., 2008). Both 
mutations, H246N and Y251S, lie in the third Ig-like domain and led to impaired translocation 
of CADM1 to the plasma membrane in vitro studies. This was due to increased accumulation 
in the endoplasmic reticulum leading to ER stress, hence more susceptibility to proteolysis. 
Both mutants showed reduced homophilic interaction, resulting in shorter or no dendrites 
formation in the neurons. These findings highlighted the significant role of CADM1 in 
synaptogenesis (Fujita et al., 2010). 
 
5.2.4.4 Increased ectodomain shedding 
The phenomenon of proteolytic cleavage of extracellular domain of CADM1 or other adhesion 
molecules is known as ectodomain shedding. This enzymatic cleavage of CADM1 by ADAM10 
results in the reduction of full-length CADM1 on the lateral membranes of epithelial cells, loss 
of homophilic cellular adhesion and increased cell apoptosis. In a few recent studies increased 
ectodomain shedding of CADM1 has been described as the main reason for pathogenesis of 
type 2 diabetes (Inoue et al., 2014), lung emphysema (Mimae et al., 2014) and idiopathic 
interstitial pneumonia (Yoneshige et al., 2015). By western blotting for CADM1 in protein 
extracts of pathological tissues from diseased cases, researchers observed lower levels of full-
length CADM1 and increased generation of -CTFs in pancreatic insulin-secreting islet β cells 
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of diabetic patients, emphysematous lungs and idiopathic interstitial pneumonia lungs 
compared to non-diseased tissues respectively. Reduced membranous staining, more 
diffused cytoplasmic staining for CADM1 was supported by significantly higher TUNEL staining 
as a measure for apoptosis was also observed in all pathological samples. 
 
5.2.5 CADM1 expression in human adrenal 
CADM1’s role in many tissue types and cancers is well establish but not much is known about 
its function in adrenal gland and aldosterone synthesis. CADM1 expression was queried in the 
published microarray study from our lab showing transcriptome analysis of laser captured 
micro-dissected (LCM) zona glomerulosa and zona fasciculata of adrenal cortex of Conn’s 
patients along with the aldosterone-producing adenomas (APAs) in the same samples (Shaikh 
et al., 2015; Zhou et al., 2015). CADM1 mRNA expression was significantly higher in ZG than 
ZF, by 2.3-fold, but no difference was observed in expression levels in ZG or APAs (Fig. 45). 
Another study comparing transcriptome of whole normal adrenal and APAs not from same 
patients reported a 2-fold higher CADM1/IGSF4 expression in the APAs, though it is not clear 
if this difference was statistically significant (Williams et al., 2010). 
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Fig. 45: Microarray expression analysis of CADM1 in adrenal cortex and APAs 
Relative expression values as log2 for CADM1 in zona glomerulosa (ZG), zona fasciculata (ZF) and aldosterone 
producing adenomas (APA) from same patients (n=13, One-way ANOVA, ****P<0.0001, compared to ZG). 
(Shaikh et al., 2015; Zhou et al., 2015). 
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5.2.6 Connexin-43/GJA1 in human adrenal 
Prompted by the finding of reduced cell surface expression of connexin-36 (encoded by GJD2) 
in the endocrine cells of mouse pancreas on silencing CADM1 expression (Ito et al., 2012), I 
queried the expression of various gap junction proteins in adrenal cortex. This was to 
investigate if CADM1 expression has a similar effect on GJIC and the regulation of aldosterone 
secretion from ZG in the adrenal cortex. The microarray analysis of ZG and ZF RNA samples 
(Shaikh et al., 2015; Zhou et al., 2015) revealed GJA1 encoding connexin-43 to be the most 
predominant gap junction protein expressed (Fig. 46). GJA1 is highly expressed in both ZG and 
ZF, but significantly higher (approx. 4-fold) in the ZF at mRNA level (Fig. 47). Slightly significant 
higher expression in matched APAs compared to ZG was also found. 
 
In an attempt to characterise the type and role of gap junction proteins in human adrenal 
gland and adrenocortical tumours, Murray et al. reported connexin-43 to be the most 
predominant of the 3 types tested, connexin-43, connexin-32 (GJB1) and connexin-26 (GJB2) 
(Murray et al., 2000). They also reported ZF to express the highest density of gap junctions in 
the whole of adrenal cortex, with reduced and lowest numbers in benign and malignant 
adrenocortical tumours, respectively suggesting the loss of GJIC to play a role in 
carcinogenesis. In the same study only negligible amount of gap junctions could be detected 
in H295 cells (Murray et al., 2000), derived from an adrenocortical carcinoma and the parental 
cell line for more commonly used H295R cells with better adherent properties (Rainey et al., 
1994, 2004). No connexin-43 expression was found in the adrenal medulla and 
pheochromocytomas (Willenberg et al., 2006). 
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Fig. 46: Microarray expression analysis of gap junction proteins in adrenal cortex 
Relative expression values as log2 for gap junction proteins in zona glomerulosa (ZG, n=20) and zona fasciculata 
(ZF, n=21) of adrenal cortex of same patients. Horizontal line at y=2 represents the minimum threshold level of 
detection in the array. (Shaikh et al., 2015; Zhou et al., 2015). 
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Fig. 47 Microarray expression analysis of GJA1 in adrenal cortex and APAs 
Relative expression values as log2 for GJA1 in zona glomerulosa (ZG), zona fasciculata (ZF) and aldosterone 
producing adenomas (APA) from same patients (n=13, One-way ANOVA, ****P<0.0001, *P=0.0102 compared 
to ZG). (Shaikh et al., 2015; Zhou et al., 2015). 
 
5.2.7 Case report of patient 184, CADM1mutant APA 
The patient with the CADM1 mutant APA was a 46 year old male, who presented with low 
renin hypertension with blood pressure of 164/116 mmHg, not managed despite being on 4 
anti-hypertensive drugs - bisoprolol, lacidipine and losartan/hydrochlorothiazide. Patient’s 
aldosterone-renin-ratio (ARR) was found to be fluctuating on several occasions. Readings at 
two visits were 1) plasma aldosterone 147pmol/L and renin 11mU/L; and 2) plasma 
aldosterone 647pmol/L and renin 5mU/L. 
Abdominal CT scan revealed normal left adrenal but presence of a 13mm adenoma on the 
right adrenal (Fig. 48). The findings were confirmed by adrenal vein sampling (AVS) for 
lateralisation to right adrenal with aldosterone-to-cortisol ratio of >12.4 compared to 1.9 for 
left adrenal vein (Table 22).  
 
Table 22: AVS results of patient 184 
Vein 
Cortisol 
(nmol/L) 
Aldosterone 
(pmol/L) 
Aldosterone/Cortisol 
(x1000) 
IVC 1,701 1,803 2.5 
Right adrenal 15,365 >190,000 >12.4 
Left adrenal 21,436 41,070 1.9 
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a. 
 
b. 
 
Fig. 48: Abdominal CT scan of patient 184. 
a. Axial view, and b. Coronal view of patient 184’s abdominal CT scans. Presence of an adenoma on right adrenal 
gland is indicated by red arrows. 
 
With this successful lateralisation and diagnosis of primary aldosteronism, the patient 
underwent right adrenalectomy. Removed adrenal was dissected by pathologists to identify 
the adenoma (Fig. 49). A yellow/brown cortical nodule measuring 6x6mm was identified. Rest 
of the adrenal also appeared to be finely nodular with nodules less than 1mm in diameter. 
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Fig. 49: Sliced right adrenal of patient 184. Adenoma is indicated by black arrow. 
 
Haematoxylin and eosin (H&E) staining and immunohistochemistry for CYP11B1, CYP11B2 
and KCNJ5 on the FFPE sections of adenoma and adjacent normal tissue was done at the 
Human Tissue Bank, Addenbrooke’s Hospital (Fig. 50). Adenoma mostly stained positive for 
CYP11B2, with a few patches of cells negative. Two APCCs were also detected by positive 
CYP11B2 staining. The pattern was similar for KCNJ5 staining, but reciprocal for CYP11B1 as 
expected. On microscopic investigations, the nodule/APA appeared to contain a mix of lipid-
rich (ZF-like) and lipid-depleted (ZG-like) cells with presence of spironolactone bodies in the 
ZG-like regions (Fig. 51). APCCs also showed many spironolactone bodies, but ZG of the 
adjacent normal cortex was negative for these and CYP11B2 expression. 
 
Post adrenalectomy, the patient was completely cured of hypertension without any anti-
hypertensive medications, with the reading of 121/88mmHg blood pressure, 27mU/L renin 
and 143pmol/L aldosterone. 
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Fig. 50: Immuno-staining for CYP11B2, KCNJ5 & CYP11B1 and H&E staining for patient 184 tumour 
and adjacent normal adrenal. 
(Courtesy: Dr Alison Marker, Department of Pathology, Addenbrooke’s Hospital) 
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a. 
 
b. 
 
Fig. 51: H&E staining for APA and APCC in adrenal section of 184. 
a. H&E staining for APA shows mix of ZG-like and ZF-like regions with spironolactone bodies in the ZG-like region 
(black arrow heads). b. Similar enrichment of spironolactone bodies was seen in the APCC within the adrenal 
cortex. 
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5.2.8 Aims and Hypotheses  
Main aim for this part of my PhD was to investigate the role of CADM1 in aldosterone 
producing adrenal cells and the effect of somatic mutations we discovered. 
 
Before investigating the effects of mutations on CADM1 function, its expression in human 
adrenal tissues was analysed. In vitro studies were carried out by shRNA mediated CADM1 
silencing in H295R cells to investigate how endogenous CADM1 regulated aldosterone 
secretion. 
 
As discussed earlier, the two somatic mutations found in CADM1 localised in the 
transmembrane domain of the protein changing uncharged amino acids, glycine (G) and 
valine (V) to negatively charged aspartate residue (D). It was hypothesised that these 
aspartate substitutions in the transmembrane -helix would lead to mis-folding of the protein 
preventing its normal translocation to the plasma membrane. This loss of CADM1 expression 
on the cell surface would result in loss of cellular adhesion and interaction supporting 
adenoma formation and hyper aldosterone secretion.  
 
If the mutations prove to be functional, by at least influencing (increasing) aldosterone 
secretion compared to the WT, this would be the first study of a cell adhesion protein in 
physiological aldosterone secretion in normal adrenal ZG and pathological condition of 
primary aldosteronism.  
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5.3 Materials and methods 
5.3.1 RNA extraction from FFPE sections of 184NT 
Due to unavailability of RNALater samples for the normal or APA tissue of patient 184, RNA 
was extracted from FFPE tissue blocks. 10 sections of 4m thickness each for normal tissue 
and APA tissue block were cut and collected separately in 2ml centrifuge tubes. Sections were 
deparaffinised in 1ml xylene by vigorous vortexing for 10sec. Dissolved sections were 
centrifuged at full speed for 2min. supernatant was discarded and pellet was washed in 100% 
ethanol for complete removal of residual xylene. Sections were centrifuged again and 
supernatant discarded. Pellet was air dried at room temperature for complete evaporation of 
ethanol. From these deparaffinised sections RNA was extracted using RNeasy FFPE Kit (73504, 
Qiagen) according to manufacturer’s instructions. DNase treated RNA was finally eluted in 
30l nuclease-free water and concentration was estimated by Nanodrop. 
  
5.3.2 RT-PCR primers and conditions 
To study CADM1 expression in H295R cells and human adrenal tissues, primers specific to 
CADM1 cDNA were designed and are listed in the Table 23. PCRs were setup under conditions 
described earlier (Section 2.1.5) using GoTaq polymerase with TD_68_60 PCR program. 
 
Table 23: List of CADM1 RT primers. 
Primer Name Location on mRNA/cDNA Sequence 
6F Exon 6 GCTTGAGTTAACATGTGAAGCCATCG 
7-8F Boundary of exon 7 & 8 GCTGTATGTATACGATCCCCCCAC 
9-10R Boundary of exon 9 & 10 AGTGAAGTATGTACCTTTATGTCTGGC 
Int7R Intron after exon 7 CCAACTGGTTTTTGATTTTCAACTTGACC 
9F Exon 9 ATTCCCGAGCAGGTGAAGAAGG 
 
5.3.3 CADM1 cloning and mutagenesis 
Full length cDNA sequence for CADM1 open reading frame was amplified from H295R cDNA 
as template using Q5 DNA polymerase. 5’ primer contained CACC sequence followed by Flag-
tag sequence upstream of CADM1 start codon and 3’ primer contained Myc-tag sequence 
downstream of last coding amino acid of CADM1 (Table 24). Amplified product was cloned 
into the gateway cloning entry vector, pENTR using directional TOPO cloning technology 
(pENTR™/D-TOPO™ Cloning Kit, K240020, Invitrogen) according to manufacturer’s 
instructions.  
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Table 24: CADM1 cloning primers. 
CADM1 cloning 
primer 
Primer sequence (5’  3’) 
Topo-Flag-
CADM1-F 
CACCATGGATTACAAGGATGACGACGATAAGGGATCCATGGCGAGTGTAGTGCTG 
Myc-CADM1-R 
GCATGAATTCCTACAGATCTTCTTCGCTAATCAGTTTCTGTTCGATGAAGTACTCTTTC
TTTTCTTCG 
 
Topo ligation reaction was transformed into TOP10 chemically competent E.coli and positive 
clones were selected on LB agar plates containing kanamycin. pENTR clones for CADM1 were 
minipreped and sequence verified. All clones corresponded to SP4 isoform of CADM1 which 
was then used as template to prepare SP1 isoform by a mutagenesis reaction using Q5 site-
directed mutagenesis kit (NEB). Mutagenesis primers were designed using NEBaseChanger 
online tool (NEB) to insert 33bp sequence corresponding to exon 9A (Table 25). Both CADM1-
SP4/SP1-pENTR plasmids were used to make the 2 mutant constructs for G379D and V380D, 
following the same procedure. Finally WT and 2 mutant constructs for SP4 and SP1 CADM1 
isoforms in pENTR vector were ready for gateway cloning reaction. 
 
Table 25: CADM1 mutagenesis primers 
Mutagenesis primer Primer Sequence 
Ins-Ex9A-F gaaccagcagttcacgATTCCCGAGCAGGTGAAG 
Ins-Ex9A-R tgtcgtcgccgttgtgtCTGTGATGATGGTAAGGATG 
G379D-F GTGATCGGTGaCGTCGTGGCG 
G379D-R GGCATGATCCACTGCCCTG 
V380D-F ATCGGTGGCGaCGTGGCGGTG 
V380D-R CACGGCATGATCCACTGCC 
 
pENTR constructs were used for transfer of cloned cDNAs into pLOC vector in a attL/attR 
recombination reaction using LR Clonase II enzyme mix (11791020, Invitrogen) according to 
manufacturer’s instructions. Recombined plasmids reaction was transformed into Stable 
competent cells (NEB) and selected on LB agar plates containing ampicillin. Positive clones 
were minipreped and sequence verified. Clones with correct sequences were maxipreped and 
used for preparing lentivirus by transfection of HEK293T cells. The PuroR-pLOC construct 
described earlier was used as the transfection control empty vector (EV) in this study. 
 
5.3.4 CADM1 shRNA cloning 
21bp long shRNA sequences for scrambled (non-targeting control) or specific to CADM1 (Fig. 
52) were inserted in the pLVTH vector using Q5 site-directed mutagenesis kit (NEB). 
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Mutagenesis primers were designed using NEBaseChanger online tool (NEB) to insert shRNA, 
consisting of sense, loop and antisense sequences into the vector (Table 26). 
 
a. 
 
b. 
 
Fig. 52: Sequences for scrambled (a) and CADM1 (b) shRNAs in pLVTH 
 
 
Table 26: CADM1 shRNA cloning primers 
Primer Name Primer sequence 
scrambled-F tccaacgaggttattacgtaaggtattTTTTTGGAAAAGCTTATCGATAC 
scrambled-R tccaacgaggttattacgtaaggtatccGGGGATCTGTGGTCTCAT 
shCADM1-F tccaattgtagaggataagtcatctgtTTTTTGGAAAAGCTTATCGATAC 
shCADM1-R tccaattgtagaggataagtcatctgccGGGGATCTGTGGTCTCAT 
 
Mutagenesis KLD reaction was used to transform NEB Stable E.coli and selected on LB agar 
plates containing ampicillin. Positive clones were minipreped and sequence verified. Clones 
with correct sequences were maxipreped and used for preparing lentivirus by transfection of 
HEK293T cells. 
 
5.3.5 Cell culture media concentration  
In the experiments to study CADM1 ectodomain shedding in H295R, cell culture supernatants 
were western blotted for -NTF levels using anti-CADM1-NT (3E1) antibody. Transduced cells 
were cultured in phenol-red and serum free DMEM F-12/HAM media for 24hr. Conditioned 
media was collected and concentrated using Amicon Ultra-0.5 Centrifugal Filter Units with 
Ultracel-30 membrane (Millipore). Filtration units containing 500l supernatants were 
centrifuged at 14,000xg for 10min at 4C to concentrate samples by a factor of 22. 
Concentrated supernatants were collected and diluted with 4X Bolt™ LDS Sample Buffer 
(B0007, ThermoFisher) for gel electrophoresis and western blotting. 
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5.3.6 Western blotting 
According to the experiment and availability of total protein after protein assay, 10-40g cell 
lysate protein or 15-20l concentrated cell culture media was diluted with the 4X Bolt™ LDS 
Sample Buffer (B0007, ThermoFisher) and 10X Bolt® Sample Reducing Agent (B0009, 
ThermoFisher). Samples were incubated at 37C for 5 min before running on Bolt® 10% Bis-
Tris Plus Gels (ThermoFisher) in Bolt® MES SDS Running Buffer at 165V for 30-35min at room 
temperature.  
 
For western blotting, gels were removed from gel-casting plates, equilibrated in the Tris-
Glycine transfer buffer containing 10% methanol and 0.05% SDS for 10min before setting up 
the transfer stacks. PVDF-FL membrane with no auto-fluorescence were activated in 100% 
methanol for 15sec and equilibrated in the transfer buffer for 5min. Protein transfer was set 
up at 60V for 1hr in cold room.  
 
PVDF membranes with transferred proteins were blocked in 5% fat-free milk-TBS solution for 
1hr at room temperature and incubated with primary antibodies diluted in 5% milk-TBST (with 
0.1% Triton X-100) overnight at 4C. Two primary antibodies from different species (mouse, 
rabbit or chicken) were used at the same time at this step as species-specific secondary 
antibodies conjugated with either IRDye 680RD or IRDye 800CW fluorophores were used for 
detection by Odyssey scanner, Li-Cor. Membranes incubated with primary antibodies were 
washed in TBST 3 times for 5min each at room temperature and incubated with secondary 
antibodies diluted in 5% milk-TBST for 1hr. Membranes were washed again in TBST for 30min 
and rinsed in deionised water before scanning for protein detection using 700nm and 800nm 
channels in the Odyssey scanner. Resulting images were analysed with ImageStudio Lite 
software (Li-Cor).  
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5.4 Results 
5.4.1 CADM1 transcripts in H295R cells, human adrenal and APAs 
Expression of different CADM1 transcripts was tested in H295R cells followed by semi-
quantitative analysis in APAs and adjacent normal adrenals by RT-PCRs. Relative expression 
levels of total CADM1 were also tested in paired normal and APA samples by qPCRs. Finally 
CADM1 protein localisation in the FFPE section of normal adrenal and APA samples was 
studied using immunohistochemistry. 
 
5.4.1.1 CADM1 expression in H295R cells 
CADM1 primers specific for targeted regions in the cDNA sequence were used for PCR and 
product sizes could differentiate between alternatively spliced transcripts’ expression in 
H295R cells. It was found that CADM1 expression was easily detectable in cDNA of H295R 
cells (Fig. 53). Primer pair, 6F + 9-10R amplified products corresponding to transcripts SP4 and 
SP1 (Lane 1), but most predominantly SP4 that translates into an isoform 442 amino acids in 
length. This expression pattern was confirmed by another pair of primers, 7-8F + 9-10R (Lane 
3) with shorter products for all isoforms. Transcript SP1 translates into a 453 amino acid long 
isoform. In addition to these two membrane localised isoforms of CADM1, positive 
amplification in Lane 2 with primer pair 6F + Int7R (where Int7R lies in the intronic sequence 
between exon 7 and 8) confirmed the expression of soluble/secreted isoform SP5 of CADM1. 
 
 
Fig. 53: RT-PCR for CADM1 expression in H295R cells. 
 
5.4.1.2 CADM1 expression in human adrenal and APAs 
RT-PCRs for paired normal (N) and APA (T) cDNA samples were performed using primers 7-8F 
+ 9-10R. This was to verify if expression pattern of CADM1 isoforms in these samples follows 
that in H295R cells. SP4 isoform was found to be the most predominant of all membrane 
localised CADM1 isoforms in normal adrenals and APAs as well. All APAs used in this analysis 
had the somatic mutations in KCNJ5, CACNA1D or CTNNB1 as indicated in the Fig. 54.  
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Fig. 54: RT-PCR for CADM1 expression in human normal adrenal and APA samples. 
RT-PCR for CADM1 expression using primers 7-8F + 9-10R to amplify membrane localised CADM1 isoforms. 
Paired normal (N) and APA (T) cDNAs were used as template for PCRs. Patient IDs are indicated above each pair 
and the mutant gene for each APA is shown in the table. 
 
5.4.2 CADM1 protein localisation in human adrenal and APAs 
FFPE sections of human adrenal of patients who underwent adrenalectomy because of 
diagnosis of pheochromocytoma or primary aldosteronism due to APAs were immuno-
stained using antibodies against CADM1 C-terminal or CYP11B2. Serial sections were stained 
for 2 proteins to minimise the histological and structure variations.  
 
Typically not much CYP11B2 staining was observed in the ZG, except for intense staining in 
random small clusters of cells that have been previously defined as aldosterone producing 
cell clusters, APCCs. As expected all APAs tested stained positively for CYP11B2 with some 
patches of cells low in expression. Interestingly, strong CADM1 staining on plasma membrane 
was observed throughout ZG and APCCs (Fig. 55, Fig. 56). No differences were observed in 
CADM1 staining patterns in normal adrenals next to pheochromocytoma or APAs. ZF and 
adrenal medulla also expressed high levels of CADM1. 
 
Within APAs CADM1 expression followed the expression pattern of of CYP11B2. Small patches 
of cells negative for CYP11B2 also expressed lower levels of CADM1 (Fig. 57). No differences 
were found in the pattern of CADM1 expression in patient 184’s APA and adjacent normal 
tissue (Fig. 58).   
129 
 
 
5.4.2.1 Normal adrenal and APCCs 
 
Fig. 55: Immunohistochemistry for CADM1 and CYP11B2 in normal adrenal gland. 
Representative image for serial FFPE sections of normal adrenal gland of patients with pheochromocytoma 
stained with anti-CADM1 (a & c) and anti-CYP11B2 (b & d) antibodies (n=3). Low magnification images for both 
antibodies (a & b) show overall staining pattern in adrenal cortex and medulla. Higher power images (c & d) 
show staining pattern in ZG, ZF, ZR and APCCs (aldosterone-producing cell clusters) within the adrenal cortex. 
Scale bars are also shown. 
 
 
Fig. 56: Immunohistochemistry for CADM1 and CYP11B2 in adrenal cortex next to APA. 
Representative image for serial FFPE sections of normal adrenal gland of patients with APA stained with anti-
CADM1 (a & c) and anti-CYP11B2 (b & d) antibodies (n=5). Scale bars are also shown. 
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5.4.2.2 APAs 
 
Fig. 57: Immunohistochemistry for CADM1 and CYP11B2 in APAs. 
Representative image for serial FFPE sections of APAs with indicated mutations stained with anti-CADM1 (a, c, 
e & g) and anti-CYP11B2 (b, d, f & h) antibodies (n=5). 
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5.4.2.3 Patient 184 
 
Fig. 58: Immunohistochemistry for CADM1 and CYP11B2 in patient 184’s adrenal sections. 
Serial FFPE sections of CADM1 mutant APA and adjacent normal adrenal stained with anti-CADM1 (a, c, e & g) 
and anti-CYP11B2 (b, d, f & h) antibodies. Low magnification images for both antibodies (a & b) show overall 
staining pattern. Higher power images (c - h) show regions ZG, ZF, ZR, medulla (e & f); APCC (c & d) and the APA 
(g & h). Scale bars are also shown. 
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5.4.3 Confirmation of mutant allele expression in 184T cDNA 
cDNA from APA sample of patient 184 was sequenced to confirm the expression of mutant 
allele of CADM1 at the mRNA level. RNA samples available for patient 184 adjacent normal 
adrenal and APA were sourced from FFPE sections. CADM1 cDNA was amplified using primers 
9F and 9-10R (Section 5.3.2) targeting only 146bp amplicon, small enough to be amplified 
given the quality of cDNA from these samples. Sanger sequencing revealed mutant allele (c. 
1139 T>A, p. V380D) expression in the APA sample (Fig. 59). Though it is not a quantitative 
measure, but height of peaks for the wild-type and mutant alleles at cDNA position 1139 
appeared approximately in similar proportion to that in the APA gDNA sample (Fig. 41). This 
confirms that the mutation does not result in gene deletion or silencing, which rules out the 
loss of tumour suppressor role of CADM1 to be the cause of APA formation. 
 
 
Fig. 59: Chromatograms for CADM1 sequencing in the cDNA of patient 184 normal adrenal and 
APA samples showing expression of mutant allele, c. 1139 T>A. 
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5.4.4 Mutant CADM1 proteins are processed differentially by proteases  
H295R cells transduced with equal transducing units of lentivirus for wild-type or mutant 
CADM1 in two isoforms, SP4 and SP1 were analysed for protein expression and susceptibility 
to processing by endogenous proteases of -, - or -secretase families. Whole cell lysates 
and cell culture media were western blotted using specific antibodies towards intracellular C-
terminal and extracellular Ig-domains in N-terminal of CADM1. In addition to CADM1 
antibodies, cell lysates were also immuno-blotted with the anti-Myc antibody as all constructs 
were tagged with Myc sequence on the C-terminal of CADM1 coding sequence. 
 
Myc antibody detected WT and both mutant CADM1 proteins in the two isoforms tested. Full-
length glycosylated and non-glycosylated forms of the protein were detected across all 
samples, but no further processed fragments were detected. Despite equal transduction 
efficiency in all samples, as revealed by equal tGFP expression, total CADM1-V380D 
expression was relatively lower as compared to CADM1-WT (Fig. 60a). No such dramatic 
effect was seen for other mutant, CADM1-G379D. Due to high endogenous CADM1 
expression in H295R cells, the over-expression of CADM1-WT and mutant proteins was not as 
obvious when blotted with the CADM1-CT antibody, except for the -C terminal fragment (-
CTF) that is produced by the action of -secretase (Fig. 60b). H295R cells overexpressing 
CADM1-WT contained -CTF as two bands (doublet) compared to that from the endogenous 
CADM1. In both isoforms of CADM1, bigger of the two bands in -CTF from CADM1-G379D 
seemed slightly smaller but at higher levels than that from CADM1-WT. -CTF from CADM1-
V380D seemed to be present only as a single band similar to that produced by endogenous 
CADM1.  
 
Due to lower levels of CADM1-V380D protein seen in the cell lysates it was tested if this was 
due to increased ectodomain shedding of V380D mutant by the proteases producing more -
NTF in the supernatant. Media collected from the transduced cells was concentrated and 
blotted for detection of -NTF using CADM1-NT (3E1) antibody. No more ectodomain 
shedding was found in the CADM1-G379D than that in CADM1-WT (Fig. 60c), but the levels 
of -NTF in CADM1-V380D expressing cells were much lower than the CADM1-WT and 
comparable to the endogenous -NTF as seen in the empty vector lane. It was concluded 
even though CADM1-V380D protein was glycosylated and probably translocates to the 
plasma membrane but not as efficiently as the WT or the G379D mutant protein and was less 
stable and degraded at higher rate. 
  
134 
 
 
 
 
Fig. 60: Western blot analysis for expression of CADM1 WT or mutants in transduced H295R cells. 
Immunoblot for whole cell-lysate from transduced H295R cells using a. anti-Myc and anti-tGFP antibodies; and 
b. anti-CADM1 CT and anti-GAPDH antibodies. c. Immunoblot for concentrated cell-culture supernatant using 
anti-CADM1 NT antibody (n=3). d. Schematic representation of CADM1 protein structure showing various 
domains and cleavage fragments generated by action of proteases, ADAM10 and -secretase. UT: Un-
transduced, EV:  Empty-vector, WT: Wild-Type, NTF: N-terminal fragment, CTF: C-terminal fragment, ICD: 
intracellular domain. Transmembrane domain amino acid sequence for WT and mutants, G379D and V380D is 
also shown.  
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5.4.5 Mutant CADM1 upregulates aldosterone synthesis 
5.4.5.1 CYP11B2 mRNA & aldosterone secretion 
H295R cells transduced with lentivirus for CADM1-WT or mutants in the two isoforms were 
tested for aldosterone synthase, CYP11B2 expression and aldosterone secretion. 72hrs post-
transduction, cells were starved overnight in serum-free media and replaced with fresh 
serum-free media for another 24hrs. This conditioned media was analysed for aldosterone 
levels and cells were harvested for RNA extraction and qPCRs for CADM1 and CYP11B2.  
 
CADM1 qPCR data revealed comparable levels of transduction for all constructs and was 
about 10-fold higher CADM1 expression compared to un-transduced and empty-vector 
controls (Fig. 61a). Overexpression of CADM1-WT led to no changes in CYP11B2 mRNA or 
aldosterone secretion compared to the controls (Fig. 61b). Interestingly both mutants, 
CADM1-G379D and CADM1-V380D upregulated CYP11B2 expression by approximately 12-
folds and 15-22 folds, respectively, compared to controls and CADM1-WT. The corresponding 
increase in aldosterone secretion ranged from 2.6-fold for CADM1-G379D to 3.7-fold for 
CADM1-V380D (Fig. 61c). No significant differences were found between the CADM1 isoforms 
SP4 and SP1 for any of the WT or mutant constructs. 
 
5.4.5.2 Immunocytochemistry for CADM1 and CYP11B2 
The significant upregulation of CYP11B2 mRNA in the H295R cells expressing mutant CADM1 
was investigated by confocal imaging in order to establish the relation between CADM1 
genotype and CYP11B2 expression at cellular level. This experiment would also show if there 
is any direct correlation between CYP11B2 expression and higher CADM1-WT expression as 
observed in ZG cells of adrenal cortex and APCCs (Section 5.4.1). H295R cells grown on 
coverslips were transduced with lentivirus for CADM1-WT or mutants, which were fixed and 
immuno-stained with anti-CYP11B2 and anti-CADM1-NT (3E1) antibodies 72hrs after 
transduction.  
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Fig. 61: Mutant CADM1 upregulates CYP11B2 mRNA expression and aldosterone secretion. 
a. Estimation of relative CADM1 mRNA expression to show equal transduction efficiency for all constructs b. 
Relative CYP11B2 mRNA expression in the transduced cells. c. Corresponding aldosterone assay (n=4 in 
quadruplicate). (One-way ANOVA, ****P<0.0001, compared to EV). Error bars represent s.e.m. 
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Transduced cells were distinguished from the un-transduced cells by turbo-GFP (tGFP) 
expression which was mainly in the nuclei. This was due to the presence of nuclear localisation 
signal (NLS) sequence present on 5’ end of tGFP sequence in the pLOC vectors. 
Overexpression of CADM1 constructs was confirmed by brighter staining with anti-CADM1-
NT antibody in the tGFP positive cells compared to the adjoining untransduced cells (Fig. 62). 
In accordance with the qPCR results for CYP11B2 (Fig. 61b), immuno-staining with anti-
CYP11B2 antibody did not give any positive signal above background in the cells expressing 
only CADM1-WT, whether endogenous or overexpressing. Notably, cells expressing either of 
the mutant CADM1 at moderate levels showed upregulated CYP11B2 expression by higher 
staining confirming the qPCR mRNA results (Fig. 62). Interestingly, this upregulated CYP11B2 
staining was only observed in the cells expressing moderate levels of mutant CADM1 and not 
in those with very high levels of mutant CADM1 as indicated by intense nuclear tGFP levels. 
 
 
Fig. 62: Confocal images for H295R cells transduced with CADM1-SP4 WT or mutants, G379D or 
V380D. 
Transduced H295R cells were fixed and immuno-stained with anti-tGFP (green), anti-CYP11B2 (red) and anti-
CADM1-NT (3E1) (yellow) antibodies. Nuclei were stained with DAPI (blue). Merge of transduced cells and 
CYP11B2 expression is shown to represent the correlation between mutant CADM1 expression and CYP11B2 
upregulation in the transduced cells. 
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5.4.5.3 Angiotensin II stimulation on CADM1 mutants 
Angiotensin II stimulation effects were studied in the H295R cells expressing WT or mutant 
CADM1 to test if the presence of mutant CADM1 has any direct effect on the angiotensin II 
stimulation pathway of aldosterone secretion. Comparison of fold-change increase in 
CYP11B2 mRNA and aldosterone secretion in the presence of angiotensin II revealed no 
significant differences between the untransduced, transduction control cells and cells over-
expressing WT or mutant CADM in either isoforms (Fig. 63). 
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 CYP11B2 Aldo 
UT 2.50 4.37 
EV 3.03 4.71 
SP4 
WT 3.72 6.09 
G379D 2.15 4.09 
V380D 3.69 4.77 
SP1 
WT 3.22 4.94 
G379D 2.11 4.19 
V380D 2.50 4.26 
 
Fig. 63: Angiotensin II stimulation on H295R cells expressing CADM1-WT or mutants. 
Transduced H295R cells were starved with serum-free media overnight before 24hr treatment with either PBS 
(black bars, Untreated) or 10nM Angiotensin II (red bars, AngII). a. CYP11B2 mRNA expression in transduced 
H295R cells. b. Aldosterone secretion from transduced H295R cells. Error bars represent s.e.m. (n=2 in 
quadruplicate). Table shows the fold increase in CYP11B2 expression and aldosterone secretion under 
angiotensin II stimulation. 
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5.4.5.4 CADM1-WT attenuates mutant-induced aldosterone secretion 
To replicate the CADM1 WT and mutant dosage as it would be in the mutant APA and study 
its effect on aldosterone secretion, H295R cells were transduced with “either WT or mutant 
CADM1” or “a mixture of mutant and WT CADM1”. Total number of lentiviral particles 
transduced in various conditions was kept uniform by supplementing with control lentivirus 
(EV). 
 
qPCR for CADM1 revealed a dose dependent increase in expression only in the cells 
transduced with CADM1-WT (EV + WT vs WT + WT in Fig. 64a). Total CADM1 expression in 
the cells transduced with mutant CADM1 in the presence or absence of CADM1-WT remain 
unchanged (EV + G379D/V380D vs WT + G379D/V380D in Fig. 64a). Despite increased dose-
dependent CADM1-WT expression, no change in CYP11B2 expression or aldosterone 
secretion was observed as compared to the transduction control cells (EV/WT + WT vs EV + 
EV in Fig. 64 b & c). Interestingly, over-expression of CADM1-WT in the cells transduced with 
mutant CADM1 reduced the effect of mutations on the upregulation of CYP11B2 expression 
and aldosterone synthesis (EV + G379D/V380D vs WT + G379D/V380D in Fig. 64 b & c). These 
results suggested the dominant negative effect of CADM1 mutants on aldosterone 
upregulation. 
 
 
5.4.6 Aldosterone secretion is not regulated by ICD of CADM1 
-secretase, a protease is responsible for intra-membrane processing of CADM1 -CTF to 
release intracellular domain (ICD) into the cytoplasm. Effect of LY-411,575 a potent inhibitor 
of -secretase activity was tested for endogenous and over-expressed CADM1 -CTF levels 
and inhibition on aldosterone secretion in H295R cells. 
 
5.4.6.1 Effect of -secretase inhibition on endogenous CADM1 processing and 
aldosterone secretion 
H295R cells were treated with LY-411,575 in a dose range of 0.1-100M for 24hr period. 
Conditioned cell culture media was collected for aldosterone assay and whole cell protein 
extracts were prepared for western blotting with anti-CADM1-CT antibody.  
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Fig. 64: CADM1-WT reduces the effects of mutants on CYP11B2 and aldosterone upregulation. 
a. Estimation of relative CADM1 mRNA expression to show transduction efficiency for all constructs. b. Relative 
CYP11B2 mRNA expression in the transduced cells. c. Corresponding aldosterone assay. (n=2 in quadruplicate). 
(One-way ANOVA, **P=0.0061, ****P<0.0001). Error bars represent s.e.m. 
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It was found that -secretase inhibition led to accumulation of -CTF at the lowest 
concentration of 0.1M LY-411,575 tested, indicating reduced cleavage of -CTF by -
secretase inhibition to produce ICD (Fig. 65a). Aldosterone assay revealed that -secretase 
inhibition by LY-411,575 at this concentration or even 10-fold higher, 1M is not sufficient to 
induce any inhibitory effect on aldosterone secretion from H295R cells and only significant 
reduction of about 60% in aldosterone was observed at 100M LY-411,575 (Fig. 65b). These 
results imply that endogenous CADM1 does not exert its effect on aldosterone secretion via 
its ectodomain shedding followed by generation of ICD by -secretase. 
 
 
 
Fig. 65: Effect of -secretase inhibitor, LY-411,575 on -CTF of CADM1 and aldosterone secretion 
from H295R cells. 
a. Immuno-blot using anti-CADM1 CT antibody on cell lysates of H295R cells treated with LY-411,575 with 
indicated  molar concentrations used. Untreated samples were either not exposed to DMSO (ND: no DMSO) 
or 0.1% DMSO (n=2). b. Dose curve of LY-411,575 effect on aldosterone secretion. At every tested concentration 
of LY-411,575 percent inhibition of aldosterone from untreated samples is represented. Error bars represent 
s.e.m. 
 
 
5.4.6.2 Effect of -secretase inhibition on overexpressed CADM1 and aldosterone 
secretion 
Following the effect of LY-411,575 on the processing of -CTF from endogenous CADM1, 
similar treatments were performed on H295R cells transduced to overexpress CADM1 WT or 
mutants. The 2 lowest concentrations, 0.1 and 1M of LY-411,575 were tested as significant 
inhibition of -secretase was observed. 
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Fig. 66: -secretase inhibition in H295R cells overexpressing CADM1-WT or mutants. 
a. Immuno-blot using anti-CADM1 CT antibody on cell lysates of transduced H295R cells treated with 0.1 or 1M 
LY-411,575. Untreated cells (0M) were treated with DMSO only. b. Effect of LY-411,575 treatment on 
aldosterone secretion from transduced cells is represented as relative to untreated empty-vector cells. No 
significant differences in aldosterone secretion was found with LY-411,575 treatment at either concentration 
compared to untreated cells expressing CADM1 WT or mutants (n=2). Error bars represent s.e.m. 
 
 
It was found that LY-411,575 efficiently inhibited processing of -CTF to ICD in all CADM1 WT 
or mutant expressing cells (Fig. 66a). Aldosterone assay in overexpressing cell treated with 
LY-411,575 revealed no inhibition in aldosterone secretion compared to untreated cells even 
in the cells transduced with the mutant CADM1 (Fig. 66b). These results imply, as with 
endogenous CADM1 which is WT, neither of the mutants in both isoforms upregulate 
aldosterone synthesis and secretion via increased shedding or generation of ICD translocating 
to mitochondria, the site of aldosterone synthesis. 
 
143 
 
 
5.4.7 Mutant CADM1 disrupts inter cellular adhesion 
H295R cells were transduced with lentivirus for WT or mutant CADM1 and fixed for immuno-
staining with CADM1-CT antibody. Confocal imaging revealed significant differences in the 
morphology of cells overexpressing mutant CADM1 compared to the WT CADM1 expressing 
cells. Cells expressing high levels of mutant protein appeared rounded and less adhered to 
adjacent cells (Fig. 67), whereas no such loss of cell-cell adhesion was observed in the cells 
expressing endogenous or transduced WT CADM1. 
 
 
Fig. 67: Sub-cellular localisation of overexpressed CADM1-WT or mutants in H295R cells. 
Confocal images for H295R cells over-expressing WT or mutant CADM1-SP4 and immuno-stained using CADM1-
CT antibody (green). Nuclei were stained with DAPI (blue) in mounting media. 
 
To replicate this observation from H295R cells, HEK293 cells were transfected with pLOC 
plasmids for CADM1 WT or mutants using PEI. 48hrs from transfection, live cells were imaged 
for distribution of tGFP expressing cells as the indicator of cells transfected with WT or mutant 
CADM1 (or empty vector). It was observed that cells transfected with WT CADM1 clustered 
together compared to those transfected with empty vector. Very few transfected cells were 
observed to be present on their own without clustering. The number of individual cells in 
mutant transfected wells was observed to be significantly higher with fewer and smaller 
clusters compare to the WT wells (Fig. 68). H295R cells grown in suspension, with lower 
cellular adhesion were found to secrete significantly more aldosterone than those cultured in 
adherent cell culture plates (Fig. 69), suggesting cellular adhesion is critical for controlled 
aldosterone production. 
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Fig. 68: Loss of cell-cell adhesion in HEK293 cells expressing mutant CADM1. 
Fluorescent images for HEK293 cells transfected with pLOC constructs of empty vector (EV), WT or mutant 
CADM1. The tGFP in pLOC localised to nuclei representing distribution of CADM1 expressing cells. Scale bars = 
400m. 
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Fig. 69: Aldosterone secretion from H295R cells cultured in monolayer or suspension. 
Equal number of H295R cells were plated in serum-free media only (UT), or in the presence of either PBS or 
10nM AngII for 24hrs and aldosterone levels were measured. (Two-way ANOVA, *P=0.0251, **P=0.0010, 
****P<0.0001 for Non-adherent vs Adherent culture plates). (n=2 in quadruplicate) Error bars represent s.e.m.  
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5.4.8 CADM1 silencing downregulates aldosterone synthesis 
To study the normal physiological function of CADM1 in adrenal cortex, studying the effects 
of CADM1 knockdown was essential. H295R cells were transduced with the lentivirus for 
either non-targeting scrambled shRNA or a shRNA sequencing specific for CADM1 mRNA. 
Efficiency of CADM1 knockdown and its effect on aldosterone secretion and CYP11B2 
expression were analysed. 
 
5.4.8.1 CADM1 mRNA and protein  
GFP fluorescence was used as the measure of transduction efficiency and over 90% of H295R 
cells were found to be GFP positive in both conditions of non-targeting or CADM1 shRNA. 
qPCR for CADM1 revealed about 80% knockdown of CADM1 mRNA in cells transduced with 
shCADM1 compared to those with the non-targeting shRNA (Fig. 70a). CADM1 protein 
knockdown was confirmed by western blot (Fig. 70b) and confocal imaging (Fig. 70c) using 
CADM1 antibodies. 
 
Fig. 70: Silencing of CADM1 in H295R cells using shRNA lentivirus. 
a. qPCR for CADM1 mRNA fold change in cells transduced with shRNA lentivirus. 18s rRNA was used as 
housekeeping gene for normalising CADM1 Ct values. Error bars represent s.e.m. b. Whole cell lysate was 
immunoblotted using CADM1-CT and NT antibodies showing reduction in CADM1 protein in the wells 
transduced with CADM1 specific shRNA. Immuno-blot for GAPDH was used as loading control and EGFP as 
transduction efficiency. c. H295R cells grown on coverslips were transduced and fixed for immunostaining with 
CADM1-NT antibody. (n=3). 
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5.4.8.2 CYP11B2 mRNA and aldosterone secretion 
Aldosterone synthesis and secretion were downregulated in the absence of CADM1. qPCRs 
showed a significant decrease in the CYP11B2 mRNA levels by 50% in the cells transduced 
with shCADM1 compared to controls (Fig. 71a) and corresponding reduction in aldosterone 
secretion by 40% was observed (Fig. 71b). 
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 Fig. 71: Effect of CADM1 knockdown on aldosterone synthesis in H295R cells. 
a. qPCR for CYP11B2 mRNA (t test, P value = 0.0029, **P≤0.01) and b. Aldosterone secretion (t test, P value = 
0.013, *P≤0.05) in H295R cells transduced with Non-targeting and CADM1 shRNA (n=3 in quadruplicate). Error 
bars represent s.e.m. 
 
5.4.8.3 Abatement of AngII response in silenced cells 
Effect of angiotensin II stimulation on aldosterone synthesis and secretion were analysed in 
the CADM1 silenced H295R cells. It was found the cells with CADM1 knockdown were less 
responsive to angiotensin stimulation as revealed by statistically non-significant upregulation 
of CYP11B2 mRNA (Fig. 72a). 2 fold increase in CYP11B2 in presence of AngII in the non-
targeting cells was reduced to 1.6-fold in CADM1 silenced cells, which was not significant 
compared to untreated cells. Corresponding aldosterone secretion in CADM1 silenced cells 
on angiotensin II stimulation was significantly reduced to only 3.8-fold of untreated as 
compared to nearly 8-fold in non-targeting cells (Fig. 72b).  
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Fig. 72: Angiotensin II treatment of CADM1 silenced cells. 
H295R cells transduced with scrambled (Non-targeting) or CADM1 (shCADM1) shRNA lentivirus were either 
untreated (PBS only, black bars) or treated with 10nM AngII (red bars). a. CYP11B2 mRNA (Two-way ANOVA, 
***P value = 0.0003 for non-targeting; and not significant, n.s. P value = 0.1079 for shCADM1, AngII vs Untreated) 
and b. aldosterone secretion (Two-way ANOVA, ****P value < 0.0001 for non-targeting; and **P value = 0.0031 
for shCADM1, AngII vs Untreated) were estimated and are expressed as fold change relative to Non-targeting 
untreated samples (n=2 in triplicate). Error bars represent s.e.m. 
 
5.4.9 Possible link between CADM1 & a gap junction protein, Connexin-43 
5.4.9.1 Increased Cx43 in silenced cells 
In order to investigate if knockdown of CADM1 has an effect on localisation of connexin-43, 
similar to that reported for Cx36 in mouse pancreatic cells (Ito et al., 2012), H295R transduced 
with shRNA for CADM1 were co-stained for CADM1 and Cx43. Not much overall expression 
of Cx43 was observed in the H295R cells and hardly any on the cell membrane (top panel in 
Fig. 73a). In the cells with CADM1 knockdown, increase in overall and membranous 
expression of Cx43 expression was observed (bottom panel in Fig. 73a), which was confirmed 
by western blotting (Fig. 73b). This increase in Cx43 protein levels was seen at the mRNA level 
as well in the RNAseq analysis (Section 5.4.11). 
 
5.4.9.2 Para-nuclear expression in ZG, APCCs and APAs 
FFPE section of dissected adrenal gland from patient 184 were co-stained for expression of 
Cx43 and CADM1-NT and visualised using fluorescently tagged anti-rabbit and anti-chicken 
secondary antibodies respectively. Another section was also stained for CYP11B2 expression 
and visualised using anti-mouse secondary antibody. As expected, Cx43 was found to be 
highly expressed at the plasma membranes in ZF of the adrenal cortex, but appeared to be 
expressed at very low levels in ZG (Fig. 74). The localisation of Cx43 in ZG was not 
membranous, but more like cytoplasmic aggregates near nuclei. This punctate para-nuclear 
aggregation of Cx43, possibly in endoplasmic reticulum or Golgi apparatus, was even more 
evident in the APCCs which express CADM1 at relatively higher levels than ZG. Again, high 
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CADM1 expression in APAs is observed with impaired Cx43 trafficking to the membranes and 
stuck in the para-nuclear organelles (Fig. 75).  
 
a. 
 
b. 
 
Fig. 73: Expression of connexin-43 in CADM1 silenced H295R cells. 
H295R cells transduced with lentivirus for non-targeting or CADM1 specific shRNAs were a. immuno-stained 
with CADM1-NT (green) and Cx43 (red) antibodies; and b. whole-cell lysate was western-blotted (n=2).  
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Fig. 74: Immunofluorescence for GJA1, CADM1 and CYP11B2 expression in adrenal cortex and 
APCC (n=5).  
 
 
 
Fig. 75: Immunofluorescence for GJA1 and CADM1 expression in APAs (n=5). 
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5.4.9.3 Effect of AngII & PMA treatment on Cx43 levels 
H295R cells were treated with 10nM angiotensin II or 200ng/ml PMA (phorbol 12-myristate 
13- acetate) to study their effect on Cx43 expression in relation to aldosterone and CYP11B2 
expression. PMA is a transient activator of protein kinase C, shown to increase ectodomain 
shedding of CADM1 (Nagara et al., 2012) and also shown here by reduced signal for full length 
CADM1 in PMA treated cells (Fig. 77b). Both AngII and PMA stimulation increased aldosterone 
secretion and CYP11B2 expression as expected (Fig. 76 a & b). Co-staining for CYP11B2 and 
Cx43 revealed downregulation of Cx43 in response to AngII stimulation, particularly in the 
cells showing higher CYP11B2 expression (Fig. 77a). This reduction in Cx43 protein levels in 
AngII treated cells was confirmed by western blot (Fig. 77b), despite minute increase in GJA1 
transcription (Fig. 76d). PMA treatment led to significant increase in Cx43 protein levels (Fig. 
77) and upregulated GJA1 transcription was observed (Fig. 76d).  
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Fig. 76: Aldosterone secretion and transcriptional analysis of H295R cells treated with   
Angiotensin II and PMA. 
H295R cells were treated with AngII or PMA for 24hrs and a. aldosterone secretion, and qPCRs for b. CYP11B2, 
c. CADM1 and d. GJA1 were analysed. All values for both treatments are represented as relative to untreated 
(UT) samples. (2-tailed T-test, *P=0.0112, **P=0.0039, ****P<0.0001 for AngII/PMA compared to UT) (n=2 in 
quadruplicate). Error bars represent s.e.m. 
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a. 
 
 
b. 
 
Fig. 77: Effect of Angiotensin II and PMA on expression of connexin-43 in H295R cells. 
H295R cells treated with AngII or PMA were a. stained with mitochondrial marker (MitoTracker, yellow) and 
immuno-stained with CYP11B2 (green) and Cx43 (red) antibodies; and b. whole-cell lysate was western-blotted 
for Cx43 and CADM1 levels (n=2). 
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5.4.10 RNAseq for CADM1-WT vs mutants overexpressing H295R cells 
Transcriptome analysis, by RNAseq for H295R cells transduced with lentivirus for CADM1 WT 
and mutants in both isoforms SP4 and SP1 was done. There were very few interesting genes 
that were significantly differentially expressed in cells overexpressing CADM1-WT compared 
to the control cells. CYP11B2 was one of the top genes upregulated (up to 31-fold) in cells 
expressing mutant CADM1 in both isoforms, with no change in the WT expressing cells  along 
with its transcriptional regulatory gene, NR4A2 (Fig. 78). Some other genes involved in early 
steps of steroidogenesis like STAR and HSD3B2 were also upregulated in the presence of 
mutant CADM1 by at least 2-folds. Mutant CADM1 not only upregulated aldosterone 
synthase, but also led to 6-10 fold increase in the CYP11B1 expression but whether it is in 
response to upregulated adrenocorticotropic hormone (ACTH) receptor, MC2R (8-13 fold) 
and accessory protein, MRAP (6.5-8.5 fold) cannot be commented.  
 
Fig. 78: Heatmap for selected genes differentially expressed in H295R cells expressing CADM1-
mutants. 
Heatmap shows selected 23 top genes significantly upregulated in the presence of CADM1-mutants compared 
to CADM1-WT (n=3 per group). Student’s two-tailed T-test with P<0.05 and fold change, FC2 vs WT. 
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Fig. 79: Heatmap for granin family of genes differentially expressed in H295R cells expressing 
CADM1-mutants. 
 
5.4.11 RNAseq for CADM1 silenced H295R cells 
Transcriptome analysis, by RNAseq for H295R cells where CADM1 expression was knocked 
down using shRNA, revealed a large number of significantly differentially expressed genes -
compared to the control cells transduced with non-targeting shRNA. CADM1 knockdown led 
to the downregulation of approximately 70% of the pool of significantly different genes, 
suggesting its critical role in normal cell physiology (Fig. 80).  
 
 
Fig. 80: Heatmap for genes significantly differentially expressed in H295R cells with CADM1 
knockdown compared to control shRNA cells. 
Hierarchical clustering of gene RKPM, with false discovery rate, FDR<0.05 and no cut-off for fold change between 
2 groups. Number of genes represented, n=739. 
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In addition to confirmation of CYP11B2 downregulation and GJA1 upregulation in shCADM1 
cells, as shown previously (Sections 5.4.8.2 & 5.4.9.1), some other genes relevant for cell-
adhesion and steroidogenesis are represented in Fig. 81. Several integrin genes were 
downregulated in shCADM1 cells, except for ITGA8 that was 2-fold upregulated in the absence 
of CADM1. No change in CYP11B1 expression was observed. Interestingly, expression of a pro-
survival factor, BCL2 (B-cell lymphoma 2) was downregulated in shCADM1 cells by ~40%. 
 
 
Fig. 81: Heatmap for selected genes differentially expressed in H295R cells with CADM1 
knockdown compared to control shRNA cells. 
Heatmap shows some selected top genes significantly upregulation in the shCADM1 cells compared to control 
shRNA (non-targeting) cells (n=3 per group). Student’s two-tailed T-test with P<0.05 and fold change indicated. 
 
 
Fig. 82: Heatmap for granin family of genes differentially expressed in H295R cells with CADM1 
knockdown compared to control shRNA cells. 
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5.4.12 RNAseq for CADM1 APA vs other ZG-like APAs 
RNAseq analysis for 3 pairs of adjacent normal and APA was done. The 3 APAs used here were 
CADM1 (184T), ATP2B3 (192T) and CACNA1D (195T) mutants. Analysis for the gene 
expression in 184T versus average of 192T and 195T is shown in Fig. 83. Most of the 
differentially expressed genes from previous 2 experiments were found to be upregulated in 
184T, but only a few, AQP2, TMEM110, TSPAN12, VPREB3 and MYOM1 were more than 2-
fold higher as compared to the average of other 2 APAs. It is important to note that we might 
be missing signals from many genes like those in the granin family due to adrenal medulla 
contaminating of our RNA prep of APA samples. For example, SCG2 that is highly expressed 
in adrenal medulla, showed no difference in its expression in three APAs in the study but was 
differentially expressed in H295R cells expressing mutant CADM1 or silenced CADM1 (Fig. 79  
& Fig. 82). 
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AQP2 24.29 1.27 19.13
TMEM110 14.89 4.25 3.51
TSPAN12 13.96 4.41 3.17
VPREB3 64.92 26.67 2.43
MYOM1 6.06 2.78 2.18
CYP11B2 578.97 362.55 1.60
KCNJ5 43.95 27.93 1.57
DPP4 1.31 0.92 1.42
MC2R 30.16 21.3 1.42
MRAP 11.77 8.6 1.37
CADM1 2.88 2.37 1.22
CACNA1D 6.27 5.22 1.20
 
Fig. 83: Dot-plot for genes’ expression in CADM1 mutant, 184T versus average of 2 other ZG-like 
APAs. 
Dot-plot represents common genes that were more than 2-fold upregulated in 184T compared to its adjacent 
normal and the average of 192T & 195T. Fold change compared to the 2 other APAs is shown in the table. Genes 
potentially be significantly higher in CADM1 mutant tumour are shown in red, and other genes that are not 2-
fold higher but relevant to adrenal/aldosterone physiology are shown in green. 
 
AQP2 encodes a protein aquaporin-2, a water channel which is expressed in response to 
vasopressin (anti-diuretic hormone), exclusively on the apical membranes of renal collecting 
tubules (Nielsen et al., 1995). Here AQP2 increases water reabsorption by collecting duct cells. 
Aldosterone on the other hand, has an opposite effect by decreasing apical AQP2 expression 
in vitro (Hasler et al., 2003) and in vivo model of CYP11B2 knockout mice (Makhanova et al., 
2006). Unexpectedly, our lab found upregulated expression of AQP2 by >2-fold in {1} APAs vs 
adjacent normal adrenal glands (Azizan et al., 2012a) and {2} CACNA1D/ATP1A1 mutant vs 
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KCNJ5 mutant APAs (Azizan et al., 2013). Transcriptome analysis of CADM1 mutant APA (184T) 
revealed exceptionally high expression of AQP2 compared to the other 2 APAs that were 
CACNA1D and ATP1A1 mutants (Fig. 83 & Table 27). This was confirmed by 
immunohistochemistry for AQP2 expression easily detected in 184T, with little or no positivity 
in the 2 other APAs (Fig. 84, IHC done by Wanfeng Zhao).  In addition to some membranous 
staining, AQP2 appeared to be aggregated in cell inclusion bodies in 184T (Fig. 84a), whereas 
such inclusion bodies in other APAs do not show AQP2 expression (Fig. 84 b & c). 
 
 
Table 27: AQP2 expression from RNAseq analysis of 3 APAs/Normal pairs 
Sample ID Normal APA 184T/Average 
184 0.93 24.29 
19.13 192 0.05 2.16 
195 0.17 0.38 
 
 
Though H295R cells do not express any AQP2 and no change was observed in cells 
overexpressing CADM1-WT SP1 and SP4 isoforms, but a few reads for AQP2 expression (1-4 
reads) were detected in CADM1-V380D expressing H295R cells in RNAseq analysis (Table 28). 
Due to no or very low read counts, no statistical analysis could done and only the raw data is 
shown here. These results are consistent with high AQP2 expression in 184T, harbouring 
V380D mutation. If AQP2 upregulation proves to be a true and direct effect of CADM1 
mutation, it might be exploited to further explore CADM1’s role in APAs. 
 
Table 28: AQP2 expression from RNAseq analysis of H295R cells overexpressing CADM1 
  No. of reads Average 
 
Untransfected 0, 2, 0 0.67   
 
Empty Vector 0, 0, 0 0.00   
SP4 
WT 0, 0, 0 0.00 
G379D 1, 0, 0 0.33 
V380D 2, 4, 1 2.33 
SP1 
WT 0, 0, 0 0.00 
G379D 1, 1, 0 0.67 
V380D 1, 1, 0 0.67 
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Fig. 84: Immunohistochemistry for AQP2 in APAs 
IHC for AQP2 in the three APAs for which RNASeq was performed. a. CADM1 mutant APA 184T. b. & c. Two other 
ZG-like APAs - 192T and 195T. Arrow heads indicate cell inclusion bodies positive for AQP2. Scale bar is shown. 
(This staining was performed by Wanfeng Zhao at Human Tissue Bank, Addenbrooke’s Hospital).  
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5.5 Discussion 
With the discovery of mutations in CADM1, a tumour suppressor gene, it was hypothesized 
that these mutations would have a pathogenic role due to the loss of function resulting in 
increased tumour cell proliferation and autonomous aldosterone secretion. To investigate 
this hypothesis and study the role of CADM1 in aldosterone secretion in normal and 
pathogenic tissues, I started with analysing CADM1 expression levels and localisation in the 
normal adrenals and APAs. RT-PCR and immunohistochemistry for CADM1 showed its high 
expression in the human adrenals, APAs and adrenocortical carcinoma derived cell line, 
H295R cells. Transcripts expression analysis in all – H295R cells and human adrenal tissue 
samples showed CADM1-SP4 to be the most predominant isoform in the samples tested (Fig. 
53 & Fig. 54) as is the case with other tissues like brain, testis, mast cells etc. Isoform with 
constitutively shed ectodomain, SP1 and the secreted/soluble isoform with retained intron, 
SP5 are also expressed in these tissues (Fig. 53). Soluble isoform has been shown to function 
in a self-antagonistic manner by inhibiting trans-homophilic CADM1 interaction between 
adjacent cells (Koma et al., 2004). Effects of soluble isoform expression in H295R cells is not 
known and was not investigated in this study.  
 
Immunohistochemistry for CADM1 localisation in normal adrenal sections revealed intense 
staining in the zona glomerulosa of adrenal cortex. There was easily detectable expression in 
zona fasciculata and adrenal medulla (Fig. 55 a & c, & Fig. 58e). In all these regions CADM1 
localised to cell membranes and no intracellular staining for cleaved products was observed 
(Fig. 55c & Fig. 56c). Interestingly, aldosterone producing cell clusters (APCCs) in adrenal 
cortex as defined by high CYP11B2 expression, normally not seen in the continuous ZG layer 
(Fig. 55 b & d; Fig. 56 b & d; Fig. 58 b & d) showed highly upregulated expression of CADM1 
(Fig. 55 a & c; Fig. 56 a & c; Fig. 58 a & c). Similarly, CADM1 is expressed in APAs in the pattern 
similar to that of CYP11B2 that is, mostly homogenous with some patches negative for both 
CYP11B2 and CADM1 (Fig. 57 & Fig. 58). These findings suggest that CADM1 plays an 
important role in aldosterone secretion. 
 
Despite the introduction of negatively charged aspartate residue in the transmembrane 
domain of CADM1 mutants, heterologous expression of WT and mutants in H295R cells, both 
mutants could translocate to the plasma membranes (Fig. 62 & Fig. 67). Western blots with 
the Myc antibody showed both mutant proteins were glycosylated efficiently as indicated by 
relatively similar proportions of 2 bands for all samples (Fig. 60a). This blot also revealed lower 
protein expression for V380D as compared to the WT or the second mutant G379D 
irrespective of the isoforms SP4 or SP1. This was not due to the excessive shedding of 
ectodomain and further proteolytic processing of CADM1-V380D as no increase in the -NTF 
levels in the supernatant was observed (Fig. 60c). -NTF for CADM1-V380D reflected the total 
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protein levels in cell lysates. Surprisingly there were no differences seen in the protein levels 
or ectodomain shedding for the WT protein in 2 isoforms expressed in H295R cells, when SP1 
is supposed to be constitutively shed. It could probably be that H295R cells do not express or 
are unable to secrete the protease, ADAM10 or similar, required for the constitutive shedding 
into the media.  
 
The differences in the number and sizes of -CTF fragments generated in cells expressing WT 
or mutant CADM1 as shown by western blotting using anti-CADM1 CT antibody (Fig. 60b), 
suggest different cleavage sites of ectodomain shedding by ADAM10. Though it is not possible 
to conclude this without 3D structure modelling of WT and mutant proteins, evidences are 
there in literature that ADAM10 and other proteases in the family proteolytically cleave 
membrane proteins at a fixed distance from cell surface rather than by recognising a specific 
amino acid sequence (Hayashida et al., 2010). It is speculated that the mutations within the 
transmembrane domain of CADM1 change the angle at which ectodomain is exposed on the 
cell surface leading to differences in the sizes of -CTFs generated compared to the WT. There 
are no reports of phosphorylation of CADM1 or cleaved -CTFs, but presence of putative 
phosphorylation sites suggests this is possibly a regulatory mechanism which can be affected 
by the presence of mutations in CADM1. Difference between the number and sizes of -CTF 
fragments generated from the 2 mutants suggest different impact the 2 variants in adjacent 
residues have on CADM1 structure and possibly the downstream mechanisms.  
 
Increased aldosterone secretion and CYP11B2 upregulation by both mutants suggested a 
gain-of-function phenotype as no change is seen with the overexpression of CADM1-WT 
compared to the control cells (Fig. 61). The effect of 2 mutations on aldosterone synthesis 
differed significantly from each other with V380D expression resulting in the most extreme 
phenotype despite the least total protein expression. These results imply very different 
mechanisms the two mutations might be functioning with. Immunofluorescence of 
transduced cells for CYP11B2 was in accordance with the qPCR analysis that no staining for 
CYP11B2 expression was observed in H295R cells expressing CADM1-WT, but only in the ones 
expressing mutant V380D mutant more than G379D (Fig. 62). 
 
To investigate if the intracellular domain (ICD) of CADM1 does play a role in aldosterone 
secretion, possibly by translocating to mitochondria like in lung epithelial cells (Hagiyama et 
al., 2015), a -secretase inhibitor LY-411,575 was used to block -secretase mediated 
proteolytic processing of -CTF to generate ICD. Treating H295R cells with LY-411,575 
resulted in accumulation of -CTF suggesting effective inhibition of -secretase activity at the 
concentration of 0.1M (Fig. 65a), though no reduction in aldosterone secretion was 
observed below 10M LY-411,575 (Fig. 65b). It can be concluded that ICD of endogenous 
160 
 
 
CADM1 does not play a role in aldosterone secretion, and any inhibition observed at 10M 
or higher LY-411,575 concentrations is non-specific and via CADM1 independent pathways. 
Similar observations from LY-411,575 treatment were seen on H295R cells overexpressing WT 
or mutant CADM1 (Fig. 66) which suggests that CADM1 perhaps regulate aldosterone 
secretion by an alternative pathway.  
 
Immunofluorescence for CADM1 localisation in H295R cells’ monolayer is very asymmetric 
and shows membranous staining only where a cell is in contact with another cell (Fig. 70c) 
suggesting a critical role in cell-cell adhesion and possibly inter-cell communication in this cell 
line as well. This inter-cellular adhesion seems to be lost in cells expressing CADM1 mutants 
as suggested by rounded morphology with no or little cell-cell contact (Fig. 67). This loss of 
cellular adhesion is probably due to inability of mutant CADM1 to form trans-
homo/heterophilic interaction with CADM1 on the cell surface of neighbouring cells. This 
phenomenon appeared to be more prominent in V380D expressing cells than those 
expressing G379D mutant CADM1. The difference in the degree of their effect on cell 
adhesion also supports much higher upregulation of aldosterone secretion in V380D than in 
G379D mutant CADM1 expressing H295R cells. Similar loss of cell-cell adhesion was also very 
obvious in the HEK293 cells transfected with either mutant CADM1 compared to that seen in 
the case of overexpressed CADM1-WT (Fig. 68). It is believed that CADM1-mutants, G379D 
and V380D lead to loss-of-function for CADM1’s adhesion properties resulting in gain-of-
function phenotype in stimulating aldosterone secretion. Interestingly, co-transduction of WT 
and mutant CADM1 showed attenuated aldosterone secretion as compared to the mutant 
alone (Fig. 64). This suggested a dominant negative effect of mutant CADM1 on aldosterone 
because of its sensitivity to CADM1-WT dosage. On the other hand, mutant CADM1 induced 
aldosterone upregulation was not additionally potentiated by angiotensin II treatment and 
remained limited to 2-3 fold increase irrespective of CADM1 genotype (Fig. 63). These 
observations suggest aldosterone secretion “in response to angiotensin II stimulation” and 
“due to loss of cellular adhesion in the presence of mutant CADM1” are two independent 
pathways. 
 
This theory is supported by the two in vitro observations. Firstly, higher aldosterone secretion 
from H295R cells cultured in suspension in the low attachment vessels (cells are less in contact 
with each other) as compared to when cell are adhered to the surface (Fig. 69). Secondly, 
elevated levels of aldosterone secretion usually seen from dispersed primary adrenal cortical 
cells that contain less than 5% cells of zona glomerulosa origin. In primary cell culture, loss of 
glomeruli entity means loss of intercellular adhesion and communication resulting in each cell 
to make aldosterone autonomously rather than in a regulated manner within a glomerulus of 
ZG. The loss of pace making activity of a glomerulus is not only executed via Ca2+ as the second 
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messenger (Hu et al., 2012) but also adhesion molecules like CADM1 in a Ca2+ independent 
manner. 
 
Apart from studying the effects of mutations on CADM1 function in pathological condition, I 
investigated the role endogenous CADM1 plays in regulation of aldosterone secretion under 
“normal” conditions. Though overexpression of CADM1-WT showed no effect on aldosterone 
or CYP11B2 expression, its knockdown resulted in downregulation of aldosterone synthesis 
and secretion in H295R cells (Fig. 71). Absence of CADM1 also resulted in lower 
responsiveness of H295R cells to angiotensin II mediated aldosterone stimulation (Fig. 72). 
The reason for contrasting effects of CADM1 dosage and its mutational status on H295R cells’ 
responsiveness to angiotensin II treatment is probably that the minimum threshold level of 
CADM1 is required for normal physiological aldosterone secretion. Above this threshold/basal 
level the mutant CADM1 functions as antagonist for adhesion lifting the regulatory checkpoint 
that CADM1 imposes under normal conditions. 
 
Transcriptome analysis of H295R cells overexpressing CADM1 WT or mutants showed a  very 
few genes to be downregulated in mutant expressing cells and most were upregulated (Fig. 
78). Interestingly, many of the upregulated genes in mutant expressing cells were also 
upregulated in the CADM1 silenced cells – MYOM1, TSPAN12, GJA1, SYNE1, MRAP and 
steroidogenesis enzymes STAR, HSD3B2, NR4A2, CYP17A1 etc. with an exception of CYP11B2 
expression which goes in opposite directions that is upregulated in mutant cells but 
downregulated in shCADM1 cells (Fig. 78 & Fig. 81). Most of granin family proteins also 
followed this pattern of opposite direction, being upregulated in the presence of mutant 
CADM1 and down in CADM1 silenced H295R cells (Fig. 79 & Fig. 82).   
 
Another surprising exception was the expression of CYP11B1, which remained unchanged in 
CADM1 silenced cells but was 6-10 fold upregulated in mutant expressing cells (Fig. 78 & Fig. 
81). These observation suggests mutants function in a way similar to reducing absolute 
availability of CADM1 in the cells by their inhibitory effects on cell adhesion as in the case of 
silenced cells. 
 
GJA1, the highest of all gap junction proteins in adrenal (Fig. 46), was upregulated in CADM1 
silenced cells (Fig. 73 & Fig. 81) and also in mutant CADM1 expressing H295R cells (Fig. 78). A 
20kD transcript of GJA1 translated from an internal start site has been reported to function 
as an auxiliary trafficking protein for the full-length Cx43 to the plasma membrane forming 
functional gap junction channels (Smyth and Shaw, 2013). Western blots showed an increase 
in full-length Cx43 and the 20kD fragment levels as well in shCADM1 cells (Fig. 73). Increased 
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Cx43 mRNA and protein in H295R cells treated with PMA (Fig. 76 & Fig. 77) was observed. 
PMA increases CADM1 ectodomain shedding resulting in lesser full-length CADM1 on cell 
surface and fewer inter-cellular adhesion points. This inverse membranous expression of 
CADM1 and Cx43 was also obvious in the immunohistochemistry of human adrenal sections. 
In ZF with relatively less CADM1 expression, Cx43 localises to cell membranes (Fig. 74). 
Complementarily, CADM1 rich regions of ZG, APAs and APCCs show no membranous 
localisation of Cx43. All Cx43 appears to be accumulated in para-nuclear aggregates which is 
possibly the endoplasmic reticulum or Golgi apparatus (Fig. 74 & Fig. 75). These observations 
suggest CADM1 probably prevents gap junctional intercellular communications (GJIC) by 
reducing the number of functional intercellular channels between adjacent cells through 
which small molecules are shared. Additionally, downregulation of TSG101 was observed in 
transcriptome analysis of shCADM1 cells (Fig. 81). TGS101 (tumour susceptibility gene 101), 
encodes for one of the proteins involved in ubiquitin mediated lysosomal degradation of Cx43 
inhibiting its recycling to plasma membrane (Leithe et al., 2009). It is also speculated that the 
possible changes in angulation of ectodomain of the mutant CADM1 prevents neighbouring 
cells to come close enough at optimum distance required to form functional connexions. In 
conclusion, CADM1 might play a role in regulating GJIC by increasing Cx43 degradation, either 
by supporting expression of TSG101 or by regulating 20kD isoform expression to limit its 
membrane trafficking. So far, the link between CADM1 and Cx43 has only been reported in 
skin wound healing process where they interact indirectly via a common interacting protein, 
CASK (Márquez-Rosado et al., 2012).  
 
Similar to the studies in nephropathic kidneys and CADM1 silencing experiments in renal 
tubular cells (Kato et al., 2018), 40% downregulation of BCL2, a pro-survival/anti-apoptotic 
gene in shCADM1 cells was found, suggesting CADM1’s role in supporting H295R cell survival.  
 
TSPAN12, a member of tetraspanin family of proteins contains 4 transmembrane domains. It 
acts as a co-receptor for ligand NDP (norrin) binding to its receptor FZD4 (frizzled 4) inducing 
the signalling pathway which results in the protection of -catenin from degradation 
(Knoblich et al., 2014; Lai et al., 2017). Elevated nuclear -catenin recruits TCF/LEF and other 
transcriptional factors independently of Wnt signalling. The observations of 2-fold 
downregulated NDP expression in the absence of CADM1, with possible 4.4-fold 
compensatory increase in TSPAN12 are supported by previous reports of increased -catenin 
signalling implicated in the development of adrenal cancers and hyper aldosterone secretion 
in APAs (Berthon et al., 2010, 2014; Teo et al., 2015). RNAseq for mutant vs WT CADM1 
expressing H295R cells (Fig. 78) and 184T vs other 2 APAs (Fig. 83), respectively showed 2-2.5 
and >3 fold higher TSPAN12 expression. This might be explained by TSPAN12’s role in 
supporting primary tumour growth but inhibiting metastasis (Knoblich et al., 2014).  
 
 
 
CHAPTER 6 
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CHAPTER 6 -  CONCLUSIONS  
 
Candidate gene screening and whole exome sequencing of APAs in our cohort revealed 
different rates of prevalence for mutated genes in the APAs investigated to that reported in 
the literature for other cohorts. CACNA1D gene was found to be the most commonly mutated 
gene followed by the KCNJ5. This was due to the presence of large number of small APAs that 
could be diagnosed by PET-CT using C11-metomidate at the Addenbrooke’s Hospital. We 
believe that small APAs could be undetected in adrenal CT scans or MRI, and therefore PET-
CT would be more efficient in diagnosis and management of PA. 
 
Increased calcium influx via mutant CaV1.3 does lead to hyper aldosterone secretion in H295R 
cells. Apart from its conventional function of voltage-gated calcium channel, we found 
evidence of its role as a transcription factor mediated by calpain cleaved intracellular c-
terminal. Nuclear translocation of cleaved CaV1.3’s c-terminal appeared to regulate 
aldosterone synthesis and secretion. Aldosterone synthase, CYP11B2 expression was found 
to be downregulated in the adrenals of CaV1.3 knockout mice. This finding was critical to 
establish the significant role that CaV1.3 plays in the physiological regulation of aldosterone 
synthesis and not just when mutated in the APAs. Moreover, the discovery of CaV1.3 selective 
3 tool compounds at  proved to be immensely promising as at least one of these, 
compound B, could inhibit aldosterone secretion both in H295R and in the primary adrenal 
cells. More primary cells/tissues are needed for testing the effects of compound B on 
aldosterone regulation, which can be developed further into a drug for treating PA patients 
not just with the CACNA1D mutated APAs but any APAs. 
 
We discovered novel somatic mutations in cell adhesion molecule 1, CADM1 in 2 APAs in 
Cambridge and Munich cohorts. Expression of mutant CADM1 was found to have a dominant 
effect by increasing aldosterone synthesis in the H295R cells. This is perhaps due to the 
disruption of physiological intercellular adhesion necessary for controlled aldosterone 
secretion. Overexpression of wild-type CADM1 does not affect aldosterone levels but 
maintenance of basal CADM1 expression is essential for sustained aldosterone secretion.  
CADM1 might be involved in regulation of gap-junctional intercellular communications by 
inhibiting membrane trafficking of connexin-43. RNAseq experiments revealed a large 
number of genes differentially expressed in presence of mutant CADM1 or silenced CADM1. 
Future studies on some of the top genes, like aquaporin-2 (AQP2) would enhance our 
understanding of the significant role CADM1 plays in physiological and pathological 
conditions of aldosterone secretion. This study again highlights the significance of 
intercellular adhesion and communication in ZG of adrenal cortex for sustained and regulated 
aldosterone secretion.  
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Appendix 
Buffer recipes 
 
1. Ca2+ bath solution  
10mM CaCl2, 150mM TEA-Br, 3mM KCl, 1mM NaHCO3, 1mM MgCl2, 10mM HEPES, 
4mM Glucose, pH 7.4 using Tris Base (pH7-9). 
 
2. Ba2+ bath solution 
10mM BaCl2, 150mM TEA-Br, 3mM KCl, 1mM NaHCO3, 1mM MgCl2, 10mM HEPES, 
4mM Glucose, pH 7.4 using Tris Base (pH7-9). 
 
3. Cs internal solution 
140mM CsOH, 140mM Aspartic acid, 5mM EGTA, 2mM MgCl2, 0.1mM CaCl2, 2mM 
K2ATP, 10mM HEPES, pH 7.2 with 3M CsOH. 
 
4. Cell lysis buffer 
50mM Tris, 0.15M NaCl, 1mM EGTA, 1mM EDTA, 1mM sodium orthovanadate, 50mM 
NaF, 10mM sodium pyrophosphate, 10mM glycerol-2-phosphate, 1% Triton X-100, pH 
7.5  
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